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The naïve and not-yet developed infant immune system exhibits heightened susceptibility to 
external factors (e.g. pathogens), and is shaped by these and others, such as maternal immunity. 
However, we do not yet fully understand their impact on development of infant immunity. A better 
understanding of these effects would benefit children world-wide, but especially those in low-
middle income countries (LMIC), where increased exposure to pathogens due to poorer living 
conditions highlights the necessity of robust early-life immunity. Mycobacterium tuberculosis (Mtb) 
and helminths are pathogens co-endemic in many LMIC and cause significant morbidity and 
mortality in children. Infant immune responses to these pathogens, whether during standalone 
infection, co-infection or resulting from maternal infection are not fully understood. To contribute 
to this knowledge gap, we investigated early-life immune responses, how they relate to childhood 
Mtb/helminth infection and how they are affected by maternal infectious history and immunity.  
Analysis of clinical humoral responses revealed total IgG that increased significantly between 
baseline and tuberculosis (TB) investigation in infants who did not acquire Mtb infection; these 
infants also exhibited raised levels of measles-specific IgG and BCG-specific IgG2. No active helminth 
infections were detected, but the presence of Ascaris lumbricoides- and Trichuris trichiura-specific 
class-switched antibodies indicated prior exposure. No association was found between helminth-
specific humoral responses and risk of Mtb infection, nor with maternal helminth-specific humoral 
responses. Conversely, data from murine experiments revealed a protective effect of maternal 
helminth infection (Nippostrongylus brasiliensis) on BCG infection in offspring, with reduced lung 
bacterial burden and increased numbers of activated CD4+ T cells and B cells. Maternal Nb infection 
may have a synergistic effect on BCG vaccination, as BCG-vaccinated/infected pups from Nb-
infected mothers had reduced lung bacterial burdens, increased CD4+ T cell and B cell responses and 
increased IFNγ-producing CD4+ T cells. 
Findings from this study suggest that childhood vaccines could provide heterologous protection 
against unrelated pathogens such as Mtb. The murine data suggest a protective effect of maternal 
helminth infection against BCG infection in offspring, but no similar finding was observed with the 
clinical data. The clear protective effect of maternal Nb infection during offspring BCG infection 
warrants a more in-depth clinical study addressing the functional effects of maternal helminth 
infection on Mtb infection outcome in infants. 
 




Chapter 1: Introduction 
1.1 The infant immune system 
A properly developed and functioning immune system is essential for our bodies to be able 
to respond to numerous internal and external factors that threaten our well-being. 
Underlying this system is the complex set of interactions that occurs between the two arms 
of the immune system, namely innate and adaptive immunity. Misplaced reactions or 
interactions within either arm of immunity gives rise to inappropriate responses to 
pathogens and other environmental stimuli, as well as auto-immune diseases. Although the 
response of the body to stimuli received after birth informs the maturation of the various 
immune cells, these responses would not be able to occur with inappropriate development 
of the immune system in utero. As such, it is important to consider how the various immune 
tissues, cells and mediators develop in utero, and then address immune maturation after 
birth and in the first years of life. 
1.1.1 The two arms of immunity 
1.1.1.1 Innate immunity 
The innate immune system consists of the first frontier of cells that allergens or invading 
pathogens encounter upon gaining access to the body. These cells are able to respond to a 
broad array of allergens and molecules expressed by pathogens within the first few hours 
of detecting them. Although innate cells are classically understood as unable to respond 
with the same specificity as adaptive immune cells, their quick response provides robust 
initial control of an infection, allowing time for the adaptive immune system to be activated 
appropriately. Figure 1.1 provides a brief overview of the innate immune cells. 
     
Figure 1.1. Innate immune cells (adapted from (1)). 




Macrophages are phagocytic cells capable of killing invading pathogens and secreting 
molecules (cytokines, chemokines) to attract and activate other immune cells; 
macrophages, along with dendritic cells, are also responsible for presenting antigen to CD4+ 
T cells to activate adaptive immune responses (1, 2). Neutrophils are granulocytes that aid 
in microbial killing, whereas eosinophils and basophils are the granulocytes involved in 
allergic responses and anti-parasite immunity (2, 3). Mast cells are mainly involved in 
allergic responses (2). Natural killer cells, innate cells derived from a lymphocyte precursor, 
are involved in anti-viral immunity and are able to kill antibody-coated cells via antibody-
dependent cell cytotoxicity (4). 
Despite the classical association of adaptive immunity alone with antigen specificity, more 
recent research investigating the roles of pattern recognition receptors (PRRs) found on 
innate immune cells has suggested this may not be wholly accurate. Toll-like receptors 
(TLRs) can detect pathogen-associated molecular patterns (PAMPs) from a wide array of 
micro-organisms (5), which is now known to occur through activation of either individual 
or combinations of TLRs (6). This stimulated cross-talk between TLRs, or between TLRs and 
other innate cell receptors, yields unique cytokine responses which can also be specific to 
a host cell type (7, 8). The inflammasome in monocytes and macrophages also requires 
activation through differential stimuli, either of TLRs alone or TLRs with an additional 
adenosine triphosphate (ATP) stimulus, which contributes to the specificity of responses by 
these cells (9). Nod1 and Nod2 receptors are able to detect distinct types of peptidoglycans 
in such a way that between these two receptors, all bacteria can be detected; these are 
also molecules which cannot be detected by TLR2 (10). Similar specificity has been 
observed with NK cells. A receptor present on certain NK cells is able to bind a particular 
MHC 1-like protein (thought to be a glycoprotein), resulting in resistance responses 
specifically to murine cytomegalovirus (11-13). Another level of specificity is added by the 
ability of NK cells to respond differently to this pathogen depending on its location within 
the host (14, 15). 
Classically, innate immunity has not been associated with the generation of a memory 
response; however, thinking regarding this point is changing. Trained immunity is the 
observed occurrence that a primary infection can enhance protective responses to 
secondary infection, or to infection with an unrelated pathogen (16). It involves the PRRs, 
is less specific than adaptive immune memory, and it is suggested that epigenetic changes 




underlie this phenomenon, at least in part (16, 17). Hallmarks of trained immunity have 
also been observed with vaccines, with certain vaccines (e.g. BCG) able to induce 
heterologous protection against unrelated pathogens (18, 19). 
1.1.1.2 Adaptive immunity 
The adaptive immune system consists of cells able to respond robustly to foreign particles 
or pathogens upon activation by specific antigens. Adaptive immune responses will only be 
initiated by the innate immune system if the pathogen cannot be controlled, and due to 
the activation process, adaptive immune cells will only contribute to protective responses 
at a later time-point, with the exact timing being dependent on the pathogen. Figure 1.2 
provides a brief overview of the adaptive immune cells. 
     
Figure 1.2. Adaptive immune cells (adapted from (1)). 
Most T lymphocytes (T cells) are either CD8+ T cells or CD4+ T cells. CD8+ T cells, otherwise 
known as cytotoxic T lymphocytes, are involved in anti-viral and anti-tumour immune 
responses (20). The CD4+ T cells have more diverse functions which are dependent on their 
development and the cytokines by which they are stimulated. Broadly, CD4+ T cells are 
classified as either Th cells or Treg cells. Upon stimulation by IL-12/IFNγ, CD4+ T cells will 
polarise to a Th1 phenotype and begin producing IL-2, IFNγ and TNF-β (1, 21). Th1 cells help 
to activate macrophages and their anti-microbial defences, and they also aid in the 
activation of B cells and their antibody production; additionally, they are involved in CD8+ 
T cell activation (21). Following stimulation by IL-4, CD4+ T cells polarise to a Th2 phenotype 
and begin producing IL-4, IL-5, IL-6 and IL-13; these cells are involved in initiating the 
adaptive immune response to allergens and parasites, and they are also able to stimulate 
antibody production by B cells (1, 21). Stimulation of CD4+ T cells by TGF-β and IL-6 yields 
Th17 cells which produce IL-6 and IL-17; these cells are involved in auto-immune responses 
(1, 22). Natural Treg cells develop as such in the thymus, whereas inducible Treg cells 
develop in the periphery in response to antigen stimulation (23). Both types express CD4, 
but are not Th cells. They are activated upon stimulation by TGF-β and produce TGF-β and 




IL-10; they are responsible for the suppression of activation and effector functions of other 
T cells and are also involved in self-tolerance mechanisms (1, 24). 
It is important to note that several classes of non-classical T cells have been identified, two 
of which will be discussed here. A small subset of T cells develops into γδ T cells as opposed 
to αβ T cells (classical T cells), and play a role in immunoregulation, immunoprotection and 
maintenance of tissue integrity (1, 25). These cells are unusual, due to their ability to detect 
antigens not recognized by classical T cells, such as non-protein or soluble protein antigens 
(1, 26). Additionally, their mode of antigen recognition is unique, as they do not require 
MHC binding (1, 25). NKT cells represent another non-classical T cell class. These cells 
express both NK and T cell markers and are reactive to CD1d, an MHC 1-like molecule (27). 
NKT cells are also known as good cytokine producers (27). These cells can respond directly 
to pathogens (e.g. Gram-negative bacteria, spirochetes) by recognizing unusual membrane 
glycolipid molecules, and indirectly by responding to cytokines produced by microbial DC 
activation (28). They have also been implicated in tumour immunology and protective anti-
viral immune responses (27, 29). 
B lymphocytes (B cells) represent the humoral component of adaptive immunity. They 
express MHC II which renders them able to act as antigen presenting cells for CD4+ T cell 
activation, but their major function is antibody production (1). The activation signal 
received by the B cell determines which class of antibody is produced and the different 
antibody classes are located within different regions of the body: IgM is produced by 
mature naïve B cells (not yet class-switched) and is located throughout the body; IgA is 
produced by activated B cells and is found on mucosal surfaces and in breast milk; IgE is 
produced by activated B cells and is found on epithelial surfaces; IgG is also produced by 
activated B cells and is found throughout the body (1). 
Adaptive immune cells also differentiate into memory cells during an immune response; 
these cells are able to circulate throughout the body and will be responsible for initiating a 
more rapid immune response should they ever encounter their cognate antigen again. 
1.1.2 Development of the immune system in utero 
Haematopoietic stem cells, the progenitors of all blood cells, can be detected from as early 
as the third week of gestation (30). At this early stage, these progenitor cells are produced 
by the yolk sac and chorion; from the second month of gestation the liver becomes the 




primary haematopoietic organ, with its cell production only decreasing after the seventh 
month (30, 31). The thymus, which when fully developed is the site of T cell maturation, 
begins to develop by the end of the sixth week of gestation and becomes lymphopoietic by 
the end of the second month (30). The spleen is fully developed by week 8, with it and the 
bone marrow become haematopoietic by approximately weeks 10-11 of gestation (30, 32). 
Large numbers of these progenitor cells can be detected in the foetal circulation by 12 
weeks (33). 
Macrophages are the first of the differentiated leukocytes to be detected, and have been 
identified in foetal liver sections taken at 4.5 weeks old (34). At 4-6 weeks gestational age, 
cells within the mesenchyme and yolk sac, showing dendritic cell morphological features, 
have been identified as expressing monocyte- or macrophage-associated markers (35). 
These cells migrated from their tissues of origin and seeded various primary and secondary 
lymphoid organs (35). Eosinophils are produced in the foetal liver at detectable levels from 
week 5, with their numbers increasing gradually (36). Putative prothymocytes have been 
detected in the liver from week 7, with TCRβ+ cells identified in the liver from week 10 (37). 
T cell precursors have been detected in the developing thymus from week 8.5, with TCRβ+ 
cells increasing from week 9.5 to birth (38); TCRγδ+ cells, although rare, could be detected 
in the thymus from week 10.5 (37). Pro- and pre-B cells can be found in both the liver and 
omentum by week 8, and are being produced in large numbers in the bone marrow by 16-
20 weeks (39). Mature naïve B cells can be detected in the spleen from week 14, and it is 
suggested that these are generated in the liver prior to their maturation (40). A substantial 
proportion of these splenic B cells (measured in weeks 19-22) express CD5 (41), a marker 
of B1-B cells; these cells respond independently of T cells and can produce polyreactive 
antibodies (39). The antibodies IgG and IgM can be detected in the spleen by week 10, with 
their production peaking during weeks 17-18 (39). Serum IgG levels are observed to start 
increasing at an earlier time-point (5.5 weeks) and increased throughout gestation; 
however, it is important to note that maternal IgG is transferred to the infant via the 
placenta and constitutes most of the IgG present at birth (39, 42). IgE can be detected in 
both liver and lung by 11 weeks, and is observed in the spleen by week 21 (43). It is 
interesting to note that at 18 weeks gestational age the spleen contains all of the cells 
required for a robust immune response, and can take part in immune reactions from this 
point onwards (39, 44). Not only are mature leukocytes present in foetal lymphoid tissues, 




but they can also be detected in the circulatory system. In a study of foetal blood samples 
taken in utero between 18 weeks and birth, the proportions of leukocyte sub-populations 
were measured to determine the normal levels of these cells at different points of foetal 
development (45). From 18-29 weeks gestational age, the following proportions were 
observed: lymphocytes comprised 85-88% of the cells present, neutrophils 6-8.5% and 
eosinophils 2-4% (45). From 30 weeks onwards, the proportion of lymphocytes decreased 
to 68.5%, and neutrophil and eosinophil proportions increased to 23% and 5% respectively; 
basophils were consistent from 18 weeks to birth (0.5%), as were monocytes (~3%) (45). 
1.1.3 The immune system at birth 
The robustness of the infant immune system at birth may have been under-appreciated 
previously, but it is clear that even though it may be naïve, the immune system at birth has 
largely completed its development. It is, however, important to note that differences in 
cellular function do exist within the infant immune system as compared to an adult’s. 
Monocytes isolated from cord blood exhibited impaired chemotactic abilities, but normal 
phagocytic and killing capacity when compared to the activity of monocytes isolated from 
adult blood (46). It has also been observed that dendritic cells derived from cord blood have 
an impaired ability to stimulate T cell responses in vitro as compared to adult responses, 
with this impairment suggested to be due to their decreased expression of ICAM-1 (a cell-
adhesion molecule) and MHC I/II (necessary for antigen presentation) (47). Mononuclear 
cells and macrophages isolated from cord blood exhibit impaired in cytokine production 
even with stimulation (48), with decreased levels of TNF-α (49) and IL-4 (50) detected and 
almost no IFN, even though cellular proliferation was not impaired (51). Natural killer cells, 
which fall within the grouping adaptive immune cells, also exhibited decreased cytotoxic 
activity at birth (52). 
T cells have been the focus of numerous studies, due to their fundamental role of utilising 
innate immune signals to activate adaptive immunity when required. Several studies have 
investigated the T cell populations within cord blood in comparison to those populations 
observed in adult blood samples, to identify functional differences yielding either beneficial 
or detrimental effects. Researchers have observed that a large proportion of cord blood 
CD4+ T cells have a naïve phenotype, expressing CD45RA, with fewer effector memory T 
cells detected (48, 53-55). These naïve T cells have been shown to exhibit decreased 
function and cannot be activated to the same extent as adult T cells (48, 56); they also 




express lower levels of the activation markers IL-2 receptor and HLA-DR (54, 57). It has been 
observed that γδ T cells are more prevalent in neonates, and that they exhibit pleiotropic 
responses and IFNγ production (58, 59). This suggests that these cells are better positioned 
for early-life immune protection than the classical T cells described above (59). It is 
important to note that the developing infant’s immune system has a significant 
immunosuppressive T cell component (60). The production of these Tregs is initiated during 
foetal development, and the process yields functionally capable cells able to suppress anti-
maternal responses and the infant’s own T cells (61, 62). The CD4+CD25+ Tregs detectable 
in cord blood are mature but naïve, and their proportions are comparable to adult levels 
(55). 
At birth infants display selective antigen reactivity, with their antigen presenting capability 
developed enough to present alloantigen (39, 63). B cells found in cord blood can be 
classified as naïve but mature, as they can produce IgM, IgA and IgE if stimulated 
appropriately (53, 64). However, as neonates have yet to be exposed to external immune 
stimuli, their cord blood contains low levels of IgM, IgA and IgE, as well as memory B cells 
(39, 53). The IgG levels at birth can be higher than the levels observed in mothers, but most 
of the IgG detectable in cord blood is maternally-derived (39, 42). A closer analysis of the 
available information reveals that infants are born with close to fully functional innate and 
adaptive immunity, with the major limitation being a lack of antigen stimulation to induce 
immune maturation. Thus it can be seen that infants are able to initiate certain immune 
responses from birth, which allows them to combat the vast antigen exposure that is 
initiated at this timepoint. 
1.1.4 Immune system development in early life 
Although the infant immune system at birth is able to initiate immune reactions and 
provide a level of protection, functional differences do exist between immune cells at this 
age and those of older children and adults. Cord blood eosinophils and neutrophils express 
lower levels of the pattern recognition receptor Mac-1, even following stimulation (65), 
rendering these cells less able to respond to pathogens. Both polymorphonuclear and 
mononuclear phagocytic cells exhibit decreased chemotactic capability at birth as 
compared to adult cells (66). Chemotaxis within the mononuclear cells remains below the 
levels observed with adult cells even up until 10 years of age, whilst it remains low within 
the polymorphonuclear cells until 2 years of age (66). Dendritic cells derived from cord 




blood monocytes produce decreased levels of IL-12 and neonatal antigen presenting cells, 
although able to stimulate cell proliferation, are less able to stimulate IL-10 and IFNγ 
production by mixed lymphocytes and purified allogeneic adult CD4+ T cells (67, 68). This is 
accompanied by the finding that mononuclear cells isolated either from cord or peripheral 
blood shows impaired production of IL-12, a cytokine important in Th1 responses (69); this 
impairment was still observed in children of 5 and 12 years of age and was suggested to be 
due to a lack of dendritic cells or an impairment in their function (69). Cord blood-derived 
macrophages exhibit elevated levels of IL-27 gene expression as compared to adults, 
suggesting the presence of higher levels of this immunosuppressive cytokine in neonates 
(70). Neutralisation of this IL-27 resulted in an augmentation of the IFNγ response to the 
BCG vaccine (70), indicating the potential potency of immunological differences between 
infants and adults. Overall, neonatal innate immune cells produce lower levels of IFNγ and 
TNF-α (inflammatory), and higher levels of IL-1β, IL-23 (inflammatory cytokines), IL-6 (both 
pro- and anti-inflammatory) and IL-10 (anti-inflammatory) than observed in adults (71); 
these differences result in a Th2/Th17 immune bias in neonates (71), leaving infants less 
able to respond to intracellular pathogens which generally require a Th1 bias. When 
investigating blood leukocyte cytokine profiles more broadly, it has been noted that the 
production of pro- and anti-inflammatory cytokines increases slowly with age (72). An 
initial upregulation in the production of IL-6, IL-10, TNF-α and IFNγ to levels comparable to 
those observed in adult blood is no longer apparent by 2 months of age (72); however, cord 
blood and neonatal peripheral blood do exhibit higher IL-6/TNF-α ratios than observed in 
adults (73). Natural killer cells develop and mature rapidly after birth, with their activity 
reaching a level comparable to adult cell responses by 1-5 months of age, with their 
proportions in blood suggested to increase with age (52, 74).  
In children followed up from birth to more than 36 months of age, differences in the ability 
of peripheral blood leukocytes to respond to antigen were observed. In children between 
6-13 months, these cells exhibited a selective ability to respond to antigens and were 
unable to present alloantigen (63). From 13-26 months, the cells showed improved antigen 
responses and by more than 36 months of age the antigen responses were equivalent to 
those observed with adult cells (63). As previously mentioned, cord blood CD4+ T cells are 
predominantly naïve. However as age increases, the proportion of naïve CD4+ T cells in the 
blood decreases, accompanied by a concomitant increase in memory CD4+ T cells (74-76). 




Following stimulation, cord blood lymphocytes were able to produce IL-2 but not IFNγ (77). 
Whereas IL-2 levels at birth were comparable to those observed in adults, IFNγ levels only 
reached this point upwards of 3 years of age (77). As with CD4+ T cells, most B cells are 
naïve at birth; from this point their numbers increase, peaking anywhere between 1 and 6 
weeks, only to decrease as age increases further (78, 79). Although some research suggests 
no significant age-associated changes in the proportion of most B cell sub-populations (74), 
it is more likely that the changes are subtle. It has been noted that the proportion of CD5+ 
B cells (B-1 B cells) decreases with age, as does the proportion of immature B cells (74, 78). 
Naïve and transitional B cells detected in peripheral blood also decrease with age, 
accompanied by an increase in IgG+ (switched) and IgG- (non-switched) memory B cells (79). 
By 1 year of age, IgG levels in infant blood have reached approximately 70% of adult IgG 
levels, but IgA only 30% (80). 
The development of a child’s immune system is not limited to any one age, but is rather 
something that occurs progressively over the first years of life. This insight is important 
when considering the potential factors that are able to influence this development, 
whether they be environmental, maternal or due to vaccination; their scope and influence 
should not be underestimated. 
1.2 Factors contributing to altered immune responses in children 
1.2.1 Transfer of maternal immunity to the infant 
An infant receives a wide array of substances from the mother via both the placenta and 
breast milk, including minerals, nutrients and various immune components that aid in their 
protection against environmental factors in the first months or years of life (81). The trans-
placental trafficking of maternal IgG provides the infant’s initial source of protection after 
birth (82). This transport is facilitated by the FcRn, which was first identified in the neonatal 
rat intestine and subsequently in humans (83, 84). The FcRn is also responsible for the 
uptake of IgG from breast milk in neonatal rats (85); since the discovery of its expression 
on cells in the human foetal intestine, it has also been suggested that it is responsible for 
IgG uptake from human breast milk (86). 
Breastfeeding is generally considered to be more protective than formula feeding. In low-
middle income countries, breastfeeding is suggested to play a role in decreasing overall 
infant morbidity and mortality, especially due to diarrheal disease (infectious or not) (87). 




In resource-rich countries, exclusive breastfeeding for at least the first 4-6 months is 
associated with protection against respiratory tract infections (including pneumonia) and a 
decrease in the severity of infections if acquired (88-90). Breastfeeding has even been 
associated with protection against the development of atopic disease in children (91). More 
detailed analysis of the composition of breast milk provides insight into its protective 
capabilities. Breast milk contains a substantial amount of secretory IgA (sIgA), with the 
exact composition of IgA antigen specificities being wholly dependent on the mileu of 
antigens to which the mother has been exposed (82). The abundance of sIgA reflects its 
importance to protection of the infant; it can opsonize and neutralize pathogens, prevent 
adherence of pathogens to host cells and even modulate inflammatory damage stimulated 
by other antibodies (82, 92). Leukocytes are also abundant in breast milk, especially in the 
colostrum, with phagocytic cells being the most prominent, followed by lymphocytes (82, 
93). These phagocytes are fully functional, live cells that are able to kill opsonized 
pathogens (93). Smaller immune mediators have also been detected in breast milk. Both 
pro- and anti-inflammatory cytokines (such as TNF-α, IFNγ and IL-10) have been observed, 
in addition to several complement proteins (94, 95). Not to be neglected are the non-
immune components that exhibit anti-bacterial activity, such as lactoferrin and lysozyme 
enzymes, both of which can inhibit bacterial growth (82). A more recent observation is the 
role of breastfeeding in the establishment of the infant microbiome. The large intestine 
microbiome of breast-fed infants is more commonly colonized by lactobacilli, bifidobacteria 
and bacteria from the Ruminococcus genus (96-98). Formula-fed infants do show higher 
microbial diversity at first, but once breast-fed infants start consuming solid foods, their 
gut microbial diversity also increases (97). These differences in initial microbiome 
colonization are significant; infants at a higher risk for developing atopic sensitization or 
those that went on to develop allergy showed higher levels of colonization by clostridia, 
and lower levels of colonization by bifidobacterial (99, 100). These differences could be 
detected prior to the development of any allergies, which suggests that the composition of 
the infant’s microbiome plays a role in protection against/susceptibility to allergic diseases 
(99, 100). As previously mentioned, it has been suggested that breastfeeding aids in the 
protection against allergic disease; its influence on the microbiome may be a contributing 
factor to the protection that has been observed. 




1.2.2 Nutrition and the infant immune system 
In low-middle income and resource-rich countries, poor maternal nutrition during 
pregnancy is associated with low birth weight of infants (101). This is significant, as low 
birth weight is associated with increased risk of morbidity and mortality in infancy and early 
childhood, especially when socioeconomic disadvantage is involved (102).  Higher numbers 
of deaths due to infectious diseases have been reported amongst adults born in times of 
food shortage (increased prevalence of maternal malnutrition), suggesting that early life 
stressors may still be able to impair immune responses years later (103).  Impaired fetal 
growth has also been implicated in increased susceptibility to tuberculosis later on in life 
(104). Maternal malnutrition limits nutrient availability during fetal development, which 
could in turn alter the transfer of immunity to the infant (105). As our bodies perceive 
malnutrition as a stress factor, it results in increased production of the stress hormone 
cortisol, which could influence the development of the infant immune system if maternal 
levels are raised during pregnancy (105). Research investigating immune function in West 
African children has suggested that there is no measurable defect in certain immune 
responses in children born to mothers who had not received nutritional supplementation 
during pregnancy as compared to those who did (106). However, this could indicate that 
immune programming could be due to something other than early-life immune 
impairment, or that the impairment may only become visible later in life (106). It has been 
suggested that birth weight could affect an infant’s response to vaccination. This is 
supported by research regarding administration of the typhoid Vi vaccine to adults or 
adolescents: in adults, responses to the vaccine correlated positively with birth weight, and 
malnourished adolescents who were also undernourished in utero were less able to 
produce an adequate humoral response to the vaccine (107, 108). This vaccine relies more 
heavily on B cell responses, suggesting that B cell development may be impaired during 
fetal growth retardation (107). 
Micronutrient deficiency and its effect on the immune system is as important to consider 
as macronutrient deficiency, with compounds such as zinc, vitamin A and vitamin D known 
to play a role in the functioning of the immune system (109-112). Zinc acts as both an 
antioxidant and an anti-inflammatory agent and its deficiency has been noted in developing 
countries (113, 114). Zinc deficiency has been linked to immune dysfunction in mice and 
humans, with the development of innate and adaptive cells being affected; it has also been 




implicated in increased susceptibility to different pathogens (110, 113, 114). It has been 
observed in mice that even mild zinc deficiency during pregnancy depresses immune 
function for extended periods of time (115). Due to the potential detrimental effects of zinc 
deficiency on immunity, studies investigating the effectiveness of maternal/early life 
supplementation have been done. Zinc supplementation during pregnancy appears to be 
beneficial to the infant’s immune response and on morbidity due to infectious diseases, 
and supplementation of preschool children significantly lowered the incidence of lower 
respiratory tract infections (116, 117). Vitamin A is a compound involved in innate and 
adaptive immune function, aiding in the appropriate development of Th cells and B cells; 
its deficiency has been associated with alterations in the immune system, such as 
decreased Th2-directed humoral responses and mucosal barrier repair (111, 118). Vitamin 
A supplementation has already been employed during pregnancy and in young children. Its 
use during pregnancy and breastfeeding boosts the production of pro-inflammatory IFNγ, 
which would in turn boost responses to intracellular pathogens, perhaps even in infants 
(119). Administration of vitamin A to children is known to reduce morbidity and mortality 
due to various bacterial and viral infections, particularly mortality associated with measles 
infection (120, 121). Vitamin D uptake generally occurs through exposure to sunlight. Its 
receptor is expressed by various innate and adaptive immune cells, and its activation 
generally results in immunomodulatory effects (112). Knowledge regarding the effect of 
vitamin D deficiency on infectious disease susceptibility in children is limited, although 
more recent research has implicated vitamin D deficiency in childhood TB and 
predisposition to pneumonia (122, 123); in adults it is strongly associated with TB and 
influenza (112, 124). It has been shown that neonatal serum vitamin D levels correlate with 
maternal serum vitamin D levels, and that subclinical vitamin D levels in neonates along 
with non-exclusive breastfeeding result in a higher risk of severe acute lower respiratory 
tract infection in these children (125, 126). The association between maternal vitamin D 
levels and children’s responses to early life stressors in strengthened by the finding that 
vitamin D supplementation during pregnancy was associated with a decreased risk of 
wheeze development in children (127, 128). 
Undernutrition forms one arm of malnutrition, with overnutrition resulting in obesity 
forming the other. Obesity is a world-wide concern, with substantial proportions of both 
children and adults in resource-rich and low-middle income countries considered 




overweight or obese (129). Obesity is often accompanied by a low level of chronic 
inflammation, and a substantial number of children and adolescents exhibit impairment of 
cell-mediated immunity, including decreased bactericidal activity of polymorphonuclear 
leukocytes (130, 131). Obesity has been implicated in susceptibility to nosocomial 
infections, but little information regarding its role in community-acquired infections is 
available; however, more recent research has shown an association with increased severity 
and risk of fatal outcome from an H1N1 influenza infection (132, 133). Maternal obesity 
during pregnancy has been shown to influence neonatal immunity, with cord blood 
exhibiting decreased numbers of eosinophils and CD4+ Th cells, reduced phagocytic cells 
responses and an increase in certain pro-inflammatory cytokines (134). Maternal obesity 
has also been associated with an increased risk of children developing either wheeze or 
asthma but not atopic eczema or hayfever, indicating this susceptibility may or may not be 
due to altered immune responses (135-137). 
1.2.3 Environmental effects on infant immunity 
Once a child is born, he/she is immediately exposed to a barrage of environmental stimuli 
never before encountered, with numerous antigens to which the child’s naïve immune 
system could respond. Therefore, it follows that the environment in which a child lives 
would have a profound impact on the development and responses of the immune system. 
Some of the earliest stimuli encountered are allergens; these are non-pathogenic 
molecules which are generally inhaled and stimulate allergic immune responses in some 
individuals. The sensitization of children to common allergens is particularly prevalent in 
developed countries; for example, in the United Kingdom, North America and Sweden early 
life exposure to house dust mite antigen or birch antigen is associated with the 
development of atopic disease (including asthma) (138-140). Higher concentrations of the 
allergens of interest were associated with earlier wheezing episodes (in the case of asthma) 
or sensitization within the first 3 years of life (139, 140). A closer look at the immune 
response stimulated by sensitization to common allergens revealed higher levels of IL-5, IL-
10 and IL-13, with a correlation between responses to birch antigen and atopic disease 
development being observed (138). Conversely, exposure to certain potential allergens 
during early childhood (potentially at a higher than normal level) can be protective. It has 
been shown and accepted that living on a farm, with exposure to animals and unprocessed 
cow’s milk among other things, is associated with protection against atopic/nonatopic 




asthma as well as other allergies (141). However, stimulation of allergic responses is not 
limited to environmental antigens, but can also be induced by dampness, atmospheric 
pollution and tobacco smoke. A questionnaire study of children living in rural areas of 
Sweden indicated that children living in damp houses with parents who smoked exhibited 
the highest level of bronchial hyperreactivity and allergic asthma; a study with young 
Canadian children also observed an association between wheezing or asthma diagnosis and 
environmental tobacco smoke and damp housing conditions (142, 143). The effects of 
tobacco smoke are not limited to the development of asthma; parental smoking is also 
associated with an increased risk of respiratory illness such as pneumonia, bronchitis or 
tracheitis within the first year of life, with maternal smoking regularly noted as having the 
most significant effect (144-146). As mentioned, pollution may also play a role; a study 
comparing respiratory variables (e.g. asthma) of children living in rural or polluted areas of 
Italy revealed higher frequencies of these variables in the polluted areas (147). This study 
also noted an increased risk of respiratory infection within the first 2 years of life with 
passive smoking, and an increased risk of developing asthma if the child’s parents were 
smokers (147). 
It has long been known that inadequate housing, including inadequate waste disposal, 
water supplies and poor ventilation, as well as overcrowding within these houses, leaves 
individuals more susceptible to health problems (e.g. infectious diseases). Due to the 
seriousness of this problem, the World Health Organization even released “Guidelines for 
Healthy Housing” in an attempt to rectify the situation (148). These problems occur most 
frequently in low-middle income countries, or in regions of countries where socioeconomic 
disadvantage is apparent.  Several studies in Brazil have revealed that an increased risk of 
illness or death resulting from respiratory infection are associated with (amongst other 
things) crowding, low socioeconomic status and poor sanitation (149, 150). In Kenya, an 
increased risk of lower respiratory infection was positively associated with the number of 
siblings; a higher number of siblings would be indicative of children living in crowded 
conditions (151). The link between crowded living conditions and respiratory infection are 
not only a recent occurrence. Data gathered in the United Kingdom in the late 1940s also 
revealed that infants born to families of a lower social class and who lived in crowded 
conditions were at a higher risk of developing respiratory tract infections such as 
pneumonia (152). Overcrowded living conditions are not only associated with an increased 




risk of respiratory infection; children in India with severe community-acquired pneumonia 
and living in such conditions required longer hospital stays and changes in their antibiotic 
treatment (153). Although overcrowding is detrimental in some cases, it appears beneficial 
in others. In several instances, it has been shown that either living in crowded conditions 
or having more siblings was associated with a decreased prevalence of asthma or atopic 
sensitization (149, 154, 155). The converse of this has also been shown; children in 
Bangladesh living in a household with fewer individuals exhibited a significantly higher 
prevalence of asthma (156). 
In low- and middle-income settings across the world, there is a high burden of diarrheal 
disease due to inadequate water supply, sanitation and hand hygiene (157). Diarrheal 
disease has been a severe burden in low-middle income countries for a long time, often 
being caused by enteric pathogens in animal excrement, as well as contaminated food and 
water sources. In several low-middle income countries it has been noted that water and 
food utilized by families, including weaning food, were contaminated with bacteria at a 
level higher than is internationally considered “safe” (158-160); use of contaminated food 
or water regularly leads to diarrheal episodes. Inadequate water and sanitation do not only 
result in diarrheal disease, but also parasitic disease. An estimate of global disease burden 
due to inadequate water, sanitation and hygiene measures showed that diseases such as 
diarrhea, schistosomiasis, trichuriasis, ascariasis, and hookworm infection were 
responsible for the majority of deaths worldwide (1999-2000) (161). As concerning as this 
is, the occurrence of these diseases is largely preventable. It has been shown that exclusive 
breastfeeding (i.e. avoiding exposure of the infant to contaminated food and water) can 
provide significant levels of protection against diarrheal disease, even without proper 
sanitation; the only measure with a stronger effect than breastfeeding was access to clean 
water within the house (162).  Meta-analyses of data from numerous countries have also 
shown that improved water, hygiene and sanitation measures significantly reduce the risk 
of and morbidity associated with diarrheal and parasitic diseases (163, 164). It was also 
noted that child mortality also fell drastically once appropriate water and sanitation 
measures had been implemented (163). 
The environmental factors mentioned are not an exhaustive list; even so, it is evident that 
environmental factors have a profound impact on the developing immune system. In some 




instances, the undue strain imposed by these stressors on the immune system may even 
result in longer lasting effects on the immune system than is currently known. 
1.3 Childhood infection and vaccination 
1.3.1 The importance of vaccination 
The initial naivety and continual development of children’s immune systems renders them 
more susceptible to infectious diseases. Although the global under-5 mortality has 
decreased significantly since 1990, diseases such as pneumonia, diarrhoea and malaria still 
pose a significant threat to infant health in the absence of appropriate health care 
interventions (165-167). The above-mentioned diseases, as well as measles, sepsis and 
meningitis cause severe morbidity and mortality in neonates and children less than 5 years 
old; the most significant illness burden is carried by low-middle income countries, 
especially in sub-Saharan Africa and South Asia (165, 168, 169). Acute respiratory 
infections, including pneumonia, are also commonly observed in children younger than 5 
and are often caused by viruses; again, low-middle income countries carry the greatest 
burden of these infections (170). 
Despite the continuing problem of these illnesses in children, the situation would be far 
more dire if not for the Expanded Programme on Immunisation implemented by the World 
Health Organisation in 1974 (171). This was established to widen the global administration 
of life-saving vaccines and the strategy has proved successful; global vaccination coverage 
is currently stable at 86% and 2-3 million deaths are prevented annually (171, 172). 
However, greater efforts are required to ensure continued success; increased coverage 
could prevent a further 1.5 million deaths, and 19.5 million infants globally still do not 
receive these vaccines (172). Most vaccines administered to children provide more than 
70% protection against the causative agents of disease, with a substantial proportion 
providing upwards of 90% protection (173). The one exception is BCG, which is known to 
provide variable levels of protection (0-80% depending on the study and region 
investigated) (173). The higher prevalence of vaccine-preventable diseases in areas such as 
sub-Saharan Africa, where vaccine coverage is known to be lower, indicates their overall 
success (173). 
Neither the importance of vaccination nor the severity of vaccine-preventable diseases 
should be underestimated. A decrease in vaccine coverage in developed countries has led 




to outbreaks of diseases such as measles and pertussis (174-178). Pertussis outbreaks have 
been linked to both waning immunity and decreased vaccine coverage (175, 176), but 
measles outbreaks are almost solely attributable to decreased vaccine coverage, with a 
substantial influence of parental refusal to vaccinate children for nonmedical reasons (176-
178). An important point to note is that refusal to vaccinate not only affects those 
individuals, but also those that cannot be vaccinated due to their age or medical reasons 
(177, 178). Mina and colleagues (179) demonstrate further why vaccine-preventable 
diseases should not be underestimated. They demonstrated that the immunomodulatory 
effect of measles infection (not vaccination) on the immune system was present for longer 
than originally thought (179). More significantly, this effect resulted in increased mortality 
due to unrelated infections acquired after measles; this effect can be avoided by 
vaccination (179). 
1.3.2 T cell-dependent versus T cell-independent responses 
The heterogeneity of pathogens targeted by the EPI necessitates unique immune responses 
to be elicited by these vaccines; as such, it is important to note the different paths of 
immunity stimulated by different antigen types. Antigens that are able to stimulate the 
adaptive immune response can be broadly classified as T cell-dependent or T cell-
independent. T cell-dependent antigens are proteins or those expressed on 
cells/pathogens (180). These proteins need to be processed by antigen presenting cells and 
presented on MHC II molecules to CD4+ T cells; once activated, these Th cells activate the 
correct antigen-specific B cells to proliferate and produce antibodies (180-182). A 
proportion of these activated B cells, located in germinal centres in the lymph nodes or 
spleen, will differentiate to form memory cells (182). T cell-dependent protein antigens are 
often those used in subunit vaccines. However, these proteins alone are unable to elicit 
protective immunity due to the lack of CD4+ T cell stimulation by activated APCs (183). In 
the case of subunit vaccines, this prerequisite activation of the innate immune system is 
performed by adjuvants such as alum; modern adjuvants take into account the necessity 
of robust T cell responses for protection against certain diseases (e.g. TB) by including 
agonists for specific innate immune receptors (e.g. TLRs) (183, 184). T cell-independent 
antigens are categorised either as type 1 or type 2. Type 1 antigens are generally capsular 
polysaccharides linked to lipids (e.g. LPS); they bind to TLRs, and via TLR signalling they 
stimulate polyclonal B cell responses (180, 181). Type 2 antigens are polymers, e.g. 




polysaccharides or polynucleotides; these molecules bind directly and specifically to the 
BCR and are able to induce memory B cell formation (180, 181). It is important to note that 
linking a T cell-independent polysaccharide to an immunogenic carrier protein can 
stimulate a T cell-dependent response, resulting in an earlier peak of antibody production 
and earlier protection; such a time difference is crucial when considering invasive bacterial 
infection in children (180). 
Vaccines licensed for use in humans fall into 2 categories: live attenuated and subunit 
vaccines. As live attenuated vaccines contain whole pathogens, they would be able to 
stimulate either T cell-dependent or T cell-independent responses (or both), depending on 
the immunogenic antigen type. Subunit vaccines consisting of polysaccharide alone would 
stimulate T cell-independent response, whereas those containing protein or protein-linked 
polysaccharide would elicit T cell-dependent responses. Live attenuated vaccines are 
considered the gold standard, as they most accurately mimic natural infection and induce 
life-long immunity (185). Subunit vaccines, on the other hand, are generally adjuvanted to 
induce longer-lasting immunity, and are generally administered several times to boost and 
strengthen the primary response (185). Vaccines on the South African EPI that fall into the 
live attenuated category are oral polio, BCG, rotavirus and measles; those that fall into the 
subunit vaccine category are the pneumococcal conjugate vaccine, Haemophilus influenzae 
type B, hepatitis B, the tetanus and diphtheria toxoids and acellular pertussis. All of these 
vaccines are known to induce protective antibody responses, with these responses used as 
the correlates of protection against infection (186). Generally, the understanding has been 
that Th cell stimulation of B cells is required to generate protective and long-lived immunity 
to foreign antigens. However, it is important to note, especially in the context of the above-
mentioned subunit vaccines, that T cell-independent antigens can induce the same effects 
in B cells (187-190). 
1.3.3 The role of cell-mediated immunity in vaccine responses 
As alluded to above, the success of most of the vaccines currently in use resides in their 
ability to induce protective antibody responses, and stimulate the formation of memory B 
cells that could target future infections; as noted above, these protective responses cover 
a wide array of pathogens (191). However, several diseases for which wholly successful 
vaccines have yet to be found require robust T cell responses for the pathogens to be 
cleared by the host. 




It has been observed that numerous viruses which cause either acute or chronic infection 
(with vaccines licensed for some of them) require either an antibody response, a cell-
mediated response or a combination of both for successful clearance (192). The influenza 
virus is an example of an infection that requires a combination of cellular and humoral 
immunity; although humoral immunity is essential in protection against the virus, cytolytic 
CD8+ T cell responses are required for viral clearance once infection occurs (193). It has 
been documented that humoral responses wane in older individuals, and that the success 
of an influenza vaccine in these individuals is linked to robust T cell responses rather than 
the humoral response (194). Several types of influenza vaccines are available, but the 
introduction of a vaccine that is able to induce humoral and cellular immunity may provide 
longer lasting immunity, especially when used in combination with more commonly used 
vaccines able to induce robust humoral immunity (193). It is well-known that measles 
vaccination induces protective, long-lived humoral immune responses, but the role of cell-
mediated immunity in response to vaccination should not be neglected. Although robust 
humoral immunity is required to prevent infection, both CD4+ and CD8+ T cells are required 
for viral clearance once infection has occurred, and for the establishment of the long-lived 
memory B cells (195). These T cells are also able to control a measles infection even in the 
absence of antibody (195). Administration of the measles vaccine has been delayed due to 
the interference of maternally-derived antibody; however, early administration (6 months) 
of the vaccine is able to prime measles-specific T cells (196-198). Although the response 
induced was not as robust as observed in adults (196), it was equivalent to cell responses 
measured in older children (197). Early administration of the vaccine may not induce a 
sufficient humoral response, but primed T cells could improve responses to booster 
vaccination (198). 
The importance of cell-mediated responses in vaccine-induced immunity are not limited to 
viral infections. In a comparative study of children vaccinated with acellular pertussis and 
those not vaccinated (with/without history of infection), cell-mediated responses were 
observed more frequently in vaccinated children (199). Humoral responses are also 
required for pathogen clearance, and serum antibody to pertussis toxin was more readily 
detectable in vaccinated children and those with a history of infection (199). Humoral 
immunity to Bordetella pertussis is known to wane without booster vaccination; this is 
accompanied by waning of the cell-mediated immunity in some children (200). An 




interesting observation is the increase of cell-mediated immunity in some children, which 
suggests that cell-mediated responses to this pathogen can be acquired naturally simply 
through exposure to the pathogen (200). 
It is well-established that a robust T cell response (in both the CD4 and CD8 arms) is 
required for the control of Mtb, so it follows that a successful vaccine against Mtb would 
be able to induce long-lived memory T cell responses in addition to a humoral response 
(201). The only vaccine currently licensed for use against Mtb is Mycobacterium bovis 
bacille Calmette-Guérin, which is used to protect against disseminated forms of TB in 
infants; it’s protection against pulmonary tuberculosis varies greatly and is dependent on 
age, location and exposure to environmental mycobacteria (202). Information on the 
mechanisms through which BCG affords protection is rare; however, a study investigating 
the immune response to BCG in young infants revealed its ability to induce robust CD8+ T 
cell responses, and whole blood stimulation revealing high levels of IFNγ or IL-10 
production (203). A recombinant BCG vaccine, designed to facilitate release of BCG into the 
cytosol and in turn activate CD8+ T cells through MHC I, provided greater levels of 
protection against Mtb infection in mice as compared to standard BCG (204). 
Administration of an adjuvanted Mtb fusion protein (Mtb72F) was able to stimulate robust 
CD8+ T cell responses and IFNγ production; it also provided a level of protection against 
virulent Mtb comparable to standard BCG (205). Antigen 85A, an immunogenic protein 
secreted by Mtb, when administered as part of a modified vaccinia virus Ankara vector, can 
stimulate the proliferation of antigen-specific T cells; it also boosts the levels of IFNγ-
secreting antigen-specific T cells in BCG-vaccinated individuals (206). Despite the 
preliminary success of some novel TB vaccines, these findings do not always translate to 
the larger population (207). It should also be noted that although the strain of BCG used 
may not affect efficacy of the vaccine (202), the responses induced by the vaccine are 
strain-dependent (208). 
It is apparent that the role of cell-mediated responses in immunity induced by vaccination 
should not be underestimated; rather, the potential benefits of designing vaccines to 
stimulate cell-mediated responses in addition to humoral responses should be considered. 




1.4 Mycobacterium tuberculosis infection and active disease 
Infection caused by Mtb, along with active tuberculosis disease represent one of the 
greatest global infectious disease burdens; cases in South Africa represent a substantial 
contribution to this burden (Fig. 1.3) (209). A major contributing factor to this high TB 
burden, is TB-HIV co-infection. In KwaZulu Natal, a province of South Africa, approximately 
80% of individuals with active TB have HIV co-infections, and increased TB case fatality rates 
have been observed in populations with high HIV prevalence, e.g. sub-Saharan Africa (210, 
211). Another point of concern in South Africa is the increasing incidence of drug-resistant 
tuberculosis, as treatment success rates and long-term outcomes for patients are poor 
(211, 212). Adding to this concern is the knowledge that, as previously mentioned, 
protection induced by BCG to Mtb infection and active TB disease is highly variable (202, 
213-216). This highlights the importance of further drug and vaccine development if this 
disease is to be brought under control.  
  
Figure 1.3. Estimated global TB incidence and mortality rates for 2016 (209). 
1.4.1 The role of the immune system in Mtb infection and active TB disease 
Upon inhalation and entry into the lung, Mtb bacteria infect and activate alveolar 
macrophages (217). Whilst some of the macrophage killing mechanisms remain functional 
and able to kill the bacteria, such as the activity of NOS2 (218), the ability of this pathogen 
to manipulate its environment to avoid killing has also been well-documented. One of the 
most well-known methods it employs is prevention of phagosomal maturation and 
phagolysosomal fusion (219-221). Experiments performed with M. avium revealed that 
although lysosomal protein LAMP-1 could still be identified on the phagosomal membrane, 
the protein required for acidification of the phagosome, ATPase, could not be detected 
(219). This is not to suggest that the cells are defective. Alveolar macrophages isolated from 
TB/HIV co-infected individuals were capable of phagocytosis and phagosomal acidification, 
but once the phagosomes contained Mtb, they were no longer able to acidify (222). The 




delay in phagosomal maturation and decreased bacterial killing can be overcome by the 
induction of autophagy (223). However, it has been observed that phagolysosomal fusion 
in the presence of Mtb does occur in both dendritic cells and macrophages, but that the 
bacteria can subsequently escape into the cytosol (224). This process is Mtb-specific, 
requires the production of the virulence factors CFP-10 and ESAT-6 by the live bacteria, and 
induces death of the host cell (224). This induction of apoptosis is important to note, as 
alveolar macrophages isolated from individuals with active TB exhibit higher levels of 
apoptosis than those isolated from controls, suggesting this process as advantageous for 
bacterial survival (225). Another method the bacterium employs to survive within host 
macrophages, is to enhance superoxide burst and decrease lipid metabolism within the 
cells via TLR2/4 signalling, a process suggested to provide nutrients for the bacteria (221). 
The establishment of an infection within the macrophages induces a host Th1 response 
largely directed against secreted antigens, with IFNγ and TNF-α identified as two of the 
important cytokines in this protective response (217). Mtb and BCG infection have been 
shown to induce the production of TNF-α, IL-12 (induces IFNγ production) and IFNγ by 
macrophages and dendritic cells (226-229). Additionally, dendritic cells exhibit upregulated 
MHC I expression following Mtb infection, which would be required for antigen 
presentation to CD8+ T cells as the infection progresses (227). The absence of IL-12 leaves 
mice unable to control Mtb infection, and reduces T cells activation and granuloma 
formation (230). Conversely, IL-12 administered to susceptible mice reduces bacterial 
burdens and improves survival times; it is important to note that these protective effects 
also required the action of IFNγ (231). Disruption of TNF-α production or its action via its 
receptors is detrimental to survival in a murine model of Mtb infection, and interferes with 
control of the infection (232). The importance of TNF-α for the control of Mtb infection in 
humans has also been highlighted through the use of TNF-α antagonists (e.g. Infliximab) 
used in the treatment of certain autoimmune disorders (233, 234). It has been observed 
that such treatment is associated with an increased risk of developing TB, suggesting an 
important role for TNF-α in controlling Mtb infection in a latent state (233, 234). The effect 
of its absence on granuloma formation is not fully agreed upon, but its lack has been shown 
to induce necrosis, the starting point of bacterial dissemination (232, 235). The presence of 
fully functional macrophages and T cells (CD4+ and CD8+), but abnormal granuloma function 
in the absence of TNF-α, has been suggested as an indication of its role in granuloma 




formation rather than cellular activation (235). Further support of this is the finding that 
TNF-α produced by human T cells stimulated macrophage aggregation, the first step in 
granuloma formation (236). The importance of IFNγ in control of Mtb infection was shown 
convincingly through studies of its disrupted function. In a murine model, mice unable to 
produce IFNγ rapidly succumb to infection; they are able to stimulate granuloma formation, 
but could not produce reactive nitrogen species and could not restrict bacterial growth 
(237). Similarly, individuals lacking IFNγ receptors either in full or in part, leave them more 
susceptible to mycobacterial infection, even with poorly pathogenic species, and decreases 
their macrophage TNF-α production (238, 239). Human cells have also been shown to 
produce the regulatory cytokine IL-10 in response to Mtb infection (236, 240). It has been 
implicated in the suppression of protective Th1 responses, as its neutralisation in PBMC 
samples obtained from TB patients resulted in increased levels of IFNγ production due to 
the presence of increased IL-12 (240). However, disruption of the IL-10 (or IL-4) gene in 
mice did not confer a greater level of protection against Mtb infection (241). 
In murine models, both CD4+ and CD8+ T cells have been observed in lung tissue soon after 
Mtb infection, with their numbers peaking at week 8 (242-244). Both cell types are able to 
produce IFNγ in mice and humans, with human T cells also observed as TNF-α producers 
(236, 242-245). Protective murine IFNγ-secreting CD4+ T cells are also able to recognise 
antigen presented by macrophages (242). Cytotoxic CD8+ T lymphocytes can also be found 
in mouse lungs during Mtb infection, lysing macrophages via MHC I-dependent perforin 
expression (246). Additionally, T cells adoptively transferred from BCG-vaccinated mice to 
Mtb-infected mice conferred protection against the infection (247). Depletion of functional 
CD4+ or CD8+ T cells renders mice more susceptible to infection and causes necrosis within 
granulomas (248-250). It has been suggested that the loss of either cell type is associated 
with increased bacterial growth (249), or that a lack of control  is only observed in the 
absence of CD4+ T cells (and that CD8+ T cell absence enhances control) (251). Whatever 
the immunological effect of CD8+ T cell depletion, mice lacking CD8+ T cells still succumb to 
Mtb infection earlier than wild-type mice (249, 251). Even though mice lacking CD4+ T cells 
can control the initial infection due to recruitment of and IFNγ production by CD8+ T cells 
and NK cells, CD4+ T cells are suggested to be the cells generally responsible for early IFNγ 
production (250, 252). CD4+ T cells have also been implicated in the normal formation of 
granulomas, a process crucial for long-term bacterial containment (252). 




As alluded to already, the formation of granulomas to contain an Mtb infection represents 
an integral part of the protective host response. Initially, cytokines (as discussed above) 
activate macrophages and initiate granuloma formation within the lung (217). The bacteria 
are able to survive within macrophages, which aggregate at the centre of the granuloma; 
the remainder of the structure consists of dendritic cells, multinucleated giant cells, 
lymphocytes and fibroblasts (253-255). The lymphocytes (including CD4+ T cells, CD8+ T cells 
and B cells) form the outer layer of the granuloma, and a proportion of these cells will be 
closely associated with it (Fig. 1.4) (256). Intracellular bacteria contained within the 
granuloma are still able to recruit uninfected macrophages, which will phagocytose 
apoptotic infected cells and in so doing, aid in dissemination of the infection (257). 
Interestingly, it has been observed that whereas the centre of the human granuloma is 
considered pro-inflammatory (containing anti-microbial peptides and reactive oxygen 
species), the region immediately surrounding the central caseum is anti-inflammatory 
(258). Once the infection has been appropriately controlled as described, it enters latency, 
with bacteria able to survive for long periods of time within the granulomas. As infection 
progresses, the induction of Tregs and IL-4 has also been observed (217). Treg induction 
has been observed in individuals with active TB, and these individuals had higher numbers 
of these cells than healthy controls who responded to PPD testing (259, 260). These Tregs 
appear to contribute to the suppression of Th1 responses, as their depletion resulted in 
increased numbers of Mtb-specific IFNγ-producing T cells, and increased IFNγ production 
by T cells (259, 260). 
    
Figure 1.4. Schematic representation of a TB granuloma (adapted from (261) and (256). 




1.4.2 Latent Mtb infection versus active TB disease 
Even though an Mtb infection is often not eradicated, it can be controlled so effectively 
that only 5-15% of latently infected immunocompetent individuals will develop active TB 
disease during their lifetime (262, 263). However, any cause of dysregulation of the 
immune response controlling the infection (e.g. HIV infection) can cause reactivation, 
resulting in a productive infection that can be spread from caseating granulomas (255). 
Individuals that progress to active TB appear to have suppressed protective responses and 
increased regulatory responses. Patients with active TB, but that were unresponsive to PPD 
stimulation have IL-10-producing but not IFNγ-producing T cells following in vitro 
stimulation, whereas non-anergic patients with active TB had T cells producing both 
cytokines (264). The production of IFNγ by PBMCs from active TB patients (with or without 
HIV infection) is suppressed, as is proliferation of the PBMCs themselves; conversely, the 
production of regulatory cytokines TGF-β and/or IL-10 has been noted (265-268). 
Individuals that were followed up post-treatment revert to normal levels of TGF-β and IL-
10 production, whereas IFNγ production remains depressed for at least 12 months (265). 
Neutralisation of these regulatory cytokines improves cellular proliferation, suggesting a 
role for these molecules in suppression of protective Th1 responses during active TB (267, 
268). Increased levels of apoptosis have also been observed in patients with active TB, 
which could result in the loss of cells required for protection against Mtb (269, 270). 
1.4.3 The role of effector and memory T cells in immunity to Mtb 
Effector and memory T cells have an important role to play in secondary immune responses 
through both cytokine production and stimulation of other immune cells (271), resulting in 
a rapid response to the invading pathogen. As Mtb is an intracellular pathogen and T cell-
mediated immunity is necessary for its control, it follows that memory T cells would be 
involved in long-term control of Mtb. In murine models the induction of long-lived, 
multifunctional memory CD4 T cells by vaccination has been observed, with these cells able 
to protect against subsequent Mtb challenge (272). Further research suggests that these 
may be central memory (CM) T cells (273). Additionally, memory CD4 T cells transferred to 
nude mice, which lack T cells, could confer protection against Mtb infection in these mice 
(274). Activated memory CD4 and CD8 T cells are able to initiate rapid IFNγ production in 
the lungs following a challenge infection, a finding not observed with primary infection 
(275); this is indicative of their importance in long-term mycobacterial control. In the 




clinical setting, it is beneficial to consider the specificity, function and phenotype of 
memory cells isolated from latently infected individuals, as latency is associated with 
control of the pathogen. Regarding specificity, a genome-wide analysis of Mtb-specific 
epitopes recognised by memory Th1 cells from individuals with latent Mtb infection (LTBI) 
revealed large-scale specificity for antigens within bacterial secretion systems (276). 
Functionally, protective memory T cells are associated with the Th1 phenotype. Circulating 
PPD-responsive T cells isolated from healthy individuals were able to produce both IL-2 and 
IFNγ, with these observations remaining constant over a period of 6 months (277). An 
investigation of T cells in different stages of tuberculosis revealed that latent infection, 
minimal TB disease and decreased bacterial burden were associated with higher numbers 
of circulating ESAT-6-specific IFNγ-secreting CD4 T cells (278). Conversely, culture-positive 
active disease was associated with lower numbers of these cells (278). Several studies have 
investigated the phenotype of memory T cells detected during LTBI and active TB disease, 
but it remains unclear which memory T cells are most protective. Some research points to 
an association between CM CD4 T cells and LTBI, whereas active TB disease or risk factors 
for active disease may be associated with an effector memory (EM) CD4 T cell phenotype 
(279-281). This association suggests that CM CD4 T cells are the more protective phenotype 
(279, 280). However, this does not always appear to be the case. With CD8 T cells, the 
predominant phenotype is suggested to be EM, with differences in the differentiation state 
of these EM CD8 T cells being the feature associated with disease state (282). Additionally, 
a study of healthy individuals who had been treated for TB decades prior to investigation 
revealed the presence of long-lived, antigen-specific EM CD4 T cells, suggesting that in 
some cases, EM cells may play a role in protective responses against Mtb (283). It is also 
important to note that the protection they provide may not always be long-lived. In mice, 
it has been shown that EM and CM CD4 T cell responses induced by primary infection 
protect against the initial stages of Mtb re-infection, but that their numbers begin to wane, 
resulting in loss of pathogen control (284). These findings highlight the importance of 
memory T cells in protective responses to Mtb, which provide some guidance for vaccine 
design. However, the understanding of how to induce these cells to ensure protective 
functions and longevity is still not complete. 




1.4.4 The role of B cell immunity in Mtb infection 
The field of TB immunology has been dominated by elucidating the nature of protective 
cell-mediated responses, and the role of B cells in anti-Mtb responses has largely been 
neglected. However, there is increasing evidence suggesting the importance of humoral 
immunity in TB, and that antibody induction by vaccines may be beneficial (285). Murine 
studies have revealed a protective effect of passively administered Mtb-specific antibodies. 
Passive administration of a lipoarabinomannan (LAM)-specific IgG1 antibody affords 
protection against Mtb infection as indicated by reduced bacterial burden and weight loss, 
and increased survival (286). An arabinomannan (AM)-specific IgG3 antibody has also been 
shown to provide moderate protection against Mtb infection, causing bacteria to localise 
to the granuloma centre (287). Additionally, an IgA antibody specific for Mtb α-crystallin 
administered intranasally resulted in significantly reduced bacterial burdens (288). 
However, antibody protection is not limited to passive antibody administration. A BCG 
booster vaccine containing a combination of Mtb-specific antigens, Ag85A-ESAT-6, caused 
a reduction in bacterial burden and resulted in significant increases in serum 
immunoglobulin and bronchoalveolar lavage (BAL) IgA (289). The use of AM conjugate 
vaccines has also proven useful, with induction of specific IgG responses and protection 
against subsequent Mtb challenge (290, 291). It has also been shown that a lack of either 
inhibitory or stimulatory antibody receptors (FcRs) can influence Mtb infection. A lack of 
the inhibitory receptor FcγRIIB resulted in decreased bacterial burden and lung 
inflammation, but a lack of stimulatory FcγRs had the opposite effect (292). Studies utilising 
B cell knockout mice yielded contradictory findings regarding the role of B cell in TB. One 
study revealed that a lack of B cells resulted in increased bacterial burden and lung 
pathology (293), whereas a lack of B cells in early infection delayed bacterial dissemination 
and decreased lung inflammation (294). However, these findings may suggest differing 
roles for B cells at different stages of Mtb infection, and may depend on the strain of Mtb 
used for infectious challenge. 
Several studies have reported on the presence of mycobacterial-specific antibodies and 
their potential role during infection and/or disease. BCG vaccination is known to induce 
antibody production, with IgG1, IgG2 and IgG3 considered the predominant subtypes (295); 
it has also been observed to induce AM- and LAM-specific IgG (296, 297). Numerous studies 
report raised levels of Mtb-specific antibody, often against AM or LAM and of various 




subtypes (mainly IgG), in patients with LTBI or active TB disease as compared to healthy 
controls (298-303). As active TB disease occurs as a consequence of dysregulated immunity, 
the presence of raised Mtb-specific antibodies during active disease can be considered 
detrimental and may be involved in disease progression (303, 304). However, often Mtb-
specific antibodies, whether from LTBI or active TB individuals, are suggested to be involved 
in the enhancement of protective cell-mediated responses. Mtb-specific antibodies have 
been associated with enhanced phagocytosis (300), phagosomal maturation (300, 305), 
classical complement activation (302), intracellular bacterial killing (305) and bacterial 
neutralisation (306). Additionally, it has been suggested that increased antigen-specific 
antibody could be associated with a reduced risk of developing TB disease, as children who 
developed TB disease exhibited significantly reduced IgG responses to Ag85A as compared 
to children who did not develop active disease (307). 
The immune response induced by Mtb infection and active disease is complex and is not 
yet fully understood. A more complete understanding of the protective immune responses 
to Mtb would aid the control of this pandemic through improved drug and vaccine design, 
as well as through potential immunotherapy treatments. Additionally, the recent evidence 
suggesting an important role for humoral immunity in the protective immune response to 
Mtb warrants further investigation, as it could better direct the vaccine design approach. 
1.4.5 Mtb infection and active TB disease in children 
Children younger than 13 years were shown to contribute 13.7% of the total TB burden in 
a South African community (308), and a wider investigation of 22 high burden countries 
predicted the proportion of childhood TB contributing to total TB burden as 4-21%, 
depending on the country (309). Dodd et al also showed that, in 2015, approximately 240, 
000 children younger than 15 years died of TB worldwide, with 80% of these deaths being 
children younger than 5 years (310). As such, TB falls within the top-ten causes of death in 
children worldwide (310). A primary Mtb infection in young children often progresses to 
serious disease within a year (311), which is accompanied by increased TB-associated 
mortality rates (312, 313). Young children generally do not present with bacteria in sputum 
samples (311), and are at the highest risk of developing disseminated forms of the disease 
(miliary TB, TB meningitis) (312, 314, 315). Children with acute TB disease have also been 
shown to exhibit impaired T cell function (316). 




Several suggestions have been made as to the cause of altered and more severe disease in 
young children, with the consensus being that the immune system has not yet developed 
appropriately to combat Mtb successfully. It is known that dendritic cell immunity is under-
developed in young children, with fewer cells detected in the circulatory system and 
downregulated IL-12 production observed (69, 317). Although chemotaxis is often 
downregulated (66, 318), the functional properties of monocytes, phagocytes and 
monocyte-derived macrophages in infants are similar to those of equivalent adult cells 
(319, 320). Conversely, neonatal alveolar macrophages exhibit impaired chemotaxis and 
reduced killing capacity (321, 322). It is also accepted that infant immunity is Th2-biased 
and that Th1 functionality is reduced (323, 324). This may have an influence on protective 
Th1 immunity to TB, as young children produce significantly lower amounts of IFNγ 
following T cell stimulation with mycobacterial antigens (325), and have an increased rate 
of indeterminate results with an Mtb-specific T cell IFNγ-release assay (326). Although such 
impairments could have a significant effect on an infant’s ability to mount a protective 
response to Mtb, it is important to note that Th1 responses are not completely impaired, 
as BCG vaccination and exposure to a household TB contact can result in robust IFNγ 
responses (327, 328). 
There is no doubt that Mtb infection and active TB disease in children, and the immune 
responses elicited are not fully understood. Considering the significant contribution of 
childhood TB to the global TB burden, further investigation of TB immunity in children is 
essential. 
1.5 Soil-transmitted helminths 
As with tuberculosis, soil-transmitted helminths are a global health concern, with 
approximately 2 billion individuals infected worldwide (329). Three of the most common 
infections are with Ascaris lumbricoides (human roundworm), Trichuris trichiura (human 
whipworm) and Necator americanus/Ancylostoma duodenale (human hookworms) (329). 
Importantly, ascariasis, trichuriasis and hookworm infection occurring in sub-Saharan 
Africa contribute substantially to the global burden of these diseases (330). Infections with 
these intestinal parasites are commonly encountered in children, and often exist as co-
infections (331). 




1.5.1 The helminth life-cycles and disease in humans 
A. lumbricoides causes infection via the faecal-oral route (332). Following the ingestion of 
eggs, hatched larvae migrate to the lungs via the liver (332). Once in the lungs, larvae are 
coughed up and swallowed, after which they migrate into the small intestine where they 
develop into adult worms (Fig. 1.5A) (332). Infection with A. lumbricoides may result in 
disrupted nutrient processing and uptake, which could in turn contribute to malnutrition, 
especially in children (333). High infection levels often result in intestinal blockage in 
children, and via migration to biliary ducts or the appendix, the parasites may cause 
hepatobiliary/pancreatic ascariasis or appendicitis (334, 335). As such, a high helminth load 
often requires surgical intervention for parasite removal (334, 335). As mentioned above, 
A. lumbricoides larvae have a lung migratory phase. As they migrate through the lung tissue 
they may cause mild respiratory symptoms and eosinophilia, a condition known as 
Loeffler’s Syndrome (336-338). The human hookworms N. americanus and A. duodenale 
have a lung migratory phase as part of their lifecycles. Infective hookworm larvae penetrate 
the skin and migrate to the lung once in the host’s circulatory system (339). Larvae are then 
coughed up and swallowed, after which they migrate to the small intestine and develop 
into adult worms (339). These adult worms burrow into the intestinal wall to gain access to 
the host’s circulatory system (Fig. 1.5B) (339). Hookworm infection has been shown to 
induce eosinophilia and gastrointestinal discomfort (340), and has also been implicated in 
stunted growth of school-age children (341). However, the most common morbidity 
associated with hookworm infection is anaemia resulting from intestinal blood loss, which 
can have far-reaching effects (339, 342, 343). 
As with A. lumbricoides, T. trichiura eggs are ingested via the faecal-oral route, but unlike 
either the hookworms or roundworms, it does not have a lung migratory phase (331). 
Instead, once the eggs have been ingested and have hatched, larvae migrate to the colon, 
burrow into the epithelial lining and develop into adult worms (Fig. 1.5C) (331). Effects 
induced by infection with this parasite are not as well-known as with human roundworm 
or hookworm. However, it is known that moderate infection results in gastrointestinal 
symptoms that may amplify preexisting nutritional deficits, and heavy infection has been 
associated with anaemia (due to intestinal blood loss) as well as appendicitis and colitis 
(344). In some heavy infections Trichuris Dysentery Syndrome may occur, a condition 




characterized by bloody diarrhea, rectal prolapse, anaemia, eosinophilia and growth 
retardation (345-347). 
   
Figure 1.5. Life-cycles of human helminths A. lumbricoides (A), human hookworm (B) and 
T. trichiura (C). Adapted from the Centers for Disease Control and Prevention 
(https://www.cdc.gov/parasites/sth/). 
1.5.2 Helminth-induced immunity 
1.5.2.1 Innate immune responses 
Please refer to Figure 1.6 for an overview of the processes outlined below. The immune 
response to helminths has been well documented in various murine models of human 
helminth infection. As such, the detailed outline of helminth-induced immunity outlined 
below consists largely of data generated using these models. However, as will be discussed, 
a similar response has been observed with clinical studies. Helminths are known to induce 
potent Th2 responses, involving eosinophilia, Th2 cytokine production (e.g. IL-4, IL-5, IL-13) 
and Th2-associated class-switched antibodies (IgG1/IgE in mice, IgG4/IgE in humans) (348, 
349). However, due to the complexity of these parasites, this Th2 response is complex and 
involves interplay between many immune and mechanical processes. Some of these 
processes will be outlined below, moving from innate to adaptive responses. Once a 
helminth parasite has entered the host, induction of alarmin (IL-25, IL-33) production is 
observed, often at mucosal sites of infection (350, 351). The presence of these alarmins, 
especially IL-33, activates innate lymphoid type 2 cells (ILC2s), recently identified cells that 
play a crucial role in Th2 cytokine production (IL-5 and IL-13) in early infection (350-353). 
This early cytokine production helps to direct the host response to the pathogen, aiding in 
the activation of innate and adaptive immune cells. It is well known that antigen presenting 
cells, such as dendritic cells (DCs) are necessary for the induction of CD4 T cell responses, 
but their exact role during helminth infection remains unclear. DCs have been shown to 
expand following helminth infection, but their phenotype and function appear to be 
modulated by the parasite (354). Research with mice resistant to Trichuris muris infection 




has revealed a significant upregulation of chemokine production by intestinal epithelial 
cells, and that these molecules were responsible for DC recruitment to the intestine, 
whereas the same process was not observed in susceptible mice (355). 
Irrespective of how they are activated, CD4 T cells are crucial in the host response to 
helminths, representing a primary cell type involved in Th2 cytokine production and 
parasite expulsion (348, 349, 356, 357). An important observation is that the robust 
induction of Th2 cytokine production is not redundant. Numerous studies have shown the 
necessity of these cytokines and the cellular pathways they activate in control of helminth 
infection, with particular importance ascribed to IL-4 for IgE production and IL-13 and the 
STAT6 cellular pathway for worm expulsion (358-364). 
Various innate immune cells are induced downstream of the initial response and play 
different roles in the immune response to helminths. The induction of alternatively 
activated macrophages during helminth infection has been noted, but their precise 
function remains unclear. It has been suggested that their exact function depends on the 
helminth, with tissue repair, immune modulation and parasite expulsion named as some 
of these functions (365, 366). Two well-documented effects of helminth infection are an 
induction of mast cells (mastocytosis) and eosinophils (eosinophilia). Despite this, their 
precise roles during helminth infection are not well understood. Trichinella spiralis 
infection is known to induce intestinal mastocytosis, correlating with parasite expulsion 
(367). Mast cells have also been identified as the predominant IgE+ cell type in the intestine 
following T. spiralis infection (368). Similarly, a lack of mast cells delayed expulsion of 
Nippostrongylus brasiliensis worms during a primary infection, but had no effect in 
subsequent infections (369). Conversely, the ablation of mast cells has no effect on T. muris 
infection, highlighting the uniqueness of responses to each parasite (370). As mentioned, 
eosinophilia is a hallmark of helminth infection, but the role of eosinophils during helminth 
infection is not fully understood (371). Migration of eosinophils towards helminths has 
been observed and they have been shown to contribute to protective responses in the lung 
during helminth infection (372, 373). However, eosinophil ablation does not render mice 
susceptible to helminth infection, suggesting a non-essential role for these cells during 
helminth infection (370, 373). Cell-mediated responses are not the only innate processes 
involved in control of helminth infection. Due to the sheer size of these parasites, several 
mechanical host responses are also required for successful infection clearance. Goblet cell 




hyperplasia with subsequent increases in mucus production are necessary for parasite 
entrapment and expulsion, and are suggested to be under the control of IL-13 during 
helminth infection (363, 374). Particular attention has been paid to 2 mucin proteins, 
namely Muc2 and Muc5ac. Muc2 production is suggested to occur only in resistant mice, 
and its production is associated with worm expulsion and lowered worm energy status 
(375). Its importance is highlighted in Muc2-deficient mice, which exhibited significantly 
delayed worm expulsion (375). Muc5ac production is associated with IL-13 and its function 
is suggested to be essential for expulsion of T. muris and important for N. brasiliensis and 
T. spiralis expulsion (376). An additional consequence of T. muris-induced IL-13 production 
is an increased rate of epithelial cell turnover in the large intestine, aiding in parasite 
expulsion (377). Lastly, it is important to consider the role of smooth muscle contraction in 
parasite expulsion from the intestine. Again, the Th2 cytokine response drives this process, 
with intestinal muscle hypercontractility induced through IL-4/IL-13- mediated activation 
of the STAT6 cellular pathway during helminth infection (378). Deletion of IL-4Rα 
expression on smooth muscle cells, resulting in reduction of IL-4/IL-13 signalling, highlights 
the importance of this hypercontractility, as this deletion results in the downregulation of 
certain Th2 responses and delayed worm expulsion (379, 380). These important innate 
responses act in concert with adaptive cell responses (outlined below) to control and 
subsequently eliminate helminth parasites from the host. 
1.5.2.2 B cell-associated immune responses 
As already discussed, CD4 T cell are required for protection against helminth. The role of B 
cells, however, appears to be more complex. The Th2 response induced by helminths also 
induces B cell antibody class switching, favouring IgG1 and IgE production (381). Whether 
these antibodies are protective appear to depend on their antigen specificity and the 
helminth species that induced their production. N. brasiliensis infection does induce IgG1 
production, but this did not relate to protective responses (358). However, a helminth 
haemoglobin-specific IgG1 antibody was able to reduce worm burden following N. 
brasiliensis infection (382), suggesting that antibodies specific for certain antigens may 
enhance protective responses to this parasite. Conversely, class-switched antibodies (IgG, 
IgG1, IgG2a/c, IgA) produced in response to Heligmosomoides polygyrus infection do play 
a role in protective responses, limiting egg production and worm development, and 
inducing larval trapping to reduce tissue damage (383-387). Similarly nuanced findings have 




been reported for the role of IgE. In one instance it has been reported as important for 
immunity to T. spiralis (388), whereas another report suggests mice lacking IgE respond 
similarly to wild-type mice during T. spiralis or N. brasiliensis infection (389). However, the 
role of IgE may be more complex than previously thought. IgE (and IgG1) can induce 
basophilia in response to H. polygyrus infection (390), and the importance of basophils in 
protective immunity has been noted with the N. brasiliensis model (391). These findings 
suggest a role for IgE in basophil-mediated responses to helminths, a mechanism which 
warrants further investigation. Studies relating to overall B cell immunity have also been 
utilized to elucidate their role, with similarly mixed results. Total B cell deficiency does not 
appear to influence Th2 responses or worm expulsion following N. brasiliensis infection 
(392), but it has been observed that the B cell’s antigen processing capability enhances 
protective responses to this parasite (358). On the other hand, the absence of B cells during 
T. muris or H. polygyrus infection is more noticeable, rendering mice susceptible (393) or 
delaying worm expulsion (392). Additionally, cytokine production by effector B cells was 
required to sustain the production of protective antibodies during H. polygyrus infection 
(383). Taken together, these studies highlight the importance of investigating both the 
humoral and non-humoral aspects of B cell function during helminth infection. 





Figure 1.6. Overview of the major protective components of the type 2-associated 
response to helminth infection in mice (394). 
1.5.2.3 Human anti-helminth immunity 
Although research into the helminth-induced immune response is more challenging in the 
clinical setting, studies have revealed results that mirror observations from murine studies. 
Both A. lumbricoides and T. trichiura infection induce Th2 polarized cytokine responses 
(395-397), with robust Th2 cytokine responses associated with reduced infection intensity 
(398) and weaker responses with susceptibility to infection (399). Responses to hookworm 
infection are not as clear-cut. In one instance of experimental human hookworm infection, 
the helminth only elicited transient Th2 responses, with only eosinophil levels remaining 
elevated throughout the infection (400). Conversely, it has also been shown that 
experimental human hookworm infection can induce robust systemic and mucosal Th2 and 
regulatory cytokine responses (401). The difference in sample sizes utilized, and the innate 
variability of clinical studies may account for these reported differences, but the immune 




response to human hookworm infection does require further study. Antibody responses in 
human helminth infection appear to follow similar patterns for different helminths, with 
IgE and IgG4 as the two most common antibody subtypes produced (402). The IgE subtype 
is most commonly associated with resistance to helminth infection and lower infection 
intensity, whereas IgG4 is associated with increased susceptibility to and higher intensity 
of infection (403-405). It has also been suggested that IgE and IgG4 antagonise each other’s 
functions during infection (403), which would account for these observations. As with the 
cytokine responses, the antibody responses to human hookworm infection are not as 
simple. It has been suggested that IgM, IgG and IgE could provide protection against human 
hookworm infection (406), but it has also been suggested that despite elevated levels in 
adults, IgG does not appear to be involved in protective responses (407). Again, this 
highlights the necessity of further research into anti-hookworm immune responses in 
clinical studies. 
Although the overarching protective response to helminths involves various pathways 
stimulated by Th2 immunity, each helminth (whether murine or human) elicits a unique 
combination of these mechanisms. Thus, despite their similarities, infection with any one 
or combination of parasites yields tailored immune responses to each parasite, rather than 
one broad response to all of them. This highlights the complexity of helminth immunology 
and how important it is not to overlook subtle differences in the responses induced, as such 
differences could have far-reaching effects on infection outcome. 
1.6 Study aim and objectives 
The above discussion reveals the pivotal role played by immune responses in disease 
outcome. These responses are especially important to consider and characterise in infants, 
a particularly vulnerable population group. The potentially important role that humoral 
immunity may play during mycobacterial and helminth infection has been mentioned, but 
its exact role is not yet fully understood, nor is the role of maternal immunity, despite it 
being one of the earliest immune influences an infant will encounter. These knowledge 
gaps are important to address, especially in the context of sub-Saharan Africa, a region with 
a substantial overlap of Mtb and helminth infection (330, 408) and often-limited access to 
appropriate healthcare. An improved understanding of the interplay between these 
infections, maternal immunity and childhood immune responses would be beneficial in the 
development of appropriate vaccines or treatments, which would be most useful to those 




individuals living in regions endemic for these infections. The aim of my study was to 
investigate the role of humoral immunity and maternal infection history in infant’s immune 
responses to vaccination and disease, with specific study objectives as outlined below: 
1. Characterise the overall plasma humoral response and compare the responses to Mtb 
infection. 
2. Investigate plasma antibody responses to childhood vaccines and compare the responses 
to Mtb infection. 
3. Investigate plasma antibody responses to helminths and compare the responses to Mtb 
infection. 
4. Investigate the influence of maternal immunity on infant childhood immune responses. 
5. Analyse the influence of maternal helminth infection on adaptive immune responses to 
BCG vaccination and infection in vivo. 
We hypothesise that anti-mycobacterial vaccination may induce antibody responses that 
afford some protection against mycobacterial infection, but that helminth infection 
(maternal or during early childhood) may interfere with these responses, or with responses 
to other childhood infections or vaccines. 




Chapter 2: Investigating the role of humoral responses on 
immunity to Mtb 
2.1 Introduction 
It is well known that cell-mediated immunity is essential to the host’s protective response 
against Mtb, due to its intracellular nature. For this reason, the ability of novel TB vaccines 
to induce cell-mediated immune responses is considered most important for vaccine 
efficacy (409, 410), despite the observation that even when a vaccine is able to induce 
robust cellular responses, this immunogenicity does not necessarily equate to a noticeable 
protective effect (207, 411, 412).  
On the contrary, most other clinically efficacious vaccines are considered successful due to 
their induction of protective antibody responses (285, 413, 414), suggesting that induction 
of humoral immunity in addition to cell-mediated immunity by a TB vaccine could be 
beneficial, rather than essential. However, the induction of heterogeneous antibody 
responses by Mtb complicates the identification of antigens that would elicit sufficient 
protective antibodies in the context of vaccination (299, 415). Despite this difficulty there 
is promising evidence from murine and clinical studies that antibodies elicited by BCG 
vaccination or Mtb infection could enhance host protective responses (287, 292, 296, 297, 
300, 307, 416). 
Although several studies have investigated antibody production and the role of antibodies 
in Mtb infection/TB disease, a comprehensive understanding of their function is lacking. 
Overall, antibodies are suggested to enhance cell-mediated protective mechanisms. 
Opsonisation of Mtb has been shown to enhance bacterial uptake by macrophages (296, 
297, 300), whereas neutralization and antibody-dependent cell-mediated cytotoxicity 
(ADCC) can inhibit bacterial growth (296, 297, 305). Subtleties such as variations in antibody 
glycosylation can also affect antibody-mediated bacterial control (305). In the case of active 
TB disease, it has been suggested that antibody isotype is important to consider, as IgA has 
been shown to enhance and IgG impair control of disease (415). Despite these promising 
findings, it is important to take into consideration that the complicated nature of Mtb 
infection and TB disease will likely translate into different roles for antibodies at various 
disease time-points. 




Host vaccination status may also influence immune responses to Mtb. It has been observed 
that measles, BCG and tetanus toxoid-containing vaccines have differing effects on all-
cause mortality (417, 418), and measles vaccination has been suggested to dampen the 
reaction to tuberculin, used to detect Mtb infection (419, 420). Despite these suggested 
heterologous effects of certain childhood vaccines, a closer analysis of their potential 
effects on Mtb infection is still required. 
I sought to investigate whether plasma antibody levels in infants from a TB-endemic setting 
associated with risk of acquiring an Mtb infection. To achieve this, total IgG and antigen-
specific IgG responses to related and unrelated antigens were measured and analysed in 
light of Mtb infection outcome. 
2.2 Materials and methods 
2.2.1 Cohort recruitment 
Study participants 
This is a sub-study of a double-blind, placebo-controlled efficacy trial of the MVA85A 
vaccine candidate, performed in the Western Cape Province of South Africa, and described 
previously (207). Infants who were 4-6 months of age and had received the BCG vaccine 
within 7 days of birth, were enrolled. Study inclusion criteria at baseline were a negative 
HIV ELISA result, a negative QuantiFERON-TB Gold In-tube (QFT) test (to detect Mtb 
infection by measuring IFNγ responses to specific mycobacterial proteins) and no known 
exposure to an adult with active TB disease. At the point of enrolment, infants must have 
received all routine childhood vaccinations as per the EPI. The parent trial showed that 
MVA85A boost vaccination did not afford more protection than BCG vaccination alone in 
newborns (207). Therefore, placebo (Candin®: Candida antigen) and MVA85A vaccinated 
infants were combined in the same analyses. One hundred and thirty-six infants were 
sequentially recruited into the sub-study at the time of TB investigation (Fig. 2.1A). 
However, complete clinical data and sample sets were not collected for thirteen 
participants, leaving clinical data and samples from one hundred and twenty-three 
participants available for analysis in this study (Fig. 2.1A). 
The sub-study and parent trial (C-020-485) were both approved by the University of Cape 
Town Faculty of Health Sciences Human Research Ethics Committee (study numbers 




032/2010 and 291/2008 respectively), and written informed consent was obtained from 
the infants’ parents or legal guardians prior to participation. 
Cohort outline 
Following recruitment at baseline, infants were followed up at 3-monthly intervals to 
identify symptoms consistent with TB disease. Identification of such symptoms triggered 
admission to the case verification ward for standardized investigation and QFT re-testing; 
such a visit is subsequently referred to as a TB investigation visit. Asymptomatic infants 
were admitted if an individual with TB disease became a new household contact (207). 
Where available, two plasma samples were analysed per infant for this sub-study: one 
taken from QFT testing at baseline, and one from QFT re-testing at a TB investigation visit 
(Fig. 2.1B). Where multiple TB investigations occurred for an infant, analysis was limited to 
one TB investigation visit sample per infant. Mtb infection was defined by a single positive 
QFT test (interferon-gamma release assay conversion). Infants who were QFT positive, but 
did not show evidence of probable or definite TB disease (421) were classified as Mtb-
infected. None of the infants, irrespective of QFT status, were diagnosed with active TB 
disease. Infants were stratified by QFT negative (Mtb-uninfected) and QFT positive (Mtb-
infected) status in the subsequent analyses. 
  
Figure 2.1. Infants recruited to the TB/helminth study. Infants enrolled in the MVA85A 
trial were randomly assigned to the placebo or MVA85A vaccination arms (A). One hundred 
and thirty six infants were recruited to the TB/helminth study; incomplete clinical data and 
sample sets were available for n=13 infants, leaving n=123 available for further analysis. 




Time-points of blood collection for QuantiFERON (QFT) (B) were at baseline, study day 336, 
at last scheduled visit and/or upon TB investigation. Per participant, serum was analysed at 
baseline and upon TB investigation. 
2.2.2 ELISA 
The concentrations at which all antigens and antibodies were used, were optimised 
specifically for use with this in-house ELISA assay. The procedures outlined below were 
adapted from similar methods described elsewhere (298, 299, 415, 422, 423). 
Vaccine antigens 
BCG (Danish strain 1331, Statens Serum Institut, Denmark), live-attenuated measles 
(Rouvax, Sanofi Pasteur) and tetanus toxoid (Tetavax, Sanofi Pasteur) vaccines were 
reconstituted in and diluted with 1X PBS to yield antigen stocks of 500µg/ml; aliquots of 
stocks were stored at -80°C until required. 
Non-specific and antigen-specific ELISA 
Both total IgG and antigen-specific antibody ELISAs were performed. Coating antigens were 
used at 5μg/ml for antigen-specific IgG or 10μg/ml for antigen-specific subtypes of IgG. 
Initial plasma sample dilutions were 1:50 (total IgG) and 1:20 (antigen-specific), followed 
by serial 1:5 dilutions of the initial dilutions across a further 7 wells. Primary and detection 
antibodies were used as described (Table 2.1); all detection antibodies were alkaline 
phosphatase-linked. 
Table 2.1. ELISA antibodies. 
Antibody Primary/ 
detection 
Dilution Clone Company 
Goat α-human IgG (Fc-specific) Primary 1:5000 - Sigma-Aldrich 
Mouse α-human IgG (Fc)-AP Detection 1:1000 JDC-10 Southern Biotech 
Mouse α-human IgG1 (hinge)-AP Detection 1:500 4E3 Southern Biotech 
Mouse α-human IgG2 (Fc)-AP Detection 1:500 31-7-4 Southern Biotech 
Mouse α-human IgG3-AP Detection 1:500 HP6050 Southern Biotech 
Nunc-ImmunoTM MicroWellTM MaxisorpTM 96-well plates (Thermo Fisher Scientific; 
Waltham, MA) were coated with primary antibody or antigen and incubated at 37°C for 3 
hours. Plates were washed 3 times with PBS-Tween20 buffer and blocked with 200μl/well 
2% milk powder/1X PBS at 4°C overnight. Plates were washed 3 times as above and 
appropriately diluted plasma sample added (50 μl/well); plates were incubated at 4°C 
overnight. Plates were washed 3 times as above and detection antibody added (50 μl/well); 
plates were incubated at 37°C for 3 hours. Plates were washed 4 times as above and PNP 
substrate (Sigma-Aldrich; St. Louis, MO) added. Reactions were stopped with 1M NaOH and 




plates read on a VersamaxTM 96-well plate reader (Molecular Devices; Sunnyvale, CA) at 
wavelength 405nm (492nm reference filter). Arbitrary antibody responses were recorded 
from sample titration curves as the dilution at which a defined OD value was reached (423). 
Subsequently, these values were log transformed prior to further analysis to normalise the 
data, enabling a relative assessment of antibody levels in serum (423) (Fig. 2.2). According 
to this analysis, antibody levels in certain samples and for certain antibody types fell below 
the detection limit and are observed at zero on the y-axes. This does not preclude the 
possibility of specific antibody responses within those samples, but may require detection 
with a more sensitive assay. 
         
Figure 2.2. Sample titration curve. Example of sample titration curve generated from ELISA 
readouts and used to determine arbitrary antibody titres. 
2.2.3 Statistical analysis 
Dot plot graphs are represented with the median and interquartile range where 
appropriate. Antibody responses in matched sample pairs were compared using the 
Wilcoxon matched-pairs signed rank test, and the Mann Whitney test was utilized for the 
analysis of unpaired two-group data. All grouped analyses were investigated by the Kruskal-
Wallis test and correlations were investigated using the Spearman correlation test; lines-
of-best-fit are overlaid on correlation graphs. The Fisher’s exact test was utilized to 
compare group frequencies as required. Where appropriate, analyses were two-tailed and 
significance was accepted at p≤0.05. GraphPad Prism software (v. 5.03) was used for all 
statistical analyses and graphs presented. 





2.3.1 Cohort description 
Of the 123 infants, plasma samples were available for 100 infants at baseline (recruitment), 
whereas at TB investigation plasma samples and QFT status were available for all infants. 
The median age of infants at TB investigation was 19.5 months (interquartile range 15.5-25 
months). Of the 123 infants, 71 (57.72%) exhibited TB symptoms, and 14 (11.38%) exhibited 
QFT conversion upon re-testing at TB investigation (Table 2.2). 
Table 2.2. Infant socio-demographic and clinical characteristics at TB investigation. 
 N=123 
Infant characteristics  
Age – months (median (IQR)) 19.5 (15.5-25) 
Gender (male) 53 (43.09%) 
Weight at admission – kg (median (IQR)) 9.23 (7.89-10.32) 
TB symptoms (weight loss, failure-to-thrive, cough > 2 weeks) (YES) 71 (57.72%) 
Positive QuantiFERON 14 (11.38%) 
2.3.2 Infants exhibit an age-related increase in total IgG titres from baseline to time 
of TB investigation 
Baseline and TB investigation plasma samples were analysed for total IgG levels. Pairwise 
analysis of the samples revealed a significant increase in total IgG titres from baseline to TB 
investigation (Fig. 2.3A); titres measure at TB investigation also reveal a bimodal 
distribution approximately around the median. Further analysis revealed a significant 
inverse correlation between total IgG titres and age at TB investigation, indicating that 
older infants exhibited lower levels of total IgG (Fig. 2.3B). Stratification of infants by QFT 
status showed that QFT+ infants were significantly older than QFT- infants (median age in 
months 28.5 vs. 19 respectively; p=0.002) (Fig. 2.3C). 
  





Figure 2.3. Infants exhibit an age-related increase in total IgG from baseline to TB 
investigation. Total plasma IgG in participants at baseline and upon TB investigation visit 
(n=100) as measured by ELISA (A). Total IgG titres vs. age in months at TB investigation 
(n=120), with samples from QFT positive participants indicated in purple (B); overlaid are 
the line-of-best-fit and 95% confidence bands (dashed lines). Association between age at 
TB investigation and QFT result (C). Antibody titres are presented as log-transformed 
arbitrary values. Comparison in (A) was assessed for significance by the Wilcoxon matched-
pairs signed rank test; comparison in (C) was assessed for significance by the Mann Whitney 
test. Strength of correlation in (B) was assessed by the Spearman correlation. 
2.3.3 Total IgG titres increase significantly in QFT negative infants 
As previously mentioned, QFT+ infants were older, but older infants also exhibited 
decreased total IgG titres. To investigate the potential role of total IgG in these associations, 
total IgG titres at baseline and TB investigation were stratified according to the infant’s QFT 
outcome at TB investigation (Fig. 2.4A). At baseline, there was no difference in median total 
IgG titre between infants who remained QFT- and those that later acquired an Mtb 
infection (QFT+) (Fig. 2.4A), whereas at TB investigation, QFT+ infants exhibited a trend for 
decreased total IgG titres (p = 0.052), suggesting an association between higher total IgG 
levels and reduced risk of acquiring an Mtb infection (Fig. 2.4A). Longitudinal analysis of 
individual infant IgG responses revealed a significant increase in total IgG titres from 
baseline to TB investigation in QFT-, but not QFT+, infants (Fig. 2.4B). To investigate this 
association quantitatively, total IgG titres were compared to IFNγ concentrations measured 
by QFT. A significant inverse association was found between total IgG titres and IFNγ levels 
as measured at TB investigation (Fig. 2.4C). 





Figure 2.4. QFT negative infants exhibit a significant increase in total IgG titres. 
Relationship between QFT outcome and total IgG titres from baseline and TB investigation 
participant samples (A). (B) is a before/after comparison of samples subdivided as in (A). 
Total IgG responses vs. quantitative QFT outcomes (C); overlaid is the line-of-best-fit and 
the 95% confidence bands (dashed lines). Antibody titres are presented as arbitrary values. 
Associations in (A) and (B) were assessed for significance by the Mann Whitney test. 
Strength of correlation in (C) was assessed by the Spearman Correlation. 
As infants were recruited from the parent MVA85A vaccine trial cohort, the potential 
influence of vaccination with MVA85A or placebo (Candin®) on total IgG responses and QFT 
outcome was investigated. Similar frequencies of QFT+ outcomes were observed between 
infants receiving placebo or MVA85A vaccination, both at baseline and TB investigation 
(Fig. 2.5). No differences between placebo treatment and MVA85A vaccination were 
observed when infant total IgG responses were stratified according to vaccination, either 
at baseline or TB investigation (Fig. 2.5). Additionally, no differences in total IgG titre were 
detected between QFT- and QFT+ infants in placebo-treated and vaccination groups (Fig. 
2.5). 




       
Figure 2.5. Increases in total IgG in QFT negative infants does not associate with MVA85A 
vaccination status. Relationship between QFT outcome, MVA85A vaccination status and 
total IgG titres from baseline and TB investigation participant samples. Column sample 
numbers left-right: 45, 4, 45, 6; 54, 4, 55, 10. Antibody titres are presented as arbitrary 
values. Comparisons were assessed for significance by the Kruskal-Wallis test, and the 
frequency of outcomes were compared by the Fisher’s exact test. 
2.3.4 BCG vaccine-specific antibody responses are not associated with age or QFT 
outcome 
Due to the high TB endemicity in the region, it is recommended that all children be 
vaccinated with BCG as soon after birth as possible (262). For inclusion in this study, 
children must have received the BCG vaccine within 7 days of birth. It is known that BCG 
can induce mycobacteria-specific antibody responses (424-426), so we investigated 
whether infants enrolled in this study generated an antibody response to the vaccine, 
measured at TB investigation. BCG-specific antibody responses were detected in a 
substantial proportion of infant samples: BCG-specific IgG was detected in 93 infants 
(75.6%) (Fig. 2.6A), IgG1 in 88 (71.54%) (Fig. 2.6C), IgG2 in 32 (26.01%) (Fig. 2.6E) and IgG3 
in 56 (45.53%) (Fig. 2.6G). To determine whether age-related differences in BCG-specific 
antibody responses were present, all antibody titres were compared to the infants’ age at 
TB investigation. However, no correlations between age and BCG-specific antibody 
responses were detected for any of the antibody subtypes tested (Fig. 2.6B, D, F, H). 




      
Figure 2.6. Antibody responses to BCG vaccination do not associate with age. BCG-specific 
antibody responses measured in plasma samples from TB investigation. Anti-BCG IgG 
(n=123) (A), IgG1 (n=120) (C), IgG2 (n=123) (E) and BCG IgG3 (n=123) titres (G) as measured 
by ELISA. Anti-BCG IgG (B), IgG1 (D), IgG2 (F) and IgG3 (H) as compared to the children’s 
age in months at TB investigation. Three fewer samples reported for BCG IgG1 due to a lack 
of sample availability. Overlaid (B, D, F, H) are the lines-of-best-fit and 95% confidence 
bands (dashed lines). Antibody titres are presented as arbitrary values. The strength of the 
correlations between antibody titres and age was assessed for significance by the 
Spearman correlation. 




Next, BCG vaccine-specific antibody responses were compared to both qualitative and 
quantitative QFT outcomes at TB investigation. There was no significant association 
between any of the antibody subtype responses and qualitative QFT outcome (Fig. 2.7A, C, 
E, G); however, the majority of QFT+ infants did not mount a detectable IgG2 response (Fig. 
2.7E). Even though the antibody responses did not associate with reduced risk of Mtb 
infection (as indicated by conversion from QFT- to QFT+), we investigated whether the 
antibody responses related to changes in IFNγ production. None of the antibody responses 
exhibited significant correlations with IFNγ production (Fig. 2.7B, D, F, H), but there was a 
trend towards an inverse correlation between BCG-specific IgG3 and quantitative QFT 
outcome, suggesting that higher antibody responses could be associated with decreased 
IFNγ production (Fig. 2.7H). 




     
Figure 2.7. Antibody responses to BCG vaccine do not associate with QFT outcome. BCG-
specific antibody responses measured in plasma samples from TB investigation and 
stratified by QFT outcome. Anti-BCG IgG (A), IgG1 (C), IgG2 (E) and IgG3 titres as measured 
by ELISA and stratified by QFT result. Three fewer samples reported for BCG IgG1 due to a 
lack of sample availability. Anti-BCG IgG (B), IgG1 (D), IgG2 (F) and IgG3 (H) vs. quantitative 
QFT outcomes. Overlaid (B, D, F, H) are the lines-of-best-fit and 95% confidence bands 
(dashed lines). Antibody titres are presented as arbitrary values. Comparisons in (A, C, E, 
G) were assessed for significance by the Mann Whitney test; strength of correlations in (B, 
D, F, H) was assessed by the Spearman correlation. 




2.3.5 Raised measles vaccine-specific IgG responses associated with a negative QFT 
outcome but not with age 
To investigate whether antibody responses to heterologous antigens from other childhood 
vaccines related to risk of acquiring an Mtb infection, IgG responses to the live-attenuated 
measles and tetanus toxoid vaccines were measured.  
Measles infection is known to induce IgG production which is necessary for long-term 
immunity, indicating that the induction of robust IgG responses by the live-attenuated 
measles vaccine is important (195, 413). In this cohort, 116 infants (95.87%) had detectable 
levels of measles vaccine-specific IgG (Fig 2.8A), but no age-related effects (Fig 2.8B) or 
gender-related effects (data not shown) on the antibody response were observed. As with 
BCG vaccine-specific responses, potential associations between measles vaccine-specific 
IgG responses and risk of Mtb infection were assessed in plasma samples taken at TB 
investigation. A trend for decreased measles-specific IgG in infants who acquired Mtb 
infection was detected (p=0.09) (Fig. 2.8C). Although this did not associate with a significant 
difference in IFNγ produced, a trend for decreased IFNγ levels in infants with higher 
measles-specific IgG levels was observed (Fig. 2.8D). It is important to note that children 
younger than 9 months were excluded from these analyses as they would not yet have 
received their primary measles vaccination. 
  




   
Figure 2.8. Raised measles IgG titres are associated with a QFT negative status. Measles-
specific antibody responses measured in plasma samples from TB investigation. Anti-
measles IgG (n=121) (A) as measured by ELISA. Anti-measles as compared to the children’s 
age in months (B), QFT outcome (C) and quantitative QFT outcomes (D). Three fewer 
samples reported as participants had not yet received the measles vaccine. Overlaid (B, D) 
are the lines-of-best-fit and 95% confidence bands (dashed lines). Antibody titres are 
presented as arbitrary values. Comparisons in (A, C) were assessed for significance by the 
Mann Whitney test. The strength of the correlations in (B, D) was assessed for significance 
by the Spearman correlation. 
2.3.6 Tetanus vaccine-specific IgG responses associated with age but not QFT 
outcome 
Protection against tetanus also requires a robust IgG response, which the tetanus toxoid 
vaccine is able to induce (413, 427). In this cohort, 101 infants (82.11%) exhibited 
detectable tetanus vaccine-specific IgG levels (Fig. 2.9A) at TB investigation. Numerous 
booster tetanus vaccines are administered early in life to ensure protective antibody 
responses are induced (427), so as expected, higher tetanus vaccine-specific IgG titres were 
significantly correlated with increasing age (Fig. 2.9B). Investigation of tetanus vaccine-




specific responses in light of Mtb infection risk revealed no association between IgG 
responses and either qualitative QFT outcome or IFNγ production (Fig. 2.9C, D). 
   
Figure 2.9. Tetanus-specific IgG responses are positively associated with age, but not QFT 
outcome. Tetanus-specific antibody responses measured in plasma samples from TB 
investigation. Anti-tetanus IgG (n=123) (A) as measured by ELISA. Anti-tetanus as compared 
to the children’s age in months (B), QFT outcome (C) and quantitative QFT outcomes (D). 
Overlaid (B, D) are the lines-of-best-fit and 95% confidence bands (dashed lines). Antibody 
titres are presented as arbitrary values. Comparisons in (A, C) were assessed for 
significance by the Mann Whitney test. The strength of the correlations in (B, D) was 
assessed for significance by the Spearman correlation. 
2.3.7 Higher total IgG titres are associated with lower tetanus vaccine-specific IgG 
responses 
To assess whether antibody responses to the BCG, live-attenuated measles and tetanus 
toxoid vaccines were responsible for the associations observed between total IgG 
responses and risk of Mtb infection at TB investigation, vaccine-specific antibody responses 
were compared to total IgG titres. These comparisons revealed that neither BCG-specific 
(Fig. 2.10A-D) nor measles-specific (Fig. 2.10E) antibody responses correlated with total 
IgG titres, although a trend for an inverse correlation between BCG-specific IgG1 and total 




IgG was observed (Fig. 2.10B). However, there was a significant inverse correlation 
between tetanus vaccine-specific IgG titres and total IgG titres, suggesting that infants with 
higher total IgG titres have lower serum tetanus-specific IgG levels (Fig. 2.10F). 
   
Figure 2.10. Higher total IgG responses are associated with decreased tetanus-specific 
IgG. Antibody responses measured in plasma samples from TB investigation. Total IgG titres 
vs. anti-BCG IgG (A), IgG1 (B), IgG2 (C), IgG3 (D), anti-measles IgG (E) and anti-tetanus IgG 
(F) titres as measured by ELISA. Three fewer samples reported for BCG IgG1 due to a lack 
of sample availability, and three fewer reported for measles as participants had not yet 
received the measles vaccine. Overlaid are the lines-of-best-fit and 95% confidence bands 
(dashed lines). Antibody titres are presented as arbitrary values. Strength of correlations 
was assessed by the Spearman correlation. 





Taken together, these data show that infants exhibiting a significant increase in plasma 
total IgG levels from baseline to TB investigation are less likely to be Mtb-infected, defined 
by a QFT+ result. This observed effect was related to a trend for increased BCG vaccine-
specific IgG2 responses and measles vaccine-specific IgG in infants who remained Mtb-
uninfected. These findings suggest that raised total, heterologous and specific IgG 
responses could be protective against Mtb infection. Furthermore, production of 
protective IgG responses in infants may be due to immune activation by antigens related 
and unrelated to Mtb. 
Investigations within a similar cohort have yielded a different outcome. Antigen 85A-
specific IgG responses were found to be associated with differences in the prevalence of 
TB disease but not Mtb infection (307). Despite this, it would be inaccurate to compare the 
two studies directly, due to differences in antigen specificity of the antibody responses 
measured, assay design and sample size. In accordance with previous research pertaining 
to the larger cohort from which these infants were recruited, we found no association 
between MVA85A vaccination and risk of Mtb infection (207). 
Initial findings indicate that total IgG responses increase significantly from baseline to TB 
investigation, however at TB investigation there was an inverse correlation between total 
IgG titres and age. It is important to note that the total IgG titres presented are from two 
distinct age ranges, namely 4-6 months at baseline and 8-37 months at TB investigation, 
and that the range of antibody titres values is wide. Additionally, older infants tend to fall 
within the lower half of the bimodal sample distribution observed at TB investigation, 
indicating why an inverse correlation between age and antibody titre is possible despite a 
higher median total IgG titres at TB investigation than at baseline. 
Although not significant, a trend for decreased BCG-specific IgG2 titres (as well as a lower 
proportion of infants producing IgG2) was observed in QFT+ infants, a finding not observed 
with other BCG-specific IgG responses. BCG vaccination has long been known to induce the 
production of Mycobacterium-specific antibodies (424-426), with IgG1, IgG2 and IgG3 
identified as the most prevalent IgG subtypes detected (295, 428). A proportion of infants 
tested positive for these antibody subtypes, supporting the current literature. However, to 
our knowledge, no association between a specific IgG subtype and protection against Mtb 




infection has been identified. Thus, our finding of decreased BCG IgG2 responses in QFT+ 
infants may warrant further investigation, especially with an increased study population 
size. 
A trend for decreased measles vaccine-specific IgG levels in infants who acquired Mtb 
infection was found; no association was found with tetanus vaccine-specific responses. 
Measles vaccination has been associated with decreased responsiveness to the tuberculin 
skin test in individuals with a known positive reaction to purified protein derivative and/or 
active TB disease (419, 420). However, these studies did not delineate which component 
of the immune response to measles vaccination could be responsible for these observed 
effects. Moreover, certain childhood vaccines (such as BCG and measles) have been 
identified as having a protective effect against all-cause mortality (417, 418). Our finding of 
higher measles-specific IgG titres in infants who do not acquire an Mtb infection provide 
support for this vaccine being able to elicit heterologous protective effects against 
unrelated pathogens, such as Mtb. 
Despite the associations discussed above, it is important to remember that the total IgG 
response contains antibodies specific for a vast array of antigens not assessed in this study, 
and the potential role of these other antibody responses in our findings should not be 
discounted. Another important consideration is the influence of maternal antibody on 
vaccine responses, especially in younger children. It is widely accepted that the transfer of 
maternal antibodies during pregnancy and breastfeeding provides neonates with essential 
protection against pathogens early in life (429). However, the presence of these passively 
transferred antibodies may also interfere with the infant’s immune responses to childhood 
vaccines (429). The presence of maternal antibody to measles is understood to result in 
suboptimal induction of protective humoral responses in infants if the measles vaccine is 
administered too early in life (430, 431). For this reason, administration of the initial 
measles vaccine is delayed to minimize the impact of maternal antibody (432). As infants 
in this study were excluded from analyses of measles antibody responses if they had not 
yet received the primary vaccine, it is reasonable to assume a negligible effect of maternal 
antibody on these findings. Historically, maternal antibodies to tetanus toxoid have not 
been thought to interfere with childhood tetanus vaccination (433). However, more recent 
research has revealed an effect, albeit subtle. Infants exhibiting higher IgG responses to 
tetanus toxoid at birth also had decreased tetanus toxoid-specific IgG responses following 




primary vaccination, suggesting interference by maternally-derived antibody (434). Despite 
this decrease, the antibody levels induced following vaccination were still considered 
protective, indicating that the interference by maternal antibody may hold no clinical 
significance in this instance (434). Although subtle, this effect could provide a plausible 
explanation for our finding of an inverse association between total IgG titres and tetanus-
specific IgG titres. Infants with higher total IgG responses were younger, suggesting that a 
more pronounced effect of maternal antibodies may be observed in these infants, which in 
turn could have a detrimental effect on the magnitude of tetanus toxoid-specific IgG 
responses induced by vaccination. However, the contribution of maternal antibody to the 
total IgG titres measured would need to be determined for a more definitive conclusion to 
be drawn. 
Another component within the serum antibody fraction that may play a role in 
heterogenous immune responses is the natural autoantibody component, thought to have 
a role in the immune effects observed with Intravenous Immunoglobulin (IVIG) treatment 
(435). IVIG was originally used to treat antibody immune deficiencies, but has also been 
observed to elicit immunomodulatory effects against autoimmune and other inflammatory 
disorders (435, 436). The immunoglobulin used is pooled from thousands of donors and 
mainly consists of IgG, with IgG1 and IgG2 as the most prominent subtypes (435, 436). 
Antibodies are not only important for protection against pathogens, but also for immune 
homeostasis, mediated via the action of natural autoantibodies on inhibitory FcRs (435, 
437-439). These are a life-long subset of antibodies (IgM, IgA, IgG) generated against 
certain self-antigens (440-442). As they are suggested to have roles in various anti-
inflammatory processes (443), it could be plausible to assume that their function may 
influence host susceptibility to pathogens by regulating the immune responses required for 
establishment of infection, such as with Mtb. Pertaining to this study, natural 
autoantibodies could play a role in reducing susceptibility to Mtb infection, although it is 
also important to note that their inhibition of immune components essential for protection 
could be detrimental (444, 445). However, this is a hypothesis that would require further 
testing and due to the very limited autoantibody profile present in an individual as 
compared to the IVIG antibody profile, any potential effects may be negligible. 
Another necessary consideration in this study is the impact that small sample size may have 
had on the findings discussed here. Although the cumulative Mtb infection incidence over 




the 2 years of follow-up in this study was approximately 11%, the number of infants 
exhibiting QFT conversion was small, indicating that a larger sample size would be required 
to investigate these findings more thoroughly. In addition to this, a larger sample size would 
allow for a group with active TB disease to be included. This study originated as an 
investigation of the role of standard childhood vaccination in acquisition of Mtb 
infection/active disease, and as such only current vaccine antigens were included. 
However, the promising protective effects of antibodies elicited against Mtb-specific 
antigens as reported by other researchers (which could be potential vaccine candidates) 
highlight the importance of future investigations with this or a similar cohort including tests 
for these Mtb-specific antibody responses. 
In summary, the data presented here suggest that childhood vaccination with both 
pathogen-related and unrelated antigens may result in activation of the immature immune 
system, resulting in reduced risk of Mtb infection. The potential role of components within 
the total IgG response that have not been addressed here should not be discounted, and 
requires further investigation. 




Chapter 3: Investigating the role of helminth exposure on 
risk of Mtb infection 
3.1 Introduction 
Soil-transmitted helminth (STH) infections are associated with poverty, capable of causing 
severe morbidity in individuals least likely to have access to appropriate living conditions 
and adequate healthcare (446). Additionally, children represent a high-risk group for 
acquiring helminth infections and are often given anti-helminthic treatment at school age 
in an attempt to alleviate the morbidities associated with these infections, such as nutrient 
malabsorption, impaired growth and anaemia (446, 447). STHs are known to induce type 2 
responses (please refer to section 1.5.2 in Chapter 1), but it remains unclear whether these 
responses are protective for the host or whether they benefit the parasite (329, 331). 
Helminth infections in children are associated with increased production of both IgE and 
IgG4, two type 2 antibodies (397, 404). Whereas IgE is more commonly observed in older 
children among whom infection levels decrease, IgG4 levels are higher in younger children, 
where infection levels increase (404). Additionally, these intestinal helminth infections 
induce the production of type 2 cytokines, although they are suggested to result in 
decreased cytokine output overall (397). 
Due to the often-observed impact and longevity of these infections, it is important to 
consider all the factors contributing to susceptibility to helminths and co-endemic 
pathogens, especially the potential modulatory role that these parasites could have on 
immune responses to unrelated vaccine antigens or co-infections (422, 448-454). The effect 
of maternal helminth exposure on their offspring’s own susceptibility to helminth infection 
is debated, with some research revealing a detrimental effect (455), and some a beneficial 
effect (456). Similar complexities are observed when investigating the effect of maternal 
helminth infection on childhood vaccine responses, again revealing a range of effects from 
negative to positive (457-461). However, anti-helminthic treatment during pregnancy is 
suggested to have no lasting impact on the effectiveness of crucial childhood vaccines, 
implying that maternal helminth infection doesn’t have a long-term influence on vaccine 
responses (462). Although not true of all vaccines investigated (448), the presence of 
helminth infection at the time of vaccination appears to have a more pronounced effect 
than maternal helminth exposure, with dampening of vaccine immune response being 
observed, although not always to a detrimental level (422, 449, 463, 464). 




The relationship between helminths and Mtb infection/active disease, along with BCG 
vaccination, is equally complex. Studies of BCG vaccination in both murine models and 
clinical cohorts reveal seemingly contradictory results. Whilst helminth infection is 
suggested to dampen protective responses induced by BCG in some instances (465-467), 
this does not appear to be the case in all conditions (468). Similarly, 
mycobacterial/helminth co-infection stimulates complex immune responses, dependent 
on both helminth species and the time at which infection occurs (450, 468-475). 
The participants in this study live in a region endemic for A. lumbricoides (human 
roundworm) and T. trichiura (human whipworm), and a substantial overlap in prevalence 
of helminth and Mtb infections exists in this region (330, 408). Due to the ability of 
helminths to affect immune responses to mycobacterial infection, we investigated whether 
an association existed between helminth exposure (maternal or otherwise) and Mtb 
infection in the infants. 
3.2 Materials and methods 
The samples used for these analyses are outlined in Chapter 2; additional information 
and/or modifications are described below. 
3.2.1 Determination of helminth infection 
In addition to the sample collection described in Chapter 2, informed consent was obtained 
for the collection of 3 stool samples from the infants during their TB investigation visit. 
These samples were collected for Kato-Katz stool egg counts (National Health Laboratory 
Service, Groote Schuur Hospital, Western Cape, South Africa) (476) to determine the 
prevalence of helminth infection in these infants. Consent was also obtained to collect stool 
samples from the mothers, and the mothers were asked to complete a questionnaire 
regarding their and their infant’s history of helminth infection and living conditions. 
3.2.2 ImmunoCAP® test 
The ImmunoCAP® in vitro assay was used to detect antigen-specific IgE responses in 
serum/plasma samples and was used according to the manufacturer’s instructions (Thermo 
Fisher Scientific). Testing services were kindly provided by Professor Michael Levin (Red 
Cross War Memorial Children’s Hospital, Western Cape, South Africa). An Ascaris suum-
derived antigen that is cross-reactive with A. lumbricoides was used to detect antigen-
specific IgE (477). We describe responses to this antigen as Ascaris-specific. 





The concentrations at which all antigens and antibodies were used, were optimised 
specifically for use with this in-house ELISA assay. The procedures outlined below were 
adapted from similar methods described elsewhere (395, 396, 423, 478). 
Helminth antigens 
Whole A. lumbricoides worms were kindly provided by Prof. Michael Levin (Red Cross War 
Memorial Children’s Hospital), and whole T. trichiura worms were kindly provided by Prof. 
Philip Cooper (St. George’s University of London). Worms were treated with a 10X 
penicillin/streptomycin solution and 1X Amphotericin B (Thermo Fisher Scientific) for 1 
hour, following which they were washed in FS 1X PBS. Worm sections (A. lumbricoides) or 
whole worms (T. trichiura) were then homogenized in FS 1X PBS before being centrifuged 
to remove insoluble cellular debris. The soluble fraction was carefully decanted and the 
protein concentration measured by BCA assay (PierceTM BCA Protein Assay Kit, Thermo 
Fisher Scientific). This soluble fraction was then diluted in FS 1X PBS and adjusted to a stock 
concentration of 500µg/ml; aliquots of the stock solution were frozen at -80°C until 
required. 
Antigen-specific ELISA 
Antigen-specific antibody ELISAs were performed. Coating antigens were used at 5μg/ml 
or 10μg/ml for antigen-specific IgG or antigen-specific IgG subtypes, respectively. Initial 
plasma sample dilutions were 1:20 (except for maternal A. lumbricoides-specific IgG which 
was 1:50), followed by serial 1:5 dilutions of the initial dilutions across a further 7 wells. 
Primary and detection antibodies were used as described in Chapter 2; all detection 
antibodies were alkaline phosphatase-linked (Table 3.1). 
Table 3.1. ELISA antibodies. 
Antibody Primary/ 
detection 
Dilution Clone Company 
Mouse α-human IgG (Fc)-AP Detection 1:1000 JDC-10 Southern Biotech 
Mouse α-human IgG4 (pFc’)-AP Detection 1:500 HP6023 Southern Biotech 
Nunc-ImmunoTM MicroWellTM MaxisorpTM 96-well plates (Thermo Fisher Scientific; 
Waltham, MA) were coated with antibody or antigen and incubated at 37°C for 3 hours. 
Plates were washed 3 times with PBS-Tween20 buffer and blocked with 200μl/well 2% milk 
powder/1X PBS at 4°C overnight. Plates were washed 3 times as above and sample added 
(50 μl/well); plates were incubated at 4°C overnight. Plates were washed 3 times as above 




and secondary antibody added (50 μl/well); plates were incubated at 37°C for 3 hours. 
Plates were washed 4 times as above and PNP substrate (Sigma-Aldrich; St. Louis, MO) 
added. Reactions were stopped with 1M NaOH and plates read on a VersamaxTM 96-well 
plate reader (Molecular Devices; Sunnyvale, CA) at wavelength 405nm (492nm reference 
filter). Arbitrary antibody responses were recorded from sample titration curves as the 
dilution at which a defined OD value was reached (423). Subsequently, these values were 
log transformed prior to further analysis to normalise the data, enabling a relative 
assessment of antibody levels in serum as previously described (423). According to this 
analysis, antibody levels in certain samples and for certain antibody types fell below the 
detection limit and are observed at zero on the y-axes. This does not preclude the 
possibility of specific antibody responses within those samples, but may require detection 
with a more sensitive assay. 
3.2.4 Statistical analysis 
Antibody responses in matched sample pairs were compared using the Wilcoxon matched-
pairs signed rank test, and the Mann Whitney test was utilized for the analysis of unpaired 
two-group data. All grouped analyses were investigated by the Kruskal-Wallis test and 
correlations were investigated using the Spearman correlation test; lines-of-best-fit are 
overlaid on correlation graphs. Where appropriate, analyses were two-tailed. Data are 
represented with the median, and significance was accepted at p≤0.05. GraphPad Prism 
software (v. 5.03) was used for all statistical analyses and graphs presented. 
3.3 Results 
3.3.1 Cohort housing, sanitation and helminth infection rates 
Of the 123 infants, data regarding housing and sanitation conditions, as well as stool 
samples, were collected from 113 infants at TB investigation. The majority of infants lived 
in houses, and had access to clean water (tap) and sanitation (flush toilet) sources (Table 
3.2). Stool samples were tested for the presence of helminth eggs, as an indication of 
current infection. However, none of the samples tested positive for active helminth 
infection (Table 3.2). As previously mentioned, maternal helminth infections have a 
complex effect on children’s immune responses to helminths, vaccines and unrelated 
pathogens (455-458, 474). To investigate whether any maternal effects were apparent in 
this cohort, the prevalence of active helminth infection and helminth-specific antibody 
responses amongst mothers were determined in samples acquired upon their infant’s TB 




investigation visit (Table 3.2). Maternal data represents the number of mothers whose 
serum samples were tested for antibody responses and who also had a stool sample 
collected. Active helminth infections were tested in several samples, with 1 testing positive 
for A. lumbricoides infection, and 2 for T. trichiura infection (Table 3.2). 
Table 3.2. Housing, sanitation and helminth infection at TB investigation. 
 N= 113 (infants); N=43 (mothers) 
Housing type  
Flat 7 (6.19%) 
House 77 (68.14%) 
Informal settlement 28 (24.78%) 
Located on farm (YES) 42 (37.17%) 
Source of drinking water  
Communal 1 (0.88%) 
Tap water 112 (98.11%) 
Sanitation type  
Bucket system 9 (7.96%) 
Flush toilet 101 (89.38%) 
Pit latrine 3 (2.65%) 
Infant prevalent helminth species  
At least one stool sample collected 113 (100%) 
A. lumbricoides 0 
T. trichiura 0 
Other 0 
Maternal prevalent helminth species  
At least one stool sample collected 43 (100%) 
A. lumbricoides 0 
T. trichiura 2 (4.65%) 
Other 1 (2.33%) 
 
  




3.3.2 Infants exhibit an age-related increase in A. lumbricoides-specific IgG titres 
from baseline to time of TB investigation 
As mentioned, none of the infants tested positive for active helminth infection (Table 3.1). 
However, the presence of helminth-specific class-switched antibodies in plasma samples 
from these infants is indicative of prior helminth exposure. At TB investigation, 2/56 
(3.57%) infant samples tested for IgE had detectable levels of Ascaris-specific IgE, as 
determined by ImmunoCAP® (Fig. 3.1A). Analysis of baseline and TB investigation samples 
for the presence of A. lumbricoides-specific IgG revealed that 85/100 (85%) infants at 
baseline and all infants at TB investigation exhibited detectable antibody levels; 
furthermore, antibody levels were significantly increased at TB investigation compared to 
baseline (Fig. 3.1B). Additionally, 61/123 (49.59%) infants at TB investigation had 
detectable levels of A. lumbricoides-specific subtype IgG4 (Fig 3.1C). Analysis of infants’ A. 
lumbricoides-specific IgG responses at TB investigation in light of their age at this time-point 
revealed a significant positive correlation between A. lumbricoides-specific IgG and age 
(Fig. 3.1D). However, no association was found between A. lumbricoides-specific IgG4 and 
age (Fig. 3.1E). 
  





     
Figure 3.1. Infant Ascaris-specific IgG increases from baseline to TB investigation. Anti-Ascaris IgE 
(n=56) (A), IgG (B) and IgG4 (n=123) (C) titres; values shown in (A, C) are from samples taken at TB 
investigation. Anti-A. lumbricoides IgG (D) and IgG4 (E) titres compared to the participants’ age in 
months at TB investigation. Overlaid in (D, E) are the lines-of-best-fit and the 95% confidence bands 
(dashed lines). Antibody titres are presented as arbitrary values. Comparison in (B) was assessed 
for significance by the Mann Whitney test. The strength of the correlations in (D, E) was assessed 
for significance by the Spearman correlation. 
3.3.3 A. lumbricoides-specific antibody responses are not associated with QFT 
outcome 
Due to the potential of helminth exposure to alter immune responses to Mtb infection and 
active disease (469, 475, 479), any potential association of infant A. lumbricoides exposure 
with risk of Mtb infection was investigated. There were no significant differences when 
either baseline or TB investigation A. lumbricoides-specific IgG responses were stratified by 
QFT outcome (Fig. 3.2A). Further longitudinal analysis of individual A. lumbricoides-specific 
IgG titres in QFT- and QFT+ infants revealed significant increases from baseline to TB 
investigation in both groups, indicating an increase in A. lumbricoides-specific IgG levels 
irrespective of acquisition of an Mtb infection (Fig.3.2B). Similarly, A. lumbricoides-specific 
IgG4 responses did not associate with QFT conversion (Fig. 3.2C). It has been observed that 
helminth infection can influence the magnitude of the QFT IFNγ response negatively, with 
an indeterminate result becoming more likely (480, 481). However, in this cohort, no 




correlation was found between A. lumbricoides-specific antibody responses and IFNγ 
measured by QFT assay (Fig. 3.2D, E). 
 
Figure 3.2. A. lumbricoides-specific IgG and IgG4 do not associate with QFT outcome at 
TB investigation. Anti-A. lumbricoides IgG titres stratified by QFT outcome (A); (B) is a 
before/after comparison of TB investigation anti-A. lumbricoides IgG titres as subdivided in 
(A). Anti-A. lumbricoides IgG4 titres stratified by QFT outcome (C). Anti-A. lumbricoides IgG 
(D) and IgG4 (E) titres vs. quantitative QFT outcomes. Overlaid in (D, E) are the lines-of-
best-fit and the 95% confidence bands (dashed lines). Antibody titres are presented as 
arbitrary values. Comparison in (A) was assessed for significance by the Kruskal-Wallis test 
(B), and comparisons in (B) by the Mann Whitney test. The strength of the correlations in 
(D, E) was assessed for significance by the Spearman correlation. 
3.3.4 T. trichiura-specific antibody responses are not associated with QFT outcome 
Further analysis of plasma samples revealed a class-switched antibody response to the 
human whipworm, T. trichiura. At TB investigation, 97/123 (78.86%) infants had detectable 
T. trichiura-specific IgG responses (Fig. 3.3A), and 59/123 (47.97%) infants had detectable 
IgG4 responses (Fig. 3.3C). The T. trichiura-specific antibody responses were compared to 
the infants’ age at the time of sample collection, but no correlation was found between age 
and either IgG or IgG4 antibody responses (Fig. 3.3B, D). 




     
Figure 3.3. T. trichiura-specific IgG and IgG4 do not associate with age. T. trichiura-specific 
antibody responses measured in plasma samples from TB investigation. Anti-T. trichiura 
IgG (n=123) (A) and IgG4 (n=123) (C) titres. Anti-T. trichiura IgG (B) and IgG4 (D) titres 
compared to the participants’ age in months at TB investigation. Overlaid in (B, D) are the 
lines-of-best-fit and the 95% confidence bands (dashed lines). Antibody titres are 
presented as arbitrary values. The strength of the correlations in (B, D) was assessed for 
significance by the Spearman correlation. 
As with A. lumbricoides-specific responses, the T. trichiura responses at TB investigation 
were stratified by QFT outcome. There was no association between either IgG or IgG4 
antibody responses and QFT outcome, with similar median antibody responses in QFT- and 
QFT+ infants (Fig. 3.4A, B). There was also no association between either T. trichiura-
specific IgG or IgG4 responses and IFNγ production as measured by the QFT assay (Fig. 3.4C, 
D). 




   
Figure 3.4. T. trichiura-specific IgG and IgG4 do not associate with QFT outcome. T. 
trichiura-specific antibody responses measured in plasma samples from TB investigation. 
Anti-T. trichiura IgG (A) and IgG4 (B) titres stratified by QFT outcome. Anti-T. trichiura IgG 
(C) and IgG4 (D) titres vs. quantitative QFT outcomes. Overlaid in (C, D) are the lines-of-
best-fit and the 95% confidence bands (dashed lines). Antibody titres are presented as 
arbitrary values. Comparisons in (A, B) were assessed for significance by the Mann Whitney 
test. The strength of the correlations in (C, D) was assessed for significance by the 
Spearman correlation. 
3.3.5 Maternal and infant helminth-specific antibody responses are variable 
The presence of A. lumbricoides-specific IgE, IgG and IgG4, as well as T. trichiura-specific 
IgG4 antibodies in maternal serum samples taken at the time of their infants’ TB 
investigation visit were also measured. A. lumbricoides-specific IgE responses were 
detected in 13/44 (29.55%) maternal samples tested, as determined by ImmunoCAP® (Fig. 
3.5A). A higher number of maternal samples could be tested for the presence of helminth-
specific IgG and IgG4 antibodies, thus more descriptive pairwise comparisons with matched 
infant samples were subsequently performed. Following analysis of subsets of 76 mother-
infant pairs (baseline infant samples) and 89 mother-infant pairs (TB investigation infant 
samples), it was observed that maternal A. lumbricoides-specific IgG responses were 
significantly higher than those observed in infants (Fig. 3.5B, C). Analysis of A. lumbricoides-
specific IgG4 responses in a subset of 49 mother-infant pairs (TB investigation infant 




samples) revealed significantly higher median responses in infants, with a greater 
proportion of infants producing IgG4 (Fig 3.5C). In the subset of 34 mother-infant pairs 
investigated for T. trichiura-specific IgG4 responses (TB investigation infant samples), 
infants again exhibited significantly higher median IgG4 responses than their matched 
mothers, with a greater proportion of infants producing detectable IgG4 titres (Fig. 3.5E). 
   
Figure 3.5. Variable associations exhibited between maternal and infant helminth-
specific antibody responses. A. lumbricoides and T. trichiura-specific IgG and IgG4 in 
maternal serum samples taken at infants’ TB investigation visit versus infant helminth-
specific IgG and IgG4 in plasma samples from baseline and TB investigation. Maternal anti-
Ascaris IgE (n=44) (A); dashed line represents assay detection limit for positive responses. 
Maternal A. lumbricoides-specific IgG vs. infant A. lumbricoides-specific IgG at baseline 
(n=76 pairs) (maternal sample dilutions started at 1:50 and infants’ at 1:20) (B) and vs. 
infant IgG at TB investigation (n=89 pairs) (C). Maternal A. lumbricoides-specific IgG4 vs. 
infant A. lumbricoides-specific IgG4 at TB investigation (n=49 pairs) (D). Maternal T. 
trichiura-specific IgG4 vs. infant T. trichiura-specific IgG4 at TB investigation (n=34 pairs) 
(E). Antibody titres are presented as arbitrary values. Comparisons in (B-E) were assessed 
for significance by the Mann Whitney test. 
It is still debated to what extent maternal helminth infection influences infant cytokine 
responses to specific antigens (458, 460, 462, 474). To investigate whether maternal 
helminth exposure (as opposed to active infection) plays a role, infant Mycobacterium 




antigen-specific IFNγ production was analysed according to maternal helminth-specific 
antibody levels. However, there was no association between A. lumbricoides-specific IgG 
or IgG4 responses and infant T cell IFNγ production as measured by QFT (Fig. 3.6). 
   
Figure 3.6. Maternal A. lumbricoides-specific IgG and IgG4 do not associate with infants’ 
quantitative QFT values. A. lumbricoides-specific IgG and IgG4 measured in maternal 
serum samples taken at infants’ TB investigation visit versus quantitative outcomes of 
infant TB investigation visit QFT test. Anti-A. lumbricoides IgG (A) and IgG4 (B) titres vs. 
quantitative QFT outcomes. Overlaid are the lines-of-best-fit and the 95% confidence 
bands (dashed lines). Antibody titres are presented as arbitrary values. The strength of the 
correlations was assessed for significance by the Spearman correlation. 
3.3.6 Infant, but not maternal, helminth-specific antibody responses are associated 
with childhood vaccine antibody responses 
As maternal helminth exposure and concurrent helminth infection are suggested to have 
different effects on vaccination responses (458, 459, 463), total and vaccine-specific 
antibody titres in the infants were investigated in light of their own helminth exposure, as 
well as maternal helminth exposure. No associations were found between helminth-
specific antibody responses and total IgG responses (Fig. 3.7A, B), but significant positive 
correlations were found between A. lumbricoides-specific (Fig. 3.7C-E) and T. trichiura-
specific (data not shown; A. lumbricoides-specific responses are representative of both 
helminths) IgG responses and IgG responses to the BCG, measles and tetanus vaccines. No 
association was found between any of the BCG-specific antibody subtypes tested and 
helminth-specific IgG except for BCG-specific IgG1 which was associated with T. trichiura-
specific IgG (Fig. 3.7F). 




   
Figure 3.7. Infant helminth-specific IgG is positively associated with antibody responses 
to childhood vaccines. Helminth and vaccine-specific antibody responses measured in 
plasma samples from TB investigation. A. lumbricoides-specific IgG (A) and T. trichiura-
specific IgG (B) titres vs. total IgG titres. A. lumbricoides-specific IgG vs. anti-BCG IgG (C), 
anti-measles IgG (D) and anti-tetanus IgG (E); T. trichiura-specific IgG vs. anti-BCG IgG1 (F) 
titres as measured by ELISA. Three fewer samples reported for measles as participants had 
not yet received the measles vaccine, and three fewer reported for BCG IgG1 due to a lack 
of sample availability. Overlaid are the lines-of-best-fit and 95% confidence bands (dashed 
lines). Antibody titres are presented as arbitrary values. Strength of correlations was 
assessed by the Spearman correlation. 
 
  




Vaccine-specific antibody titres were analysed in light of helminth-specific subtype 
responses. As with the IgG responses (Fig. 3.7A, B), helminth-specific IgG4 responses did 
not associate with total IgG titres (data not shown). However, both A. lumbricoides-specific 
and T. trichiura-specific (data not shown; A. lumbricoides-specific responses are 
representative of both helminths) IgG4 responses were significantly correlated with BCG-
specific IgG, IgG1, IgG2 and IgG3 titres (Fig. 3.8A-D), as well as with measles- and tetanus-
specific IgG responses (Fig. 3.8E, F). 
  
Figure 3.8. A. lumbricoides-specific IgG4 is positively associated with childhood vaccine 
antibody responses. Helminth and vaccine-specific antibody responses measured in 
plasma samples from TB investigation. A. lumbricoides-specific IgG4 titres vs. anti-BCG IgG 
(A), IgG1 (B), IgG2 (C), IgG3 (D), anti-measles IgG (E) and anti-tetanus IgG (F) titres as 
measured by ELISA. Three fewer samples reported for BCG IgG1 due to a lack of sample 




availability, and three fewer reported for measles as participants had not yet received the 
measles vaccine. Overlaid are the lines-of-best-fit and 95% confidence bands (dashed 
lines). Antibody titres are presented as arbitrary values. Strength of correlations was 
assessed by the Spearman correlation. 
To determine whether maternal-infant antibody transfer of helminth-specific antibodies 
could be responsible for these positive associations, maternal helminth-specific antibodies 
were compared to infant vaccine antibody responses. Unlike the infant helminth-specific 
responses, maternal A. lumbricoides- and T. trichiura-specific responses did not associate 
with the infants’ antibody responses to the BCG, measles or tetanus vaccines (Fig. 3.9; A. 
lumbricoides-specific IgG responses are representative of A. lumbricoides- and T. 
trichiura-specific IgG4 responses). 




   
Figure 3.9. Maternal A. lumbricoides-specific IgG responses are not associated with infant 
childhood vaccine responses. A. lumbricoides-specific IgG in maternal serum samples 
taken at infants’ TB investigation visit versus infant vaccine-specific antibodies in plasma 
samples from TB investigation. Maternal A. lumbricoides-specific IgG vs. anti-BCG IgG (A), 
IgG1 (B), IgG2 (C), and IgG3 (D) titres; maternal A. lumbricoides-specific IgG vs. anti-measles 
IgG (E) and anti-tetanus IgG (F) titres. Three fewer samples reported for BCG IgG1 due to a 
lack of sample availability, and three fewer reported for measles as participants had not 
yet received the vaccine. Overlaid are the lines-of-best-fit and 95% confidence bands 
(dashed lines). Antibody titres are presented as arbitrary values. Strength of correlations 
was assessed by the Spearman correlation. 





Findings from this study reveal that despite the fact that these mothers and infants live in 
a region endemic for helminth infection (330), no current A. lumbricoides or T. trichiura 
infections were detected in the infants, and the rate of infection in mothers was low. This 
could be due to the availability of appropriate sanitation and water sources (Table 3.2) 
(482, 483), as well as mass deworming campaigns in the community (484). 
Despite low levels of active infection in the participants tested, helminth exposure is 
observed in this population, as indicated by the presence of antigen-specific class-switched 
antibodies. Associations between infant helminth-specific antibody responses and age 
were dependent on both helminth species and antibody subtype, whereas associations 
with vaccine responses did not show the same limitations. However, there was no 
association between helminth-specific antibody responses and either risk of Mtb infection 
or total IgG responses, nor between maternal helminth-specific and infant vaccine-specific 
responses. Taken together, these observations suggest that, in this setting, helminth 
exposure does not influence the risk of acquiring an Mtb infection, nor that the humoral 
response to the helminth antigens tested underlies the association observed between total 
IgG responses and risk of Mtb infection, but we substantiate previous findings that soil-
transmitted helminths may influence infant vaccination.  
A higher number of mothers than infants exhibited Ascaris-specific IgE production, with 
mothers also exhibiting greater levels of A. lumbricoides-specific IgG, a finding which may 
be accounted for by the presence of A. lumbricoides-specific IgG1 (395); however, this 
would need to be tested to confirm whether this is true of our cohort. Conversely, more 
infants produced A. lumbricoides- and T. trichiura-specific IgG4, with the IgG4 titres 
measured being significantly higher than those observed in maternal samples. These 
findings are in agreement with prior reports that young children exhibit raised helminth-
specific IgG4, and older children and adults raised IgE (404, 485), but contradict a report 
showing no relationship between maternal and neonatal A. lumbricoides-specific IgG4 
levels, with most neonatal samples testing positive for A. lumbricoides-specific IgG4 
seemingly unrelated to maternal infection status (486). Further investigation would be 
required to determine whether these observations represent a causal relationship. The 
increased levels of helminth-specific antibodies in the infants could also be explained by 
passive antibody transfer (456). However, due to the wide age range (8-36 months) of 




infants at the time of testing for helminth-specific antibodies, it is difficult to assess 
whether these antibodies were present due to passive transfer or helminth exposure alone. 
Additionally, the lack of current infection limits our ability to investigate whether these 
antibodies, passively transferred or not, could provide protection against helminth 
infection. 
The current understanding of the effect of helminth infection/exposure on Mtb infection 
remains unclear. In rodent models, the effects of helminth infection on mycobacterial 
infection has been reported as neutral (468, 470, 471, 473), negative (469, 472) or positive 
(450), with similarly complex findings reported in clinical studies (472, 474, 475).  However, 
it is important to consider the effect that helminth species, time of helminth infection 
(acute versus chronic) and stage of mycobacterial infection (latent vs. active disease) could 
have on the outcomes reported in these studies, as immune responses are contingent on 
these factors. For example, helminth infection may not influence immune responses to or 
acquisition of latent Mtb infection in certain populations (487, 488), whereas they could 
play a role in active TB disease in certain instances (472). In this study, no association was 
found between either A. lumbricoides- or T. trichiura-specific antibody responses and risk 
of Mtb infection, with similar median antibody titres in QFT- and QFT+ infants, which is in 
agreement with the literature reporting a neutral effect of helminth infection/exposure on 
mycobacterial infection. This finding also suggests that the humoral response to the 
helminth antigens tested does not account for the differences observed in risk of acquiring 
an Mtb infection when compared to total IgG responses (shown in Chapter 2), a suggestion 
supported by a lack of association between helminth-specific antibody responses and total 
IgG titres. 
Previous studies report an association between helminth infection and the outcome of a 
QFT test, with more indeterminate results being observed when helminth infection is 
present (480, 481). However, neither A. lumbricoides- nor T. trichiura-specific humoral 
responses from this study, in mothers or infants, were associated with IFNγ production as 
measured by QFT. Despite the differing results, it is important to consider that the effects 
reported in the literature are helminth species-dependent, and may only be observed in 
the presence of active infection and not helminth exposure. 
It has been postulated that the immunomodulatory effects induced by helminths or their 
antigenic products can result in an impaired response to vaccination (489). Several 




published reports are in agreement regarding this, with protective responses to tetanus 
(422, 463), cholera (449, 464) and BCG vaccines (465-467) suggested to be downregulated 
by helminth infection. However, a detrimental outcome is not always observed (468, 490). 
A comparison of infant humoral responses to helminths and childhood vaccines in this 
study revealed positive associations between antibody responses to both helminths and all 
vaccines tested, including BCG, measles and tetanus, but only tetanus-specific IgG was also 
correlated with total IgG (refer to Chapter 2). Despite the importance of a robust humoral 
response to most childhood vaccines (413), the interaction of helminth infection with 
antibody responses to vaccine antigens is not always addressed. Where vaccine humoral 
responses are investigated, there is no consensus on their relation to helminth infection. 
Vaccine antibody responses are either suggested to be prone to immunomodulation by 
helminths (422, 464), or not affected at all (490). Despite the positive correlations between 
helminth and vaccine humoral responses described above, neither of them underlie the 
association between total IgG responses and reduced risk of Mtb infection addressed 
previously (refer to Chapter 2). The potential benefits of a mycobacterial-specific antibody 
response to BCG have only recently come to light (285), are not often addressed in the 
literature (465, 468, 490) and are not yet well understood. As such, we cannot say 
definitively whether an increased BCG-specific response that is associated with the 
humoral response to helminths, equates to enhanced protection against Mtb. Finally, the 
observation that maternal helminth-specific antibody responses do not associate with the 
infants’ IgG responses to childhood vaccination support findings published previously (457, 
459, 462). 
Taken together, these data show that despite low overall rates of helminth infection, the 
presence of class-switched helminth-specific antibodies in mothers and infants indicates 
prior helminth exposure. However, this exposure does not relate to the risk of Mtb 
infection acquisition or IFNγ production by Mycobacterium-specific T cells, and its effect on 
vaccine responses is suggested to be minimal. These findings suggest that the 
immunomodulatory effects often shown to be induced by helminths are associated with 
active infection, whereas helminth exposure (maternal or otherwise) may have a more 
subtle effect on the host immune system. 




Chapter 4: An in vivo model investigating the influence of 
helminth exposure on BCG vaccination and infection 
4.1 Introduction 
Our clinical investigation touched on the role of maternal influences on infant immunity 
(please refer to Chapter 3). An original aim of the clinical component of this research was 
to investigate the role of maternal helminth infection on infant risk of acquiring an Mtb 
infection; however, with the clinical and sample data available, we were limited in what we 
could pursue. Paired with this limitation is the scarcity of clinical data addressing the impact 
of maternal helminth infection on infant Mtb infection outcomes. These cross-sectional 
study outcomes are restricted to measuring cytokine and/or antibody responses to 
relevant antigens, limiting inferences that can be drawn regarding how Mtb infection risk 
would be affected by alterations of these responses (458, 460, 462, 474). A murine model 
of maternal helminth infection and infant mycobacterial infection represents an elegant 
way of overcoming these limitations, and thus was used to address the study questions. 
Immune responses induced by Mtb are complex; in vivo models of mycobacterial infection 
and disease provide mechanistic insight that allows us to understand the significance of 
observations made in clinical studies. Commonly used laboratory mouse strains (e.g. 
BALB/c, C57BL/6) are resistant to Mtb infection, limiting bacterial growth and tissue 
damage, a phenotype somewhat reflective of the response in humans exposed to Mtb (491, 
492). Moreover, robust Th1 responses required for protection against Mtb infection are 
observed in both humans and mice (493). Thus, considering the benefits of a murine model 
and the similarities in immune responses to Mtb in mice and humans, murine TB models 
are appropriate models for clinical TB (493), albeit with acknowledged limitations (494, 
495). BCG vaccination also elicits protective responses in mice to subsequent Mtb infection, 
even with clinical Mtb strains (496, 497). As such, murine models have often been used to 
understand immune responses induced by BCG vaccination. Additionally, murine BCG 
infection models are also useful for understanding primary Mtb infection in humans (498), 
while circumventing the practical challenges involved with clinical Mtb animal models. 
Successful BCG infection can be induced in genetically resistant mouse strains (499), it is 
non-pathogenic (500), and can be controlled by the host (unlike Mtb infection) (501). Its 
uptake to the lungs and spleen mimic that of virulent mycobacterial infection, with 




protection characterized by classical Th1 responses (as outlined in section 1.4.1 of Chapter 
1) (498, 501).  
Nippostrongylus brasiliensis (Nb), a rodent helminth, is commonly used as a model of 
human helminth infections, such as hookworms (502, 503). This parasite induces potent 
Type 2 immune responses upon infection, from mucous and cytokine production (IL-4, IL-
5, IL-13), to eosinophilia (described in more detail in section 1.5.2 of Chapter 1) (502, 504). 
Some of these induced components are required for parasite clearance (364), whilst others 
contribute to wound healing (505). Importantly, although the patent infection is located in 
the intestine, establishment of patency requires larval migration through the lung (503, 
506). Their movement through the lung tissue causes physical damage (breakdown of 
alveoli), resulting in decreased lung function (507); this is also an important feature of 
certain human helminth infections (please refer to section 1.5.1 of Chapter 1). Additionally, 
these helminths and their excretory/secretory (NES) products induce type 2 responses in 
the lung, stimulating reactions that could contribute to lung immune pathology (380, 508). 
The opposing immune effects that mycobacterial and helminth infections induce in the 
host, and even in the same tissue, are important to consider in light of either co-infection 
or prior exposure to either pathogen occurring. Such differences may cause a profound 
effect on the host’s ability to control either pathogen; in one such example, prior 
mycobacterial infection was shown to abrogate immunity to Nb (509). Several studies 
investigating the effect of helminth infection on mycobacterial disease reveal the spectrum 
of effects that can be induced by different helminths, from detrimental (469, 472) to 
beneficial (450). These findings show that helminth infections can influence Mtb, but 
whether this influence is positive or negative depends on the context and species of 
helminth. 
Maternal immunity is a critical determinant of infant survival especially in low-middle 
income countries, with various immunological factors such as cells, cytokines and 
antibodies transferred trans-placentally and via breast milk. The influence of maternal 
helminth infection on offspring immunity was introduced in Chapter 3; however, little data 
exists as to how maternal exposure to helminths may influence offspring immunity to Mtb. 
Helminth infection during pregnancy has been observed to alter offspring immunity in 
several ways. Helminth-specific CD4 T cells and IgG, IgG1, IgG2 and IgE antibodies have 
been detected in offspring born to helminth-infected mothers, transferred either in utero 




or via breast milk, and often accompanied by Th1 and Th2 cytokine production by cord 
blood cells (456, 474, 510, 511). Maternal helminth infection can influence (negatively or 
positively) both antibody transfer and cytokine responses to Mtb-specific antigens (474, 
512), BCG immunization (460) and even unrelated conditions such as allergic airway asthma 
(513). However, maternal helminth infection does not always influence infant vaccine-
specific responses, as observed in a large Ugandan mother-infant cohort where infant 
tetanus and BCG-specific responses were unaffected by maternal helminth infection (458). 
These studies reveal that the effects of maternal helminth infection are not limited to 
helminth-specific responses, either in the mother or the offspring, but these effects may 
also be more complex than previously thought. 
In order to provide further insight on the potential effects of maternal helminth infection 
on offspring immunity to unrelated pathogens and childhood vaccines currently of 
relevance in sub-Saharan Africa, we utilized murine models of hookworm and 
mycobacterial infection. These were used to investigate whether maternal Nb infection 
alters offspring immunity to M. bovis BCG infection, and whether it alters the effectiveness 
of BCG vaccination in the offspring. The preliminary data presented here show that 
helminth infection prior to pregnancy enhances offspring ability to respond to BCG 
vaccination and infection. 
4.2 Materials and methods 
4.2.1 Animal husbandry and ethics 
All procedures performed using rodents were in accordance with protocols 011/018 and 
012/054, as approved by the University of Cape Town Animal Research Ethics Committee. 
Passage through Wistar rats was used to maintain the Nb life-cycle; these were ~150g at 
the time of infection. The rats were housed in open cages with continuous access to food 
and water. All related procedures were performed in the Biosafety Level 1 facilities of the 
University of Cape Town Animal Unit. 
For experimental procedures, wild type BALB/c mice (males, females and offspring) were 
used. All animals were bred and housed in a specific pathogen-free environment (Animal 
Unit, University of Cape Town), and were housed in closed individually-ventilated cages 
with continuous access to food and water. All experiments were performed in a Biosafety 
Level 2 facility in accordance with the University of Cape Town’s Health and Safety 




guidelines. All experimental mice used were 2-15 weeks of age, and offspring used for the 
experimental outputs were age-matched. Mice were euthanized by halothane inhalation 
and death confirmed by cervical dislocation at the end of an experiment. 
4.2.2 Mating and litter-swaps 
Matings were set up as follows: 2 females of 7-8 weeks of age and 1 male were included 
per cage. The mice were housed together for 2 weeks, after which the male was removed. 
If successful, females gave birth to offspring 21 days post-fertilisation; cages were 
monitored daily to identify the birth of offspring. A maximum of 2 females and 8 offspring 
per mother were housed in each cage. For long-term experiments, offspring were weaned 
and separated from their mothers at 3 weeks of age; male and female offspring were 
housed separately.  
4.2.3 Nb life-cycle 
Nb is a rodent parasite that is used as a model of hookworm infection (514-516). The 
characteristic features of the life-cycle are outlined by Sotillo et al and Camberis et al (502, 
515) and important steps are highlighted here. Helminth eggs are released into the soil as 
a component of faecal matter excreted by infected rodents. Once in the soil, the eggs hatch 
following an incubation period of approximately one week. The newly hatched worms then 
molt through two stages, L1 and L2, to become infective L3 larvae. L3 larvae penetrate the 
host’s skin and enter the bloodstream. Larvae migrate to the lungs 1-2 days after entering 
the circulatory system, where they molt to the L4 stage of the life-cycle. These newly 
molted larvae are coughed up and swallowed, and continue migrating through the 
digestive system until they reach the small intestine (day 3-4 post-infection). There, the 
larvae molt one last time to become mature adult worms (L5) that can produce eggs, which 
are released in the faeces. Adult worms are cleared naturally by the host in 
immunocompetent mice by day 9 post-infection.  
4.2.4 Nb infection, laboratory life-cycle and anti-helminth treatment 
As previously mentioned, Wistar rats were used to maintain the laboratory Nb life-cycle to 
generate the infective larvae required for experimental procedures. L3 larvae were injected 
SC into the scruff of the neck (5 000 L3/rat in 0.5ml of 0.9% NaCl, 18-gauge needle). Faecal 
pellets were collected from days 6-8 post-infection. These were liquefied in 5µg/ml 
Amphotericin B before being plated out on moist filter paper in petri dishes at room 
temperature to facilitate egg hatching. One week post faeces collection, L3 larvae migrated 




to the edges of the filter paper and were harvested for use in life cycle maintenance or 
experimental procedures. 
For murine infections, L3 larvae were washed off the filter paper into 0.9% NaCl, and 
counted under a dissecting microscope to establish a concentration of 2500 L3/ml. Mice 
were infected SC in the skin of the abdominal cavity (500 L3/mouse in 0.2ml FS 1X PBS, 21-
gauge needle). As previously mentioned, the mice would naturally clear the infection by 
approximately 9 days post-infection, but to ensure complete expulsion of the parasite, 
potential mothers were treated with 10µg/ml Ivermectin (Virbamec® LA) in their drinking 
water from days 7-14 post primary infection. The correct dose is approximately 4µg 
Ivermectin per 20g mouse per administration, which equates to 400µl per mouse of the 
drinking water containing 10µg/ml Ivermectin. To account for potential immune effects 
induced by Ivermectin treatment, helminth-uninfected mice were also treated with 
Ivermectin as described above. 
4.2.5 Mycobacterium bovis BCG culture 
The procedure for mycobacterial culture, infection and CFU measurement were adapted 
from methods outlined by Du Plessis et al (450). Stocks of BCG were kept at -80°C until 
required for experiments. One 100µl aliquot of frozen stock was inoculated into 20-40ml 
of liquid broth (Middlebrook 7H9 – DifcoTM) supplemented with OADC (Becton Dickinson) 
in a flask and incubated at 37°C for one-and-a-half weeks. The optical density reading of 
the culture was measured at a wavelength of 600nm, following de-clumping of the culture 
with a 26-gauge needle; bacteria were harvested in log phase, at an OD reading of 0.7-1.0. 
To maintain bacterial stocks, a portion of the culture was mixed with 10% glycerol, divided 
into aliquots and stored at -80°C. To confirm the integrity of the stocks and determine 
bacterial concentration, an aliquot was thawed 1-2 days after initial freezing, serially 
diluted and plated on 7H11 (Difco) agar culture plates supplemented with OADC. Following 
a three-week incubation, CFU counts were determined and recorded. 
4.2.6 BCG vaccination and infection 
Offspring were vaccinated IP at two weeks of age with 100µl BCG in FS 1X PBS (Danish strain 
1331, Statens Serum Institut, Denmark) at a dose of 0.1mg/ml (0.01mg/pup, equivalent to 
dose-by-weight recommended for infants). Offspring used in control groups were given 
100µl 1X PBS IP. Three weeks post-vaccination, PBS- and vaccine-treated mice were 




infected IN with live BCG (cultured as described above) at a dose of 5x105CFU/mouse in 
50µl FS 1X PBS. 
4.2.7 Sample collection and tissue processing 
Three weeks after BCG infection, offspring were euthanized as described above, and tissues 
of interest harvested. The lungs, MST lymph nodes and spleen were removed by incision 
under sterile conditions for further analysis. Prior to processing, lung samples were 
incubated in digestion buffer (containing collagenase and DNase) at 37°C for one hour. 
Once harvested, whole lung and spleen weights were recorded prior to further processing. 
To determine bacterial burden, segments of lung tissue were removed and weighed. 
Subsequently, the tissue segments were homogenized (Omni Prep® homogenizer, Omni-
International) in sterile 1X PBS containing 0.05% Tween-80 (Sigma Aldrich). Once 
homogenized, serial dilutions of each sample were generated, and relevant dilutions plated 
onto Middlebrook 7H11 agar plates supplemented with OADC. Plates were incubated at 
37°C for three weeks, after which plate CFU counts were performed and used to calculate 
CFU/ml for each sample. 
The remaining tissue samples were processed in preparation for further analysis by flow 
cytometry. Tissue segments were homogenized in DMEM with 40 μM cell strainers to 
generate single cell suspensions. Once homogenized, red blood cells in lung and spleen 
samples were lysed with RCLB for 2 minutes, after which samples were centrifuged at 
1200rpm for 5 minutes at 4°C to remove the lysis buffer. The cells were then washed and 
resuspended in DMEM. Viable cells in each sample were counted with a haemocytometer 
by Trypan Blue exclusion and counts used to determine total number of cells per organ. 
Cells were washed and resuspended in DMEM at a concentration of 5x106 cells/ml, and 
were kept on ice until required. 
All 4 experimental groups discussed in this chapter would be included in a single 
experiment and can be compared. For the sake of clarity in explanation, only 2 
experimental groups were discussed at a time. 
4.2.8 Cell staining for flow cytometry 
Once processed and counted, cells were stained for analysis by flow cytometry as outlined 
below. For staining of extracellular markers, 1X106 cells per sample were aliquoted into 
wells of a 96-well plate. The plate was centrifuged at 1200rpm for 5 minutes at 4°C to 




remove excess medium, after which 25μl of the relevant antibody master mix was added 
to each well, and the plate incubated in the dark at 4°C for 20 minutes. Following staining, 
the plate was centrifuged as above and cells washed to remove unbound antibody. If flow 
cytometric analysis was performed immediately, cells were resuspended in 200μl MACS 
buffer and left in the dark at 4°C until required. If flow cytometric analysis was delayed, 
cells stained for the relevant cell-surface markers were fixed in 2% PFA in the dark at 4°C 
for 20 minutes. Following this, cells were washed and resuspended in MACS buffer, ready 
for acquisition, or permeabilization buffer to prepare cells for intracellular staining. 
Prior to intracellular staining, cells were stimulated with PMA/ionomycin (20ng/ml and 
1µg/ml respectively) and treated with GolgiStopTM (used according to manufacturer’s 
instructions) at 37°C for 4 hours. Subsequently, cells were fixed as described above, and 
fixed cells were incubated in permeabilization buffer in the dark at 4°C for 45 minutes. Cells 
were then incubated in a blocking solution (containing rat serum and an FcγRII/III blocker) 
to prevent non-specific binding of antibodies for a further 10 minutes at 4°C in the dark. 
Next, 25μl of the primary antibody intracellular mix (or appropriate isotype control) was 
added to each well, and the plate incubated for 45-60 minutes at 4°C in the dark. Cells were 
then centrifuged as described above, and washed with 1X MACS buffer to prepare them 
for acquisition. Table 4.1 details all antibodies used for intra- and extracellular staining. 
Table 4.1. Antibodies used for flow cytometry. 
Antibody for Fluorochrome Clone number Company Isotype control 
CD4+ T cells     
CD3 A700 500A2 BD Pharmingen N/A 
 PE 500A2 BD Pharmingen N/A 
CD4 PerCP-Cy5.5 RM4-5 BD Pharmingen N/A 
 V450 RM4-5 BD Pharmingen N/A 
CD44 FITC IM7 BD Pharmingen N/A 
IFNγ APC R4-6A2 BD Pharmingen IgG1 
IL-4 FITC 11B11 In-house IgG1 
B cells     
B220 V500 RA3-6B2 BD Pharmingen N/A 
MHC II FITC M5/114 In-house N/A 
 A700 2G9 BD Pharmingen N/A 
CD19 PerCP-Cy5.5 ID3 BD Pharmingen N/A 
CD21 APC 7G6 BD Pharmingen N/A 
CD23 PE B3B4 BD Pharmingen N/A 




4.2.9 FACS procedure and gating strategies 
Once appropriately stained, samples were acquired on a BDTM LSRFortessa flow cytometer, 
using FACSDivaTM software to record outputs. To account for spectral overlap between 
fluorochromes, single fluorochrome-labelled compensation bead tubes were prepared and 
acquired prior to sample acquisition. Following acquisition, data were analysed using the 
FlowJo® software package. The gating strategies used to identify cell populations of interest 
are presented below (Fig. 4.1, 4.2). For intracellular staining, isotype controls were used to 
set the gates for positive cytokine staining. 
     
Figure 4.1. T cell flow cytometry gating strategy. Staining from spleen samples utilised to 
show T cell gating strategy (A). Forward scatter (cell size) and side scatter (cell granularity) 
parameters are used to identify cells from the raw data. Within the lymphocyte population, 
helper T cells (CD3+CD4+) are identified and the proportion of activated CD4 T cells (CD44+) 
determined. Staining from lung draining lymph node samples utilised to show intracellular 
staining for cytokines in CD4 T cells (B). Cells are identified as in (A), following which 
intracellular IFNγ and IL-4 expression of CD4+ T cells are analysed. 
 




    
Figure 4.2. B cell flow cytometry gating strategy. Staining from spleen samples utilised to 
show gating strategy. Forward scatter (cell size) and side scatter (cell granularity) 
parameters are used to identify cells from the raw data (A). Within the lymphocyte 
population, B cells(CD19+B220+) are identified (A). The B cell subpopulations are 
determined as follows: newly-formed (NF – CD21-CD23-), follicular (FO – CD21lo-intCD23hi) 
and marginal zone (MZ – CD21hiCD23lo) B cells, as well as the proportion of MHC II+ FO and 
MZ B cells (A). Relative MHC II expression on FO and MZ B cells is also recorded (B). 
4.2.10 ELISA 
The concentrations of antigens and antibodies described here were chosen specifically for 
use with this in-house ELISA assay. The procedure outlined below were adapted from 
similar methods described elsewhere (358, 517). BCG vaccine antigen was prepared as 
described in Chapter 2. 
Nb antigen 
Somatic Nb antigen was prepared from whole L3 larvae as described previously (456). 
Larvae were washed from the filter paper on which they are maintained into distilled water 
containing 50µg/ml P/S to kill larval-associated bacteria. Larvae were incubated in this 




solution at room temperature for 1 hour, following which they were washed twice in 
distilled water and resuspended in 2ml distilled water. To disrupt cell walls, larvae were 
snap-frozen in liquid nitrogen and then homogenized in the distilled water. Following this, 
the homogenized solution was centrifuged to remove cellular debris. Once centrifuged, the 
soluble fraction was carefully decanted and the protein concentration in this fraction 
measured by BCA assay (PierceTM BCA Protein Assay Kit, Thermo Fisher Scientific). Once the 
protein concentration was recorded, the soluble fraction was adjusted to a stock 
concentration of 500µg/ml and aliquots of the stock solution were frozen at -80°C until 
required. 
Antigen-specific ELISA 
Antigen-specific antibody ELISAs were performed. Coating antigens (BCG vaccine and Nb 
antigen) were used at 10µg/ml. Initial serum sample dilutions for the measurement of Nb-
specific antibodies were 1:3, followed by a 1:3 serial dilution of that across a further 5 wells. 
Initial serum sample dilutions for the measurement of BCG-specific antibodies were 1:5, 
followed by a 1:5 serial dilution of that across a further 5 wells. The horse radish peroxidase 
(HRP)-linked IgG-specific secondary antibody was used at 1:5000, whereas the biotinylated 
IgG1 and IgG2a-specific antibodies were used at 1:2000. Streptavidin-HRP was used at 
1:5000. 
Nunc-ImmunoTM MicroWellTM MaxisorpTM 96-well plates (Thermo Fisher Scientific; 
Waltham, MA) were coated with antigen and incubated at 37°C for 3 hours. Plates were 
washed 1X with PBS-Tween20 buffer and blocked with 200μl/well 2% BSA/1X PBS at 4°C 
overnight. Plates were washed 1X as above and sample added (50μl/well); plates were 
incubated at 4°C overnight. Plates were washed 3X as above and secondary antibody added 
(50μl/well); plates were incubated at 37°C for 3 hours. Prior to development, plates utilising 
biotinylated secondary antibodies were washed 3X as above and streptavidin-HRP 
(50μl/well) added. Plates were washed 3X as above and TMB substrate – prepared 
according to the manufacturer’s instructions (TMB Microwell Peroxidase Substrate System, 
Roche Diagnostics GmbH, Mannheim, Germany) - added (50µl/well). Reactions were 
stopped with 0.5M H2SO4 and plates read on a VersamaxTM 96-well plate reader (Molecular 
Devices; Sunnyvale, CA) at wavelength 450nm (540nm reference filter). Optical density 
readings (y-axis) vs. sample dilutions (x-axis) were plotted. 




4.2.11 Statistical analysis 
The Mann Whitney test was utilized for the analysis of unpaired two-group data. For the 
analysis of antibody data, individual dilutions were compared for significance with the 
Mann Whitney test. All analyses were two-tailed, and data are presented with the mean 
and standard deviation (SD). Significance was accepted at p≤0.05. GraphPad Prism software 
(v. 5.03) was used for all statistical analyses and graphs presented. 
4.3 Results 
4.3.1 Maternal helminth infection reduces lung bacterial burden following M. bovis 
BCG infection of offspring 
Female BALB/c mice were infected with 500 L3 Nb larvae, and after 7 days the infection 
was cleared with a 5-day oral Ivermectin treatment. Once cleared, these mice were mated 
with male BALB/c mice. At 5 weeks of age, offspring were infected intranasally with M. 
bovis BCG. Once the infection had progressed for 3 weeks, offspring were killed and 
samples collected for further analysis (Fig. 4.3A). 
Offspring of Nb-exposed mothers exhibited a significant decrease in lung bacterial burden 
(Fig. 4.3B). Importantly, these data show that maternal prenatal Nb exposure results in a 
clear protective effect against BCG infection in mature offspring and to the best of our 
knowledge, this is the first demonstration of such a finding. 




   
Figure 4.3. Maternal Nb infection results in reduced bacterial burden and increased cell 
infiltration in BCG-infected offspring. (A): BALB/c female mice were infected with 500 L3 
Nb larvae, and 7 days later the infection was cleared with Ivermectin treatment. Once the 
infection had been cleared, mice were mated with BALB/c males. Pups were infected 
intranasally with BCG at 5 weeks of age. Samples were collected 3 weeks post BCG 
infection. Lung CFU/mouse values (B) and total cell numbers (C) were calculated. Data are 
pooled from 2 experiments (mean ± SD) with n=10-16 pups and n=4 mothers per group. 
Significance was assessed by the Mann Whitney test (*p ≤ 0.05). 
4.3.2 Maternal helminth infection increases pulmonary cellularity, reflected by an 
upregulation of CD4 T cells, following M. bovis BCG infection of offspring 
Associated with this protection was a significant increase in total lung cell numbers (Fig. 
4.3C), indicative of cellular expansion or infiltration. Analysis of lung T cell responses 
revealed no difference in the proportion of CD4+ T cells between offspring of Nb-exposed 
vs. unexposed mothers, but CD4+ T cell numbers were significantly upregulated in offspring 
of Nb-exposed mothers (Fig. 4.4A), reflecting the upregulation observed with total lung cell 
numbers in (Fig. 4.3C). Similar findings were observed upon investigation of CD4+ T cell 
activation, with similar proportions of activated (CD44+) CD4+ T cells in both groups, but 
significantly increased cell numbers in offspring of Nb-exposed mothers (Fig 4.4B). 




   
Figure 4.4. Maternal Nb infection is associated with increased numbers of activated Th 
cells in the lungs of BCG-infected offspring. Proportions and numbers of lung CD4+ T cells 
(A) were calculated, following which activated (CD3+CD4+CD44+) CD4 T cells were identified 
(B). Data are pooled from 2 experiments (mean ± SD) with n=15-16 pups and n=4 mothers 
per group. Significance was assessed by the Mann Whitney test (*p ≤ 0.05). 
4.3.3 Maternal helminth infection upregulates CD4 T cells in the lung draining lymph 
nodes following M. bovis BCG infection of offspring 
Mediastinal lymph nodes (lung draining lymph nodes) were harvested and analysed. No 
significant difference in the total number of lymph node cells between experimental groups 
was found (Fig. 4.5A). Similar to observations with lung tissue, no difference was found in 
the proportion of lymph node CD4+ T cells, but offspring of Nb-exposed mothers exhibited 
significantly increased numbers of CD4+ T cells as compared to offspring of unexposed 
mothers (Fig. 4.5B). Offspring of Nb-exposed mothers also showed a significant increase in 
the proportion and number of activated CD4+ T cells present in the lymph nodes as 
compared to offspring of Nb-unexposed mothers (Fig. 4.5C). To observe whether maternal 
helminth infection caused skewing of CD4+ T cell cytokine production to a type 1 or type 2 
phenotype, IFNγ and IL-4 expression were measured. However, there was no difference in 
the proportion or number of IFNγ+ or IL-4+ CD4+ T cells between experimental groups (Fig. 
4.5D). 





Figure 4.5. Maternal Nb infection is associated with an increase in activated Th cells in 
the lung draining lymph nodes of BCG-infected offspring. Total mediastinal lymph node 
cell numbers were calculated (A). Proportions and numbers of draining lymph node CD4+ T 
cells (B) were calculated, following which activated (CD3+CD4+CD44+) CD4 T cells were 
identified (C). Proportions and numbers of draining lymph node CD4+ T cells producing IFNγ 
and IL-4 were calculated (D). Data are pooled from 1-2 experiments (mean ± SD) with n=5-
13 pups and n=2 mothers per group, for each experiment. Significance was assessed by the 
Mann Whitney test (*p ≤ 0.05). 
Lymph node B cell responses were also measured. Both the proportion and number of B 
cells were significantly increased in offspring of Nb-exposed mothers as compared to 
offspring of unexposed mothers (Fig. 4.6A). Additionally, the relative expression of MHC II, 
a molecule associated with antigen presentation to CD4+ T cells, was significantly 
upregulated on B cells from offspring of Nb-exposed mothers (Fig. 4.6B). 




   
Figure 4.6. Maternal Nb infection is associated with an increase in lung draining lymph 
node B cells and their MHC II expression in BCG-infected offspring. The proportion and 
number of B cells in the draining lymph nodes were calculated (A), as well as their 
expression of MHC II (B). Data are representative of 1 experiment (mean ± SD) with n=5 
pups and n=2 mothers per group. Significance was assessed by the Mann Whitney test (*p 
≤ 0.05). 
4.3.4 Maternal helminth infection modulates splenic B cell levels and MHC II 
expression following M. bovis BCG infection in offspring 
The spleen represents another important site of adaptive immune responses to pathogens, 
and as such, splenic B cell responses were investigated. Although no difference was 
observed in spleen weight between offspring of Nb-exposed and unexposed mothers, total 
spleen cell number was significantly upregulated in offspring of Nb-exposed mothers (Fig. 
4.7A). A trend for an increased proportion of B cells in offspring of Nb-exposed mothers 
was observed, but this was not significant; however, these offspring did have a significant 
increase in B cell numbers, a difference reflective of total spleen cell numbers between 
groups (Fig. 4.7B). Splenic B cells can be divided into 2 distinct subpopulations, namely 
follicular (FO) and innate-like marginal zone (MZ) B cells. These subpopulations are most 
commonly involved in responses to T cell-dependent and independent antigens, 
respectively (518, 519). Analysis of B cells by subpopulation revealed no difference in the 
proportion of follicular (FO) B cells between groups, but offspring of Nb-exposed mothers 
exhibited a significant increase in the proportion of marginal zone (MZ) B cells as compared 
to offspring of Nb-unexposed mothers (Fig. 4.7C). However, the numbers of both FO and 
MZ B cells were significantly higher in offspring of Nb-exposed mothers (Fig. 4.7C), again 
reflective of the difference in total spleen cell number. Investigation of MHC II expression 
on FO and MZ B cells revealed no difference in the proportions of MHC II+ FO or MZ B cells, 
but both subpopulations had a significant increase in numbers of MHC II+ cells in offspring 




of Nb-exposed mothers (Fig. 4.7D). However, there were no differences in the relative 
expression levels of MHC II between experimental groups for either FO or MZ B cells (Fig. 
4.7D), suggesting a limited effect of maternal helminth exposure on the antigen-presenting 
capabilities of spleen B cells during BCG infection. 
  
Figure 4.7. Maternal Nb infection is associated with increased numbers of splenic FO and 
MZ B cells expressing MHC II. Spleen weight and total cell numbers were calculated (A). 
Splenic B cell proportions and numbers were calculated (B), and stratified as (CD23hiCD21lo-
int) FO and (CD23loCD21hi) MZ B cells (C). The proportion and number of FO and MZ cells 
expressing MHC II, as well as the mean fluorescence intensity of MHC II expression were 
calculated (D). Data are representative of 1 experiment (mean ± SD) with n=8 pups and n=2 
mothers per group. Significance was assessed by the Mann Whitney test (*p ≤ 0.05). 
4.3.5 Maternal helminth infection upregulates Nb antigen-induced IgG1 levels in M. 
bovis BCG-infected offspring 
To investigate whether the upregulation of B cells and their MHC II expression in offspring 
of Nb-exposed mothers translated to differences in antibody production, serum samples 




were tested for the presence of antibodies to Nb somatic antigen and BCG vaccine antigen. 
Firstly, BCG-specific total IgG responses were measured to observe whether maternal Nb 
infection affected the vaccine-specific IgG response. Production of BCG-specific IgG was 
observed, but there was no difference in the IgG levels between experimental groups (Fig. 
4.8A). To determine whether there were differences in IgG subtype production, and if so, 
whether antibody production was skewed either to a Type 2 or a Type 1 phenotype, the 
subclasses IgG1 and IgG2a were investigated (520, 521). Additionally, although the mature 
offspring were helminth-unexposed, IgG subtype-specific responses to Nb antigen were 
measured to detect whether maternal Nb infection had induced any longer-lasting 
antibody responses. Offspring born to Nb-exposed mothers had significantly higher Nb-
specific IgG1 levels in their serum than offspring born to naïve mothers, but no differences 
in BCG-specific IgG1 levels were observed (Fig. 4.8B). There was no significant difference in 
Nb-specific IgG2a levels, but offspring born to Nb-exposed mothers showed a trend for 
increased BCG-specific IgG2a levels (Fig. 4.8C). 
   
Figure 4.8. Maternal helminth infection results in significantly increased Nb-specific IgG1 
in BCG-infected offspring. Serum BCG vaccine-specific IgG (A), and Nb-specific and BCG 
vaccine-specific IgG1 (B) and IgG2a (C) levels were measured. Data are pooled from 2 
experiments (mean ± SD) with n=12 pups and n=4 mothers per group. Significance at each 
dilution was assessed by the Mann Whitney test (*p ≤ 0.05). 
4.3.6 The effect of maternal helminth infection on M. bovis BCG infection of offspring 
is less prominent following early-life BCG vaccination 
Female BALB/c mice were infected with 500 L3 Nb larvae, and after 7 days the infection 
was cleared with a 5-day oral Ivermectin treatment. Once cleared, these mice were mated 




with male BALB/c mice. At 2 weeks of age, offspring of these females were vaccinated with 
BCG, following which they were infected intranasally with M. bovis BCG 2 weeks after 
vaccination. Once the infection had progressed for 3 weeks, offspring were killed and 
samples collected for further analysis (Fig. 4.9A). 
   
Figure 4.9. Maternal Nb infection is associated with decreased bacterial burden in BCG-
vaccinated and infected offspring. (A): BALB/c female mice were infected with 500 L3 Nb 
larvae, and 7 days later the infection was cleared with Ivermectin treatment. Once the 
infection had been cleared, mice were mated with BALB/c males. Pups were vaccinated 
with BCG (or PBS control) 2 weeks after birth, and infected intranasally with BCG 3 weeks 
post BCG vaccination. Samples were collected 3 weeks post BCG infection. Lung 
CFU/mouse values (B) and total cell numbers (C) were calculated. Data are pooled from 2 
experiments (mean ± SD) with n=7-17 pups and n=4 mothers per group. Significance was 
assessed by the Mann Whitney test (*p ≤ 0.05). 
BCG vaccination administered to offspring of Nb-exposed mothers resulted in a near 
significant decrease in lung bacterial burden as compared to vaccination in the absence of 
maternal helminth infection (Fig. 4.9B), but did not result in differing total lung cell 
numbers (Fig. 4.9C). Analysis of lung CD4+ T cell responses revealed no significant 
differences in either proportion or number of CD4+ T cells between experimental groups 
(Fig. 4.10A). Additionally, there were no differences in the proportion or number of 




activated lung CD4+ T cells between vaccinated offspring of Nb-exposed or unexposed 
mothers (Fig. 4.10B). 
  
Figure 4.10. Maternal Nb infection does not associate with changes in lung Th cells in 
BCG-vaccinated and infected offspring. Proportions and numbers of lung CD4+ T cells (A) 
were calculated, following which activated (CD3+CD4+CD44+) CD4 T cells were identified 
(B). Data are pooled from 2 experiments (mean ± SD) with n=10-17 pups and n=4 mothers 
per group. Significance was assessed by the Mann Whitney test (*p ≤ 0.05). 
4.3.7 Maternal helminth infection upregulates activated CD4 T cells, IFNγ-expressing 
CD4 T cells and B cells in lung draining lymph nodes following BCG vaccination 
and infection of offspring 
There were no differences in total draining lymph node cell number (Fig. 4.11A) nor in the 
proportion or number of CD4+ T cells between vaccinated offspring born to Nb-
exposed/unexposed mothers (Fig. 4.11B). However, vaccinated offspring of Nb-exposed 
mothers did exhibit significantly increased proportions and numbers of activated CD4+ T 
cells (Fig. 4.11C). Additionally, vaccinated offspring of Nb-exposed mothers exhibited 
significantly increased proportions and numbers of IFNγ+ CD4+ T cells, but there was no 
difference in the levels of IL-4+ CD4+ T cells (Fig. 4.11D).  





Figure 4.11. Maternal Nb infection is associated with an increase in activated Th cells and 
IFNγ-producing T cells in the lung draining lymph nodes of BCG-vaccinated and infected 
offspring. Total mediastinal lymph node cell numbers were calculated (A). Proportions and 
numbers of draining lymph node CD4+ T cells (B) were calculated, following which activated 
(CD3+CD4+CD44+) CD4 T cells were identified (C). Proportions and numbers of lung draining 
lymph node CD4+ T cells producing IFNγ and IL-4 were calculated (D). Data are pooled from 
1-2 experiments (mean ± SD) with n=3-14 pups and n=2 mothers per group, for each 
experiment. Significance was assessed by the Mann Whitney test (*p ≤ 0.05). 
Analysis of B cells in the draining lymph nodes revealed no difference in the proportion of 
B cells between experimental groups, but vaccinated offspring of Nb-exposed mothers did 
have significantly increased numbers of B cells (Fig. 4.12A). The B cells from vaccinated 
offspring of Nb-exposed mothers also exhibited significantly reduced relative MHC II 
expression levels as compared to vaccinated offspring of Nb-unexposed mothers (Fig. 
4.12B). 




   
Figure 4.12. Maternal Nb infection is associated with an increase in lung draining lymph 
node B cells and decreased MHC II expression in BCG-infected offspring. The proportion 
and number of B cells in the draining lymph nodes were calculated (A), as well as their 
expression of MHC II (B). Data are representative of 1 experiment (mean ± SD) with n=3-5 
pups and n=2 mothers per group. Significance was assessed by the Mann Whitney test (*p 
≤ 0.05). 
4.3.8 Maternal helminth infection modulates splenic B cell subpopulations of BCG-
vaccinated and -infected offspring 
There was no difference in either spleen weight or total cell number between experimental 
groups (Fig. 4.13A). Investigation of splenic B cells revealed no difference in the proportions 
or numbers of B cells between experimental groups (Fig. 4.13B). More detailed 
investigation of the B cell subpopulations revealed a significant increase in the proportion 
and number of MZ B cells in vaccinated offspring of Nb-exposed mothers, but no 
differences were observed with FO B cells (Fig. 4.13C). Vaccinated offspring of Nb-exposed 
mothers exhibited a significant decrease in the proportions, but not numbers, of MHC II+ 
FO and MZ B cells (Fig. 4.13D). Analysis of the relative MHC II expression levels revealed 
significantly decreased MHC II expression on FO and MZ B cells from vaccinated offspring 
of Nb-exposed mothers (Fig. 4.13D), reflecting the differences observed with proportions 
of MHC II+ cells. 





Figure 4.13. Maternal Nb infection is associated with increased splenic MZ B cells, but 
decreased MHC II expression on splenic B cells in BCG-vaccinated and infected offspring. 
Spleen weight and total cell numbers were calculated (A). Splenic B cell proportions and 
numbers were calculated (B), and stratified as (CD23hiCD21lo-int) follicular (FO) and 
(CD23loCD21hi) marginal zone (MZ) B cells (C). The proportion and number of FO and MZ 
cells expressing MHC II, as well as the mean fluorescence intensity of MHC II expression 
were calculated (D). Data presented are representative of 1 experiment (mean ± SD) with 
n=3-8 pups and n=2 mothers per group. Significance was assessed by the Mann Whitney 
test (*p ≤ 0.05). 
4.3.9 Maternal helminth infection modulates Nb-specific antibody levels in BCG 
vaccinated and infected offspring 
As described previously, to investigate whether the differences observed with B cell 
populations in the lymph node and spleen translated into changes in their antibody 
production, serum samples were tested for the presence of Nb-specific and BCG-specific 
antibodies. Maternal helminth infection did not associate with differences in the levels of 
BCG-specific IgG between experimental groups (Fig. 4.14A). Offspring of Nb-exposed 




mothers had significantly increased levels of Nb-specific IgG1 (Fig. 4.14B), but not of IgG2a 
(Fig. 4.14 C). There was no difference in the levels of BCG-specific IgG1, but there was a 
trend for decreased BCG-specific IgG2a in offspring of Nb-exposed mothers (Fig. 4.14B, C). 
   
Figure 4.14. Maternal helminth infection results in significantly increased Nb-specific 
IgG1 in BCG-vaccinated and infected offspring. Serum BCG vaccine-specific IgG (A), and 
Nb-specific and BCG vaccine-specific IgG1 (B) and IgG2a (C) levels were measured. Data are 
pooled from 2 experiments (mean ± SD) with n=11 pups and n=4 mothers per group. 
Significance at each dilution was assessed by the Mann Whitney test (*p ≤ 0.05). 
4.4 Discussion 
Observations from this in vivo model of maternal helminth and offspring bacterial infection 
reveal that maternal Nb infection alone can protect offspring against an intranasal BCG 
infection, most noticeably observed as a significant decrease in lung bacterial burden in the 
offspring of Nb-exposed mothers. Additionally, maternal Nb infection enhances cell 
recruitment to the site of infection, and may influence activation of the adaptive cell 
responses to BCG infection in the offspring. Investigation into the influence of maternal Nb 
infection on BCG vaccine effectiveness in offspring revealed a subtle synergistic effect, with 
the vaccinated offspring of Nb-exposed mothers exhibiting a near significant decrease in 
lung bacterial burden, and some upregulation of adaptive cell responses. Importantly, at 
the experimental endpoint for both BCG infection and BCG vaccination offspring were 8 
weeks old, suggesting that the effects of maternal helminth infection were no longer being 
mediated through maternally-derived factors in the offspring. This could be indicative of 
fundamental immune changes induced in the offspring by maternal immunity. 




Although our understanding of the influence of helminth exposure or infection on 
mycobacterial infection remains incomplete, the role of maternal helminth infection has 
been addressed in some studies. The upregulation of TB-specific antibody transfer (474) 
and cytokine responses to TB-specific antigens (512) suggests a potential protective effect 
of maternal helminth infection. Contradictory findings have also been reported, with 
children born to helminth-infected mothers exhibiting lower levels of IFNγ production in 
response to PPD (460). However, these studies do not address the impact of the altered 
immune responses on mycobacterial disease outcome. Varied effects of helminths on lung-
associated pathology and bacterial burden have been reported. Chronic filarial infection in 
cotton rats didn’t induce significant changes either in lung Mtb burden or Mtb-specific 
immune responses (470), and toxocariasis in mice yielded similar results (471). Conversely, 
infection with the trematode Schistosoma mansoni is suggested to have a more 
pronounced effect on mycobacterial infections, with increased bacterial burdens and 
dampened splenic responses reported (472, 522). Acute Nb pre-infection of mice was 
shown to have a transitory deleterious effect on control of lung Mtb burden, but is 
suggested to have a positive effect during BCG infection, with reduced bacterial burdens 
reported in co-infected mice (450, 469). Our finding of significantly decreased bacterial 
burden in offspring of Nb-exposed mothers lend support to the suggestion that helminth 
exposure or infection may provide protection against mycobacterial infection. The effects 
of helminth infection on lung inflammatory responses, indicative of cell infiltration, are just 
as varied. Either no difference in inflammation (469, 471), or an increase in inflammation 
are often reported (450, 472, 522). Our study suggests that even maternal helminth 
exposure can induce cellular infiltration in the lungs, potentially inducing lung 
inflammation. A similar study investigating maternal/offspring Nb infection alone did not 
reveal differences in pup total lung cell numbers (456); however these pups were 
investigated at a younger age and were not exposed to BCG. 
It is well-known that opposing adaptive immune responses play a crucial role in the immune 
response to both helminth and mycobacterial infection. As such, it is important to consider 
the potential immune consequences of co-exposure to pathogens able to stimulate such 
different responses. It is generally accepted that helminth co-infection decreases CD4 T cell 
frequencies and responses to mycobacteria or mycobacterial-specific antigens, which could 
result in a dampened Th1 response in the lung (475, 523, 524). It has also been shown that 




helminth co-infection can downregulate proliferation of PBMCs and spleen cells, as well as 
affecting their protective functions in response to stimulation with PPD (522, 525). 
However, such dampening effects do not always occur (470), nor are they always 
detrimental (524). We found a significant upregulation of overall CD4+ and activated CD4+ 
T cell numbers in the lung, with the increase in activated CD4 T cell numbers reflective of a 
co-infection study utilizing a model of Nb and BCG co-infection (450). Additionally, 
activated CD4+ T cells in the lung draining lymph nodes were significantly increased, which 
is contrary to data suggesting dampened Th1 cell responses in the lymph nodes (524). 
Despite the increase in activated CD4+ T cells, there was no associated skewing of cytokine 
expression by these cells. It is important to note that these are overall CD4+ T cell responses, 
and may be specific for either pathogen. Additionally, cytokine analyses were performed 
with mitogen-stimulated cells alone and not unstimulated controls. As such, the values 
reported may be influenced to some degree by the presence of cytokines produced under 
homeostatic conditions. Although the cytokine milieu investigated here provides some 
insight to the immune environment under these experimental conditions, additional 
experiments with unstimulated controls would need to be performed to confirm whether 
these observed responses are specific to mitogen stimulation, or simply due to background 
cytokine production. Equally, as mitogen stimulation induces general cell activation, it 
would also be beneficial to investigate whether pathogen-specific antigens are able to 
induce cytokine production under these experimental conditions, or if maternal helminth 
exposure leaves the cytokine environment relatively undisturbed 
B cells and the antibodies they produce have long been marked as important in helminth 
infection. As part of helminth-induced Th2 immunity, the production of IgA, IgG1, IgG4 and 
IgE have been reported; whether the antibodies are protective depends on the helminth 
studied, with IgE often identified as the subtype associated with protection (358, 384, 394, 
526-528). However, alternative B cell functions may also be important in protective 
immune responses against helminths. B cell antigen presenting capabilities have been 
reported as important for protection against secondary Nb infection (358), and although 
not essential for Nb expulsion, B cells are important in expulsion of H. polygyrus (392). 
Conversely, the role of B cells and antibody in Mtb infection have long been under-
appreciated, and have only recently been reinvestigated as an important component of 
anti-mycobacterial immunity (529). Various class-switched antibodies have been reported 




as potentially protective against Mtb (305, 415). Additionally, patients with active TB 
disease or latent Mtb infection exhibited B cells with an atypical phenotype; treatment 
corrected this and increased T cell activity, highlighting the importance of healthy B cells in 
immunity to Mtb (530). Studies with B cell-deficient mice, on the other hand, yield 
conflicting findings, with both detrimental and beneficial roles for B cells against Mtb 
described (294, 531). Limited information is available regarding the role of B cells in 
helminth-Mtb co-infection, but it has been suggested that helminths are able to modulate 
mycobacterial-specific B cell responses, with potentially detrimental effects (532, 533). Our 
findings reveal that maternal Nb infection results in increased levels of B cells in lung 
draining lymph nodes and spleen, which contradicts the suggestion that helminth infection 
down-modulates mycobacterial-specific B cell responses (532, 533). However, it is 
important to note that a difference in helminth species and maternal infection vs. co-
infection could be responsible for the differences observed. Additionally, the levels of MHC 
II expression on lymph node B cells and the number of MHC II+ spleen B cells were increased 
in offspring of Nb-exposed mothers. Specific non-humoral functions of B cells, such as CD4 
T cell co-stimulation and antigen presentation are important to consider in this context 
(358, 534). As mentioned, the necessity of the B cell’s antigen presenting capabilities in 
protection against secondary Nb infection has been reported, with the presence of MHC II 
on the B cells being required (358). Thus, an upregulation of MHC II expression on B cells 
induced by maternal helminth infection may indicate an increased ability of these B cells to 
present antigen to CD4 T cells, thus boosting CD4 T cell responses to BCG infection. Our 
findings also reveal significantly increased levels of Nb-associated IgG1 in offspring of Nb-
exposed mothers, along with moderate IgG2a production. Nb-associated antigens are 
known to induce IgG1 production, but not IgG2a (535). This points to either a helminth-
associated or maternal immune component that is able to induce long-lasting IgG1 
production in offspring without the offspring experiencing helminth infection, as the IgG1 
antibody’s half-life of 4-6 days indicates that no maternal antibody would still be present 
in the mature offspring (536). Importantly, IgG2a is a Th1-associated antibody not generally 
produced in a Th2 setting (520, 535). A possible explanation is that the IgG2a antibodies 
detected are specific for bacterial antigens. It has long been known that Nb requires a 
healthy gut microbiome to develop appropriately, indicating a close association between 
the helminth and bacteria (537). Although larvae are treated with antibiotic and washed 




prior to processing for antigen, there may still be bacteria or bacterial antigens present in 
the homogenate, which would be able to induce antibody responses in the mouse. There 
was limited production of BCG-specific IgG1 in our study, and a trend for increased IgG2a 
in offspring of Nb-exposed mothers, which could suggest a mild beneficial effect of 
maternal helminth infection on the induction of Th1-associated antibodies to BCG. Another 
plausible explanation for the presence of long-lived helminth-specific responses in 
helminth-naïve offspring is maternal microchimerism. This a process during which 
maternally-derived cells are transferred to and tolerated by offspring and which can 
influence offspring immune responses (538, 539). The transfer of maternal helminth-
elicited CD4 T cells to offspring has been observed and implicated in protective responses 
to subsequent helminth infection in the offspring (456), suggesting that maternal 
microchimerism may play an important role in the development of long-term immunity in 
infants. The data presented here support this, as the offspring investigated were weaned 
and fully grown, removing the possibility that the effects observed were purely due to 
passive maternal immunity.  
BCG vaccination is known to induce protective responses to Mtb infection in mice, 
characterized by decreased lung and spleen bacterial burdens and lung pathology, as well 
as increased Th1-specific responses (e.g. enhanced IFNγ production) (497, 540). Several 
studies have investigated whether helminth infection can alter these protective responses. 
Certain helminths are able to modulate protective responses induced by BCG vaccination, 
with increased bacterial burden noted in a murine model and decreased IFNγ responses 
observed in murine and clinical studies (466, 467). However, the effects appear to be 
species-specific, as not all helminths elicit the same effect (468). Similarly, the effect of 
maternal helminth infection on BCG-associated responses are also species-specific, as 
reports range from potentially detrimental to potentially beneficial (458, 460, 512). The 
findings from our study suggest that the effect of maternal helminth infection on BCG 
vaccination may be more subtle than that observed with either mycobacterial infection or 
helminth-mycobacterial co-infection. A trend for decreased bacterial burdens in vaccinated 
offspring of Nb-exposed mothers mimicked the finding with unvaccinated offspring from 
Nb-exposed mothers; however, there were no differences in total lung cell number or lung-
specific CD4 T cell populations. As observed with unvaccinated offspring from Nb-exposed 
mothers, lung draining lymph node activated CD4 T cells were significantly increased in 




vaccinated offspring from Nb-exposed mothers. Additionally, IFNγ+ but not IL-4+ CD4 T cells 
were significantly upregulated in vaccinated offspring from Nb-exposed mothers, which is 
in agreement with prior research showing a potential positive effect of maternal helminth 
infection on mycobacterial cytokine responses (512). Although the majority of T cell 
findings mimic our observations with maternal helminth infection and BCG infection, the 
effect of helminth exposure was decreased. 
It is well-known that BCG induces antibody production, with IgG, and the subtypes IgG1, 
IgG2 and IgG3 (Th1-type antibodies) as the most prominently produced subtypes (295, 
428). More recently, it has also been observed that BCG vaccination elicits long-lived 
memory B cells that respond well to PPD stimulation (541). However, it remains unclear 
how helminths may affect B cell responses to BCG vaccination. As observed with the T cell 
responses, the effect of maternal helminth infection on B cells following BCG vaccination 
was not as pronounced as the effect on BCG infection alone. Lymph node B cell numbers 
were upregulated, as were MZ B cells, but no differences were observed with overall spleen 
B cells or the spleen FO cell subpopulation. Interestingly, vaccinated offspring from Nb-
exposed mothers exhibited decreased MHC II expression on lymph node B cells, and 
decreased proportions of MHC II+ and MHC II expression levels on spleen B cells, which was 
not observed with maternal helminth-BCG infection alone. This could indicate a decrease 
in the antigen presenting capacity of these cells. There was also a significant increase in Nb-
associated IgG1 levels and a trend for decreased BCG-specific IgG2a levels in vaccinated 
offspring of Nb-exposed mothers. It has been shown that although not substantial, BCG 
vaccination is able to induce both IgG1 and IgG2a production, but that the antibodies are 
more readily detectable from 8 weeks post infection (542-544). This provides an 
explanation for the low levels of BCG-specific antibodies in this study, as offspring were 
euthanized 6 weeks post BCG vaccination. Alternatively, the difference in overall IgG and 
levels of IgG1 and IgG2a suggest contribution by other antibody subtypes, for example 
IgG2b. The trend for decreased IgG2a in offspring of Nb-exposed mothers suggests a 
moderate down-regulation of Th1-associated antibodies by Nb exposure. However, these 
effects do not appear to influence the effectiveness of BCG vaccination, as attested to by 
the reduction in bacterial burden in offspring of Nb-exposed mothers. 
Taken together, these findings reveal that modulation of immune responses is not limited 
to concurrent helminth infection, but that maternal helminth infection/exposure can 




influence her offspring’s response to antigens unrelated to the helminth in question. 
Although the effect is subtle, it may reveal a more potent modulatory effect induced by Nb, 
as analyses were performed in offspring that had never experienced a helminth infection. 
Additionally, our data suggest that maternal helminth infection may act synergistically with 
BCG vaccination to enhance immune responses that are protective against a live BCG 
infection. These data highlight the fact that helminth exposure may be able to influence 
mycobacterial infection and BCG vaccination in subtle but complex ways, and that its 
effects are not limited to the site of BCG infection. These findings also lend support to the 
potential influence of helminth exposure on antibody responses to childhood vaccines as 
discussed in Chapter 3, and are in agreement with our finding that although an association 
exists between helminth and vaccine antibody responses, helminth exposure does not 
appear to have more than a mild effect on vaccine efficacy. An important consideration is 
that, although there are some parallels, there are several differences in the findings 
between this chapter and Chapter 3, highlighting the importance of careful comparison 
within translational research. A variety of factors could be responsible for these 
differences, for example the use of peripheral blood (clinical) versus lung tissue (murine 
model), samples which explore different compartments of Mtb immune responses. 
Additionally, the study of Mtb versus BCG and the use of different helminth types could 
yield varying results. These differences in study design are important to consider for future 
work; nevertheless, the findings from this study provide an insightful starting point. 
A caveat of this exploratory study is that certain findings are only representative of one 
experiment, and as such these experiments would need to be repeated and findings 
confirmed prior to firm conclusions being drawn. However, the compelling evidence for a 
protective effect of maternal helminth infection on BCG infection and vaccination, as 
discussed, warrants further study. 




Chapter 5: Concluding remarks and future work 
5.1 Summary of findings 
In our clinical study, which used humoral responses as an indicator of immune responses 
to various antigens and pathogens, we found that total non-specific plasma IgG responses 
were significantly lower in children who acquired an Mtb infection, suggesting that higher 
total IgG responses may be associated with a decreased risk of Mtb infection. The same 
association was observed with certain vaccine responses, as a significant increase in 
measles-specific IgG and a trend for increased BCG-specific IgG2 responses were observed 
in QFT- infants. The measles and BCG vaccines have been associated with a reduction in all-
cause mortality (417, 418), and BCG vaccination is known to provide partial protection 
(202) and may enhance anti-Mtb protective responses (297, 496, 497). In light of this, our 
findings could be attributed, at least in part, to vaccination with these childhood vaccines. 
However, as the measles and BCG-specific responses did not correlate with the total IgG 
responses, it is important to consider that other components of this non-specific IgG 
response could play a role in protection against Mtb infection. 
The geographical overlap of tuberculosis and helminth infections in the study region (330, 
408) led us to investigate the potential influence of helminth infection on Mtb-associated 
outcomes. Appropriate water sources and sanitation are effective control measures against 
helminth infection (482, 483), and available to most participants in this study along with 
anti-helminthic treatment (484). Despite this, helminth infections do still occur, as the 
presence of class-switched helminth-specific antibodies indicate. However, this helminth 
exposure does not affect the risk of acquiring an Mtb infection or IFNγ production by Mtb-
specific T cells. Helminth-specific antibody responses relate positively to vaccine-specific 
antibody responses, but this association does not appear to translate to any wider 
outcomes measured in this study, suggesting a modest influence of helminth exposure on 
responses to childhood vaccines. 
A more in-depth investigation of the interaction between helminth exposure and 
mycobacterial infection in a murine model revealed that maternal helminth exposure 
protected offspring against M. bovis BCG, an unrelated pathogen. Additionally, it may 
enhance protective responses to mycobacteria induced by BCG vaccination. Our findings 
suggest that these protective effects are mediated through the induction of protective 




adaptive cell responses in the secondary lymphoid tissues. Interestingly, the antigen-
presenting function of B cells rather than their antibody production may be more important 
in these responses. Importantly, the presence of helminth-specific antibodies in helminth-
naïve adult offspring of helminth-exposed mothers suggests a longer-term impact of 
maternal immunity on infant immune development than previously thought. This is 
supported by prior studies in our research group, where maternal helminth infection was 
shown to increase innate and adaptive cell populations, as well as induce early germinal 
centre development (456, 545), responses one would only expect to occur following 
exposure to a foreign antigen or pathogen. This suggests that one or more components 
transferred from mother to offspring do not only confer passive protection, but can actively 
induce the development of long-lasting protective responses in the offspring. The 
protective effect of maternal helminth exposure on BCG infection was less pronounced if a 
BCG vaccine was administered prior to BCG infection in the offspring. This suggests that the 
high level of control induced by BCG vaccination partially masks any protective effect the 
maternal helminth exposure may have. Albeit subtle, maternal helminth exposure was still 
able to upregulate cellular responses in the offspring secondary lymphoid tissues, 
suggesting a synergistic effect of maternal helminth exposure and BCG vaccination in 
protecting offspring against a subsequent BCG infection. 
Taken together, our findings suggest that the induction of heterologous protective adaptive 
immune responses in children, through vaccination or maternal helminth infection history, 
could provide protection against childhood mycobacterial infection and may enhance 
vaccine effectiveness. 
5.2 Caveats, limitations and future work 
Various factors contribute to the robust nature of this research. The clinical research 
component had both longitudinal and cross-generational components, two factors which 
aid in our understanding of longer-term effects on infant immunity. Additionally, our broad 
analysis of both vaccine and helminth humoral responses and how these relate to Mtb 
infection susceptibility provide a wider view of the interplay between the responses to 
various immune challenges and how these relate to susceptibility to a largely unrelated 
pathogen. Moreover, the use of a murine model to investigate mechanisms potentially 
underlying observations made with our clinical cohort, adds a translational element to our 
research. This approach provides an increased scope for insights which may not be possible 




with either clinical or animal research alone. However, as with any study, there are certain 
caveats and limitations to the research presented here which would be important to 
address in future work; these are discussed below. 
Our clinical cohort was a sub-study that was part of a larger parent trial, as described in 
Chapter 2 (materials and methods section). The resulting sample set that was available for 
testing and analysis was, therefore, only a fraction of the entire cohort. A greater sample 
number could have leant more power to the findings presented here, and may have 
allowed for a parallel analysis in those infants who subsequently developed active TB 
disease, an approach that could not be utilised currently due to low numbers of active TB 
disease cases in the sub-study. Unfortunately, this cannot be addressed with the current 
cohort, as a limited number of infants were enrolled to this sub-study, and the parent trial 
has already been concluded and as such, no more enrollments are possible. As the mothers 
were not the focus of the trial, the information collected from them via questionnaire was 
limited. This resulted in insufficient data on maternal Mtb infection status and feeding data 
(e.g. breastfed vs. bottle-fed), factors whose potential influence on infant immune 
responses to Mtb could be important to consider, as maternal immune history and infant 
nutrition do influence immune development (discussed in detail in Chapter 1, sections 1.2.1 
and 1.2.2, respectively). Infants enrolled in this study had ready access to good sanitation, 
clean water and regular deworming treatments. Subsequently, no current A. lumbricoides 
or T. trichiura infections were detected in the infants, and as such we were limited to 
analyzing the effect of helminth exposure rather than current infection on the infants’ 
immune responses, where current helminth infection may have had a more pronounced 
effect. A more detailed analysis would require samples from a cohort located in another 
helminth-endemic region, where appropriate sanitation, clean water and deworming are 
not as readily accessible. Alternatively, a more stringent study design with an emphasis on 
the recruitment of infants with active helminth infection could be informative in assessing 
the role of current helminth infection on the outcomes discussed. 
Within the clinical study, our focus on in-depth analysis of the infants’ samples and clinical 
characteristics confined our analysis of maternal samples, as did the limited data available 
for the mothers. Despite this, it would be interesting to test a greater number of maternal 
samples, and to increase the breadth of antibody responses tested, to provide a more 
detailed description of the association between maternal and infant humoral responses in 




this cohort. Additionally, as maternal samples were expected to exhibit an antibody 
response of greater magnitude than infant samples, different sample starting dilutions 
were used; however, a more accurate comparison would be achieved if the same starting 
dilution were used, a method that will be employed in future. 
There is increasing interest in the role of Mtb-specific humoral immune responses in 
protection against Mtb (285, 305). This, paired with the fact that we have not yet identified 
the protective component of the total IgG response, point to an analysis of antibody 
responses to Mtb-specific antigens as an important subsequent step. There is some 
indication of pertinent antigens to investigate such as Ag85A or ESAT-6, (289, 307), or the 
capsular components AM/LAM (286, 287, 302), with antibodies specific for these antigens 
suggested to be involved in protective anti-Mtb responses. Thus, analysis of antibody 
responses to these antigens would be a good starting point. 
Thus far, this clinical study represents a phenotypic analysis of immune responses to the 
various antigens and pathogens. However, a prominent caveat is the absence of functional 
assays, which would investigate the mechanisms underlying the observations we have 
made. Such functional studies could identify antibody-mediated processes involved in 
protective responses to mycobacterial infection in this cohort, providing further insight into 
host immune responses that could be targeted by new treatments and vaccines. Several 
studies have shown that mycobacterial-specific antibodies can enhance cell-mediated 
protective responses, often by enhancing macrophage-associated effector functions (296, 
300, 305). We have begun optimizing an opsonophagocytosis assay to assess the functional 
response of antibodies already measured in the serum samples, to test whether the 
protective effect observed translates into an enhanced ability to control mycobacterial 
infection. The assay we have employed uses a human macrophage-like cell line and 
mycobacteria labelled with pHrodoTM, a dye which fluoresces at low pH and is used to 
measure bacterial uptake and killing by phagocytosis (detailed methods can be found in 
Chapter 6 – Appendices). Preliminary findings show that plasma from QFT- infants may 
have an enhanced capability to induce phagocytosis as compared to QFT+ infants, as 
indicated by the greater proportion of dye+ cells (Fig 5A). This was not due to differing 
activation levels of the stimulated cells, as the cells all expressed equivalent levels of 
CD11b, a marker that is known to be expressed on differentiated THP-1 cells (546) (Fig. 5B). 
Although this is promising, the optimization would need to be completed and more 




samples analysed to confirm whether this finding is valid. A confirmatory procedure that 
could also be used is the measurement of phagocytic uptake of GFP-expressing bacteria by 
flow cytometry and confocal microscopy to confirm uptake and co-localisation with the 
phagolysosome as a proxy of intracellular killing. 
     
Figure 5. Higher antibody levels from QFT- infants may enhance phagocytosis of 
mycobacteria. Auxotroph Mtb bacteria were stained with pHrodoTM and opsonised with 
heat-inactivated plasma from QFT- and QFT+ infants, following which phagocytosis by 
differentiated THP-1 cells was allowed to proceed. Cells were subsequently analysed for 
pHrodoTM positivity (A) and CD11b expression (B). Comparison in (A) was assessed for 
significance by the Mann Whitney test, and comparisons in (B) by the Kruskal-Wallis test (p 
≤ 0.05). 
The promising results from our murine model provide a good starting point and strong basis 
for future work. Certain experiments need to be repeated to provide confirmation of the 
results, but the clear findings already obtained, such as bacterial burdens, reveal that these 
experiments are worth pursuing and more in-depth experiments to investigate certain 
components of the immune responses involved, e.g. the role of B cell antigen presentation, 
could prove to be insightful. Due to time and sample constraints, analysis of cytokine 
responses was limited. However, this would be an important analysis to extend, and it 
would be beneficial to include other pertinent cytokines such as IL-12 and TNF-α (type 1), 
and IL-5 and IL-13 (type 2). It could also prove insightful to measure levels of cytokines 
produced in addition to analyzing the proportions of CD4 T cells producing each cytokine, 
as presented here. With the model as is, an in-depth analysis of alveolar macrophage 
populations would also be interesting, as these are some of the first cells encountered by 
Mtb in the lung (217), and it would be important to investigate changes in lung pathology 
via histology. 




The findings obtained thus far provide the basis for several potential avenues of 
investigation which could be followed. The longevity of increased cell activation and 
presence of helminth-specific antibody in offspring long after they have been weaned 
suggests that the influence of maternal immunity is not merely passive. Whether these 
upregulated responses are due to general immune activation or due to stimulation by 
cross-reactive molecules, e.g. antigens, remains to be tested. An initial approach to this 
could be an investigation of the antigen specificity of T and B cells, to observe whether they 
are helminth or Mycobacterium-specific, or if they are specific for an epitope allowing for 
cross-reactivity between these organisms. Additionally, certain important maternal 
immune components could be neutralized and the effect on offspring responses to BCG 
measured. For example, an investigation of the influence of maternal helminth infection 
on offspring helminth-specific immune responses revealed that maternal memory CD4 T 
cells were transferred to pups via breastmilk and that they may be involved in protection 
against helminth infection in the pups (456). Neutralisation of such transferred cells in 
offspring prior to BCG vaccination and/or infection could reveal whether offspring are more 
susceptible without the protection afforded by those cells, whatever their antigen 
specificity. It would also be interesting to investigate whether helminth during pregnancy 
alters any of these findings. Although anti-helminthic treatment during pregnancy does not 
appear to have a substantial effect on infant cytokine responses as measured in blood 
samples (462), immune effects induced by helminth infection during pregnancy may have 
more subtle effects than can be detected with blood samples alone, suggesting that an in 
vivo model may provide more insight. Additionally, due to the complexity of immune 
responses induced by different helminth species (outlined in Chapter 1- section 1.5.2), it 
would be beneficial to determine whether these same protective effects are observed with 
helminth species other than N. brasiliensis. 
Although some confirmatory experiments would need to be performed to substantiate this 
research, the data presented here are promising. Our findings highlight the importance of 
heterologous immune activation, which could provide another pathway to boost general 
immunity. Additionally, the significant protective effect that helminth exposure or infection 
could provide against mycobacterial infection exhibits that helminths are not always 
detrimental to the immune control of other pathogens and can, in fact, be beneficial. These 
surprising findings highlight the benefit of novel approaches to the study of pathogens such 




as Mtb that remain a global challenge, as they may provide new insights into unusual 
mechanisms that could be employed in the control of these pathogens, such as 
heterologous immune responses or helminth exposure. 




Chapter 6: Appendices 
6.1 Supplementary methods 
6.1.1 Opsonophagocytosis assay 
6.1.1.1 THP-1 cell culture 
For in vitro investigations of antibody function, a human monocyte cell line, THP-1, was 
kindly provided by Dr. Georgia Schӓfer; the cell line can also be acquired from ATCC® (TIB-
202TM). Cells were maintained at 37°C in 5% CO2 in RPMI-1640 medium containing 2mM L-
glutamine (Gibco®, Thermo Fisher Scientific); 10% FBS was added to generate complete 
medium, and a penicillin/streptomycin mix was added to prevent bacterial contamination. 
Cultures were maintained at a density of 1X105-1X106cells/ml in 75cm3 flasks and media 
was replaced as necessary. 
To ensure availability of cells for all experiments, aliquots of cells were periodically frozen. 
Each 1ml aliquot contained 1X106 cells in a mixture of 90% FBS/10% DMSO. Cells were 
frozen slowly overnight at -80°C, after which they were transferred to long-term liquid 
nitrogen storage. When required, an aliquot of cells was removed from storage, rapidly 
thawed at 37°C and immediately transferred to pre-warmed media. Cells were centrifuged 
to remove DMSO and resuspended in fresh medium prior to incubation. 
To generate macrophage-like cells that could be used for phagocytosis assays, THP-1 cells 
were differentiated in RPMI-1640 containing 100nM PMA. Cells were left to differentiate 
for 3 days (37°C in 5% CO2), after which they were washed to remove the PMA and rested 
for one day prior to their use. 
6.1.1.2 M. tuberculosis auxotroph culture 
For the purposes of these experiments an Mtb auxotroph strain, kindly provided by 
Associate Professor Digby Warner, was used. This attenuated, Mtb H37Rv-derived strain 
(mc26206), is unable to produce the essential nutrients leucine and pantothenate due to 
mutations inserted in the genes required for their production. Thus, this auxotrophic 
bacterium is alive but unable to replicate (547). Due to its severe attenuation, all 
manipulations with this bacterium can be performed in Biosafety Level 2 facilities. 
Stock aliquots of mc26206 were stored at -80°C until required for experimental procedures. 
When required, one aliquot of bacteria (1ml, harvested at OD ≈ 0.8; 600nm) was thawed 
and added to 4ml Middlebrook 7H9 broth supplemented with OADC, 0.5% glycerol, 24mg 




pantothenate and 50mg leucine (supplement concentrations used for 1000ml of broth). 
The initial culture was left undisturbed for 5 days at 37°C with 5% CO2. Once bacteria had 
recovered from freeze/thaw shock, 1ml was taken and sub-cultured in 9ml fresh broth for 
a further 9 days, with the OD at 600nm measured every 2 days from day 5 to monitor 
growth. Once in the log growth phase (OD = 0.7-1.0), bacteria were either harvested and 
used for in vitro assays, or sub-cultured to ensure continued growth. To determine CFU 
counts, bacterial cultures or samples were plated on Middlebrook 7H9 broth supplemented 
as above, with bacterial agar powder added as the solidifying agent. 
6.1.1.3 Fluorescent labelling of Mtb 
Bacteria grown to log phase (as described above) were harvested and labelled with 
pHrodoTM Red, a pH-sensitive dye that fluoresces at low pH. Lyophilised pHrodo was 
reconstituted in DMSO per the manufacturer’s instructions to generate a stock solution of 
10.2mM. Bacteria were washed and re-suspended in FS 100mM sodium bicarbonate (pH = 
8.5), and 2µl of the pHrodo stock solution added (final concentration of pHrodo = 51µM). 
The staining reaction was allowed to proceed at room temperature for 40 minutes in the 
dark, with gentle agitation. Bacteria were washed twice in FS 1X PBS (pH = 7.4) following 
this incubation step, and resuspended in FS 1X PBS (pH = 7.4) at the required concentration. 
To confirm whether labelling of the bacteria had been successful, some bacteria were kept 
aside at the higher concentration used during staining. These bacteria were washed and 
resuspended in 0.1M citric acid/0.2M di-sodium hydrogen orthophosphate dehydrate 
buffers with pH values adjusted to 4.6, 6 and 7.6. Once resuspended, bacteria were 
analysed under a fluorescent microscope (ZEISS Axio Observer 7 with Colibri 7) for positive 
staining at low pH (4.6). 
6.1.1.4 Opsonophagocytosis assay 
Cells used for these assays were differentiated as described, and maintained in media 
supplemented with FBS. Prior to the start of the experiment, cells were washed twice and 
resuspended in media without FBS and without penicillin/streptomycin, to ensure no 
interference of these components with experimental outcomes. All subsequent steps 
requiring media were performed with serum-free media. Prior to the start of the assay, 
serum samples to be tested were heat inactivated at 56°C for 30 minutes to remove 
complement proteins; the positive control sample was not heat inactivated. Once bacteria 
were labelled (as described above) and sera heat inactivated, serum was added to bacteria 




at 10% v/v (of final volume) and opsonisation allowed to occur for 30 minutes at room 
temperature, with gentle agitation. Once completed, the opsonised bacteria were diluted 
to the required concentration in FS 1X PBS. Bacteria were added to differentiated THP-1 
cells (10:1 ratio of bacteria to cells), with triplicate wells per serum sample. Plates were 
incubated at 37°C with 5% CO2 for 2 hours to allow time for phagocytosis. Cells were 
washed twice with pre-warmed media to remove extracellular bacteria; fresh media was 
added and the experiment allowed to run for a further 2 hours at 37°C with 5% CO2. The 
differentiation procedure results in cell adherence, so a solution of 4mg/ml lidocaine 10mM 
EDTA in 1X PBS was used to lift cells (40-60 minutes at 37°C) prior to staining for FACS. 
Once removed from the tissue culture plate, cells were stained for viability (LIVE/DEADTM 
fixable Aqua staining kit; Life Technologies) and CD11b (Pacific blue, BD Pharmingen) 
expression to confirm differentiation. Cells were stained with the viability marker for 10 
minutes at room temperature, followed by CD11b staining for 20 minutes at 4°C. Once 
stained, cells were fixed in 1% PFA for 20 minutes at 4°C. Staining and fixing steps were 
performed with samples protected from light. Once stained and fixed, samples were 
acquired on a BDTM LSR II flow cytometer, and data were analysed using the FlowJo® 
software package. The gating strategies used to identify pHrodo- and CD11b-labelled cells 
are presented below, as are individual experimental outcomes for the samples being 
investigated (Fig. A). 





Figure A. Opsonophagocytosis assay gating strategy and individual sample outcomes. 
Forward scatter (cell size) and side scatter (cell granularity) parameters are used to identify 
differentiated THP-1 cells. Within this population, the LIVE/DEADTM Aqua viability marker 
was used and within the live cell subpopulation the proportion of pHrodoTM positive cells 
and mean fluorescence intensity of CD11b were determined (A). The proportion and 
number of pHrodoTM positive cells for individual experimental samples, as well as 
appropriate controls, were determined (B). Data presented in (B) are an expansion of data 
presented in Figure 5A. 
6.2 General Buffer Recipes 
6.2.1 ELISA buffers 
10X Phosphate-buffered saline (PBS) 
80g NaCl 
2g KCl 




14.4g Na2HPO4 or 18g Na2HPO4.2H2O 
2.4g KH2PO4 
Dissolve the above in 1L distilled H2O, and adjust the pH to 7.2-7.4. To make 1X PBS, mix 
100ml of 10X PBS with 900ml distilled H2O. Solution can be filter sterilised; store at room 
temperature. 




Make up to 1L final volume using distilled H2O, and adjust the pH to 9.5 using 1M citric acid. 
Solution can be filter sterilised if required; store at 4°C. 
Blocking buffer 
2g bovine serum albumin (BSA) OR 2g milk powder (2% w/v) 
Dissolve in 100ml 1X PBS; store at 4°C. 
Dilution buffer 
1g BSA (1%w/v) 
Dissolve in 100ml 1X PBS; store at 4°C. 





50ml Tween 20 
Make solution up to 5L with distilled H2O. To make 1X solution, mix 1L of the 20X solution 
with 19L distilled H2O. 
Substrate buffer (for use with p-Nitrophenyl phosphate (PNP) substrate powder) 






97 ml di-ethanolamine (liquefy in water bath if too viscous to use) 
Add components to 700ml distilled H2O, and adjust the pH to 9.8 with 10M HCl. Make up 
to 1L; store at 4°C. 
PNP substrate 
The substrate should be made up immediately prior to use. Measure volume of substrate 
buffer (described above) required for experiment. Weigh amount of PNP substrate powder 
required to yield a 1mg/ml solution; dissolve in substrate buffer and protect from light. 
6.2.2 Mycobacterial culture solutions 
Liquid growth medium 
4.7g Middlebrook 7H9 broth powder (DifcoTM) 
2ml glycerol 
Add components to 900ml distilled H2O. Autoclave solution for 10min (121°C and 100kPa). 
Let solution cool down to 50-55°C, and add 100ml (10%) OADC enrichment medium. 
Agar plates 
21g Middlebrook 7H11 agar powder (DifcoTM) 
5ml glycerol 
Add components to 900ml distilled H2O. Autoclave solution for 10min (121°C and 100kPa). 
Let solution cool down to 50-55°C, and add 100ml (10%) OADC enrichment medium. To 
pour plates: work in a sterile tissue culture hood. Add 16ml agar to each petri dish while 
still warm. Leave lids off and allow to cool and set. Once cool, wrap stacks of plates in sterile 
plastic bags and store at 4°C until use (do not keep for more than one month and check for 
contamination prior to use). 
6.2.3 Tissue processing and flow cytometry solutions 
Complete DMEM (Dulbecco’s modified Eagle medium - culture media) 
500ml sterile DMEM (Gibco®, MA) 
50ml sterile foetal bovine serum (FBS, heat inactivated) (Gibco®, MA) 




2.5ml penicillin/streptomycin (200X) (Thermo Fisher Scientific, MA) 
Add FBS and penicillin/streptomycin to DMEM and mix well. Filter sterilise (0.22µM filter) 
and store at 4°C; check for contamination prior to use. 
Lung digestion buffer 
0.002g DNase I (Roche, Germany) 
0.02g Collagenase Type I (Gibco®, MA) 
Add components to 150ml complete DMEM (as described above). Filter sterilise (0.22µM 
filter) and store at 4°C for up to 1 week. 




Add components to 1L distilled H2O. Filter sterilise (0.22µM filter) and store at 4°C. 
MACS buffer 
0.745g (2mM) EDTA 
5g (0.5%) BSA 
Add components to 1L 1X PBS. Filter sterilise (0.22µM filter) and store at 4°C. 
Phorbol 12-myristate 12-acetate (PMA) 
Freeze aliquots of purchased stock PMA at -20°C. When required for cell stimulation, 
prepare working solution in complete DMEM. 
Ionomycin 
Freeze aliquots of purchased stock Ionomycin at -20°C. When required for cell stimulation, 
prepare working solution in complete DMEM. 
Permeabilization buffer 
0.5g saponin 
0.055g CaCl2 or 0.073g CaCl2.2H2O 







10mM HEPES (5ml of 1M solution) 
Add components to 400ml 1X PBS and adjust pH to 7.4. Adjust volume to 500ml with 1X 
PBS. Filter sterilise (0.22µM filter) and store at 4°C. 
Paraformaldehyde (PFA, 4%) 
4g paraformaldehyde powder 
Add powder to 100ml 1X PBS and allow to dissolve at 70°C. Once dissolved, allow to cool 
to room temperature and adjust the pH to 7.2. Store aliquots at -20°C until required. 
6.2.4 Cell culture solutions 
Complete RPMI-1640 medium 
500ml sterile RPMI-1640 (Gibco®, MA) 
50ml sterile FBS 
2.5ml penicillin/streptomycin (200x) 
Add FBS and penicillin/streptomycin to RPMI-1640 and mix well. Filter sterilise if desired 
(0.22µM filter) and store at 4°C; check for contamination prior to use. 
PMA 
Prepare PMA stock solution of 5mg/ml by dissolving powder in DMSO; freeze aliquots at -
20°C. When required, prepare a 100nM PMA solution in RPMI-1640 medium for cell 
stimulation. 
Cell lifting solution 
Prepare a solution of 4mg/ml lidocaine-HCl, 10mM EDTA in sterile 1X PBS. Add this solution 
to wells to lift cells when desired. 
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